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Defensins are integral mediators of the immune system were they function at 
common sites of infection as direct killing agents and as chemical signals to amplify the 
cellular adaptive immune response. The dysregulation of defensin expression often manifests 
itself as chronic inflammatory diseases and in part results from increased infiltration of 
immune cells through specific peptide/GPCR interactions. Chemokine receptor 6 (CCR6), 
expressed on the outer surface of immature dendritic, memory T and B cells, is one such 
GPCR that various 13-defensins can activate. However investigations into this interaction 
have been hampered by the difficulties in obtaining both f3-defensins and CCR6 in the 
required quantities. In this study, optimization of both recombinant human 13-defensins and 
human CCR6 purification has been performed in heterologous expression systems. Success 
in the production of human 13-defensin 2 (HBD2) in milligram quantity subsequently allowed 
the functional importance of the HBD2 structural framework to be investigated. 
Codon-optimized recombinant I-IBD2 was expressed in E.coli cells as an insoluble 
mutated ketosteroid isomerase (KST) fusion protein. Efficient cyanogen bromide (CNBr) 
chemical cleavage released a soluble HBD2 peptide that upon RP-HPLC purification 
resulted in a highly pure reduced peptide. Oxidation using the redox partners cysteine/cystine 
resulted in a properly folded, functionally active HBD2 as assessed by both antimicrobial 
killing assay and chemotactic assay using CCR6 expressing human embryonic kidney (HEK) 
293 cells. Subsequent purification of HBDI and H13D2 single disulfide bond mutants 
revealed that this method could be used for the future production of other 13-defensins. 
Single disulfide mutant HBD2 peptides were analysed to investigate the effects that 
removing two disulfide bonds had on 13-defensins functions. It was clearly shown that 
although still retaining antimicrobial activity in an in vitro assay the concentration of single 
disulfide mutants needed to kill an equivalent number of E.coli colonies was higher as 
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compared to wild-type HBD2. Comparison between the three individual mutants revealed 
little difference in their potency, although HBD2 with a disulfide bond between cysteines 2 
and 4 did possess slightly increased activity. Unlike both HBD2 and N-terminally 
biotinylated I-IBD2, single disulfide mutants failed to chemoattract CCR6 expressing 
H1EK293 cells. This indicates that all three structurally constraining disulfide bonds are 
necessary for full antimicrobial activity and chemotactic ability. 
CCR6 was expressed in the HEK 293 cell line and expressed with an N-terminal 
FLAG tag and a C-terminal decahistidine tag. CCR6 expressed on the outer surface of these 
mammalian cells was solubilized in mild detergents, and its purification was optimized using 
various chromatographic techniques. The identity of purified CCR6 was subsequently 
confirmed by nanoelectrospray MS/MS analysis. Three separate peptide fragments were 
identified with identical sequences to the predicted fragments of an in-solution CNBr/trypsin 
digest. Sufficient quantity was purified to also analyze the receptors glycosylation state. A 
gel-shift western blot assay resulted in CCR6 being the third chemokine receptor in the 
family to be identified as N-glycosylated. N-terminal CCR6 truncation, resulting in removal 
of the first 27 amino acids (AA), was expressed in the same cell line. Although western blot 
analysis revealed transfection had been successful, surface expression of the mutated 
receptor could not be detected and as such the N-terminus has been implicated as necessary 
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Chapter 1 
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Chapter 1: Introduction 
1.1 - Antimicrobial Peptides in Innate and Adaptive Immunity 
Multicellular organisms are constantly bombarded by thousands of potentially 
pathogenic microorganisms, with intestinal epithelium alone exposed to more than 400 
bacterial species and 1014  microbial cells [1]. Their survival depends initially on the physical 
barrier provided by skin keratinocytes and epithelial cells lining the exposed tissues such as 
intestines, lungs and urinary tract. The breach of this barrier initiates the beginning of the 
innate immune response, which in higher vertebrates can then interact with elements of the 
adaptive immune system if needed. Efficient detection of microbial invasion is via 
evolutionary-conserved pathogen-associated molecular patterns (PAMPs) [2]. These PAMPs 
are often major components of the bacterial outer membrane, such as lipopolysaccharide 
(LPS), or the bacterial cell wall such as peptidoglycan (PGN) or lipoteichoic acid (LTA) [3]. 
However these are not restricted to extracellular components, with both viral double-
stranded RNA and CG dinucleotide DNA sequences being shown to act as PAMPs [4]. 
Binding of PAMPs to cell surface receptors, such as the Toll-like receptor family, initiates an 
inflammatory response consisting, in part, of increased synthesis and secretion of soluble 
antimicrobial peptides (AMPs) [5]. 
AMPs are found in a multitude of multicellular organisms ranging from bacteria to plants 
and from invertebrates to vertebrates. AMPs can be roughly grouped into four structural 
categories: (i) 13-sheet structures stabilised by multiple disulfide bonds; (ii) linear a-helical 
peptides without disulfide bonds; (iii) extended peptides with an unusually high proportion 
of one or two amino acids; (iv) loop structures constrained with a single disulfide bond 
(Table 1.1) [6]. AMPs can be synthesized via both ribosomal and nonribosomal mechanisms, 
with the latter restricted to certain bacteria and fungi [7]. Gene-encoded, ribosomally -
synthesized polypeptides typically consist of less than 100 AA which, when folded, form an 
amphipathic structure (distinct hydrophobic and cationic patches on the surface), and yield 
an overall charge of +2 - +11. This amphipathic structure has been shown to be extremely 
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Family Name Secondary Primary structure 3D 
Structure  STRUCTURE 
Human LL-37 cz-helical 
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 
Cathelicidin 
Bovine Indolicidin Extended Structure ILPWKWPWWPWRR 
Cathelicidin -with major one  
type of AA.  
Human I 	I 	I 




Plant Rs-AFPI n-sheet 
QKLdERPSGTWSGVGNNNALNQLNLEKARHGSNYVFPAHKCUYFPd fir Defensin Multiple disulfide 
bonds  
Loop Structures 
 Insect Thanatin Single disulfide GSKKPVPIIYCNRRTGKCQRM 











B I thr 
dab— Fatly acid (C,) 
Table 1.1. Family Characterizatio n and Structure of Antimicrobial Peptides. Structures were downloaded from protein data bank; 
PBD accession numbers: LL-37:2K60, lndolicidin:1G89, HNP-3.1DFN, Rs-AFP1:1AYJ, Thanatin:8TFV. Disulfide bonds are indicated with 
connecting lines. Superscript d  indicates a D-amino acid and dab represents 1-diamino-butyrate. 
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1.2 - Defensins 
1.2.1 - Classification 
A family of AMPs termed defensins have been identified in plants, invertebrates, 
birds and mammals and represent the only family of AMP conserved in all of these 
multicellular organisms [11-13]. A database dedicated to only defensins has been established 
to compile all the available defensin knowledge (http://defensins.bii.a-star.edu.sg/)  [14]. 
Mammalian defensins constitute a major component of the antimicrobial armoury of 
granulocytic leukocytes, macrophages and epithelial tissues however further roles for 
defensins in the immune response are constantly being identified leading to them being 
renamed 'Host Defense Peptides' or 'Alarmins' in recent reviews [15, 16]. Despite low 
sequence homology, most mature mammalian defensin peptides share certain common 
properties. They are cationic, invariably arginine-rich, nonglycosylated peptides with a 
molecular mass of 3-5 kDa. However, more recently discovered defensins can be 
considerable larger in molecular mass with an extended C-terminus [17]. They contain six 
family conserved cysteines that form three intramolecular disulfide bonds and stabilise a 
triple-stranded antiparallel 13-sheet. The distribution of cysteines, connectivity of disulfide 
bonds and overall molecular structure, allow defensins to be divided into three subfamilies: 
a-defensins, 13-defensins, and 0-defensins (Figure 1.1). 
El 
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a-Defensin 	 Cysi -Cys6 
X(12)C1XC2 RX(23)C3XXXEXXXC4XXXGXXXXXC 5C6X(1) 
Cys2-Cys4 Cys3-Cys5 
f3-Defensin 	 Cysi -Cys5 
I 	X(210)ClX(5)G/AXC2X C3X 	C4X (34) 	(9-13) 	(47)CCX(fl) 
Cys2-Cys4 	Cys3-Cys6 
9-Defensin 
Figure 1.1. Differences in the Distribution of Cysteines and Connectivity of Disulfide 
Bonds between Defensin Families. X represents any amino acid except proline. 
1.2.2 - a-Defensins 
The first realization that granulocytes from polymorphonuclear leukocytes contained 
antimicrobial cationic peptides came in 1966 when Zeya and Spitznagel acid extracted a 
group of arginine and cysteine rich peptides that contained lysozyme-independent 
antimicrobial activity [18]. Surprisingly it wasn't until improvements in technical equipment 
in the mid 1980's that allowed subsequent characterisation of individual components 
responsible for this activity. Six individual rabbit antimicrobial peptides rich in cysteines and 
arginines were purified from peritoneal granulocytes and shown to be antimicrobial [19, 20]. 
Within a year three peptides, with homology to the previously isolated peptides from rabbit 
granulocytes, were purified and sequenced from the azurophil granules of normal human 
neutrophils [21, 22]. Based on their "oxygen-independent" antimicrobial activity and 
mobility they were named human neutrophil peptides 1-3 (HNP 1-3) and, for the first time in 
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the literature, referred to as "defensins" [21]. These three defensins have identical sequences 
except for the N-terminal amino acid (AA), which in HNP-2 is absent and HNP-3 is an 
aspartic acid compared to alanine in I-INP-1. A fourth member of the human neutrophil 
peptide family called I-INP-4 was isolated later and characterised [23]. Although more 
hydrophobic and having lower sequence homology as compared to the previously identified 
a-defensins, it still retained the "classical" cysteine motif and was highly cationic. It was 
found that FINP 1-3 constitute between 30-50% of the protein content in human azurophil 
granules and together with HNP-4 reach a concentration of>10 mg/ml [24]. 
The first human defensins shown to be expressed in cells other than neutrophils were 
HD-5 and HD-6 in Paneth cells [25, 26]. Conservation of the sequence encoding the 5' 
signal sequence of all ct-defensins allowed the design of oligonucleotide probes to hybridize 
to these two novel defensin genes. Paneth cells, a specialised epithelial cell, are located at the 
base of crypts of Lieberkuhn throughout the small intestine and colon. They are granule-
containing secretory cells that upon stimulation release various molecules involved in our 
defence system e.g. lysozyme, defensins and secretory phospholipase [27]. Using both ileal 
neobladder tissue and urine, mature HD-5 and HD-6 were later isolated and their sequences 
verified [28]. 
a-defensins contain between 29-3 5 AA and the six cysteines are disulfide-linked 
between residues Cysl-Cys6, Cys2-Cys4 and Cys3-Cys5. The genes encoding a-defensins 
are clustered on chromosome 8p23, except for I-INP-2 which is thought to be a proteolytic 
product of HNP-1 or -3 rather than a separate gene-encoded peptide [29]. The myeloid cx-
defensin genes (three exons) are synthesised as 90-100 AA pre-pro-peptides. They contain 
20 AA signal sequence which is proteolytically cleaved to leave a 75-residue pro-defensin. 
A further pre-aspartate proteolytic cleavage results in an intermediate 56-residue 
antimicrobial inactive pro-defensin before the active mature 29 or 30 AA peptide is stored in 
the azurophil granules (Figure 1.2) [30]. The inactive pro-peptide is thought to be a 
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consequence of the anionic nature of the propiece which acts as a charge balance to the 
cationic mature peptide. Although it is now known that the posttranslational processing of 
myeloid defensins occurs, the identity of the enzymes responsible for the proteolytic 
cleavage to generate the mature peptides are still not known. 
More success has been achieved in deciphering the enzymes involved in enteric 
defensin processing. Studies using the murine Paneth cell a-defensins (Cryptdins) showed 
that recombinant matrix metalloproteinase matrilysin (MMP7), which co-localizes with the 
cryptidins in Paneth cells, converts cryptdin into its mature form primed for secretion into 
the crypt lumen [31]. This finding was subsequently enforced in the same study when mice 
with a homozygous disruption of the matrilysin gene prevented cleavage of the propeptide 
and resulted in decreased antimicrobial activity [31]. Similar to the human myeloid 
defensins, HD-5 and -6 genes (two exons) are transcribed and translated as prepropeptides. 
Isolation of HD-5 from ileal neobladder tissue and in secreted urine revealed multiple N-
terminally processed peptides, indicating that HD-5 is stored in its proform and subsequently 
posttranslationally processed upon degranulation [28]. The major identified forms had 
putative cleavage sites for trypsin and were hypothesized to be responsible for the 
processing. Further evidence for a role of trypsin in the maturation process came when in 
vitro studies showed partially purified trypsin from ileal tissue cleaved prol-JD-5 into the 
mature luminal form [32]. In the same study both cLl-antitrypsin inhibitor and two isoforms 
of trypsin (meso and anionic) were found co-localized with HD-5 in secretory granules and 
therefore thought to regulate the process (Figure 1.2) [32]. 
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I 	signal 	 Propeptide 	 103 
PreproHNPl (1) MRTLAI LAM LLVALQAQAEPLQARADEVAAAPEQIAADIP------EVVVSLAWDESLAPKHPGSRKNM 	.. 	 IQGRLWAvCC---- 
HNP2 (1) ----------------------------------------------------------------------- 4 	ACIAGERRYGTC1YQGRLWAFCC ---- 
PreproHNP3 (1) MRTLAILPAILLVALQAQAEPLQARADEVAAAPEQIAADIP ------ EVVVSLAWDESLAPKHPGSRKNM 	ACIAGERRYGTCIYQGRLWAFCC ---- 
4 
PreproHNP4 (1) MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQD ------- ISISFAWDKSSALQVSGSTRGM'C.CRLVFCRRTELRVGNCLIGGVSF'rYCCTRV 
PreproHD-5 (1) MRTIAILAAILLVALQAQAESQERADE*TTQKQSGEDNQD
LAISFAGNGLSALTSGSQARCYCRTGRCATRESLSGVCEISGRLYRLCCR 
PreproHD-6 (1) MRTLTILTAVLLVALQAKAEPLQAEDDPLQAKAYEADAQEQRGANDQDFAVSFAEDASSSLRALGSTPJkF - "rCliCRR- SCYSTEYSYGTCTVMGINHRFCCL --- 
00 
Cryptdin-1 (1) MKKLVLLFALVLLGFQVQADPIQNTDEETKTEEQPGEEDQA ------- VSVSFGDPEGTSLQEE-S1 DIVCYCRSRGCKGREPMNGTCR1.1YF!CCR" 
Figure 1.2. Sequence Alignment Showing Cleavage Sites of Full-length Prepro a-Defensins. Cleavage sites are identified by a change in colour 
and arrows indicates the positions of intermediate cleavage sites. Conserved residues in the mature peptide are indicated in green. 
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1.2.3- 13-Defensins 
The first realisation that other defensin families existed came in 1991 when extracts 
of bovine tracheal mucosa contained a 38 AA peptide with potent antimicrobial activity; 
hence being named tracheal antimicrobial peptide (TAP) [33]. However, it was not until 
1993 that the term 13-defensin was suggested when thirteen structurally similar peptides 
isolated from bovine blood neutrophils (BNBD) shared a consensus sequence with TAP [34]. 
Using the most abundant BNBD- 12, Edman degradation analysis revealed the spacing and 
topology of their cysteine residues differed from previously analysed defensins [35]. These 
new defensins displayed a novel disulfide connectivity Cysl-Cys5, Cys2-Cys4, and Cys3-
Cys6 and were called 13-defensins with the original defensins now called a-defensins. 
The first human 13-defensin (HBD1) was purified from the human blood filtrate of 
renal disease patients [36]. This isolated, mature 36 AA peptide was named due to its 
homology to the previously identified TAP. Analysis of large volumes of urine found 
various HBD1 isoforms ranging in length from 36-47 AA [37]. In the same study multiple 
forms of HBD1 were also identified in kidney tissue, blood filtrate, vaginal and lavage fluid. 
The 47 AA isoform is suspected to be the pro-defensin with proteolytic N-terminal 
processing responsible for resultant variations in the mature peptides (which was also 
identified in HD-5). The second and third human 3-defensins were first purified from 
patients suffering with psoriasis. Since psoriasis is a chronic inflammatory disease, psoriatic 
scales have been used as a rich source of various antimicrobial peptides including Psoriasin, 
LL-37 and Elafin [38]. Harder and Schroder have cleverly applied the antimicrobial activity 
of the 13-defensins to produce an array of bacterial affinity columns which they used to 
isolate HBD2 and HBD3. Using an E. coli affinity column, a 41 AA antimicrobial peptide 
was recovered from psoriatic scales and termed HBD2 [39]. Unfortunately no experimental 
details of this purification procedure accompanied the publication. Later this same 41 AA 
peptide was isolated from immortalized lung epithelial cell supernatant using a P. 
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aeruginosa affinity column indicating, like other 3-defensins, HBD2 is epithelia stored 
before being secreted [40]. Using Gram-positive S. aureus as the affinity "bait" a 45 AA 
antimicrobial peptide, termed HBD3, was purified from both psoriatic scales and human 
skin-derived stratum comeum [41]. Almost simultaneously I-IBD3 was also discovered using 
a BLASTp search based on the six cysteine 3-defensin motif, a strategy also used to identify 
HBD4 [42, 43]. This was the beginning of a change in novel defensin identification with new 
bioinformatics methods being used to explore the recently published human and mouse 
genomes. Recently, a computational strategy utilizing both BLAST and I-IM1s'IER programs 
identified five 3-defensin clusters in total identifying 28 putative human 13-defensin genes 
(Figure 1.3) [17]. Since this discovery various studies identifying transcripts for these genes 
have been successful, including the defensin genes on chromosome 20p13 (DEFB125-129) 
and 20q11. 1  (DEFB1 18-23) [44, 45]. However, apart from I-IIBD4, which was identified in 
the epithelial lining fluid of patients with chronic lower respiratory tract infection, and 
DEFB 118, which was extracted from human sperm, no other newly-identified defensin 
peptides have been detected [46, 47]. 
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HBD1 (1) -DHYN VS- - SGGQ LYSA PIFTKIQ ---- GTCY-RGKAK 
RD02 (1) --------------GIGDPVT LK--SGAI HPVF PRRYKQI ---- GTCG-LPGTK 
HBD3 (1) -----------GIINTLQKYY RV--RGGRAVLS LPKEEQI ---- GKS-TRGRK 
HD4 (1) --------------EFELDRI G--YGTARRK-K RSQEYRI ---- GR--PNTYA 
HBD5 (1) ---GLDFSQPFPSGEFAVCES K--LGRGK RK-E LENEKPD ---- GN --RLNFL 
HBD6 (1) -------------- --FFDEK NX--LKGT KN-N GKNEELI ---- AL --QKSLK 
HBD7 (1) ----------------AIHRALISKRMEGR EA-E LTFEVKI ---- GGRAELAPF 
HBD8 (1) -------------- - -KFKEI E--RPNGS RD-F LETEIRV ---- GR--LNSQP 
HBD9 (1) ------------------ -GM LN--LFGV RTDV NIVEDQI ---- GA --RRRMK 
HBD11 (1) ----------------- --RE RI--GNGQ KN-Q HENEIRI ---- AY I-RPGTH 
HBD12 (1) TEKISThRSEGHHITFSRWKS TA--IGGR KN-Q DDSEFRI ---- SY A-RPTTH 
HD14 (1) --------------TLVNADR T--KRYGR KR-D LESEKQI ---- DI S-LPRKI 
HBD18 (1) ---------------YSGEKK WN--RSGH RK-Q KDGEAVK ---- DT --KNLRA 
HBD19 (1) ---------------KRHILR MG--NSGI MA-S KKNEQPY ---- LY --RNCQS 
HBD20 (1) ----------------- --yE WM --- DGH RL-L KDGEDSI ---- IR --RNRKR 
HBD21 (1) ------------------VMK WG--KSGR RT-T KESEVYY ---- IL --KTEAK 
HBD23 (1) -----------------GTQR WN--LYCK RY-R SKKERVY ---- VY --INNKM 
HBD25 (1) ---------------SFEPQK WK-NNVGH RR-R LDTERYI ---- LL --RNKLS 
HBD26 (1) ---------------NWYVKK LN--DVGI KK-K KPEEMHVKNGWAM --GKQRD 
HBD27 (1) --------------- -EQLKK WNNYVQGH RK-I RVNEVPE ---- AL --ENGRY 
HBD28 (1) ------------------LKK FN-KVTGY RK-K KVGERYE ---- IG --LSGKL 
HBD29 (1) --------------EFIGLRR LM--GLGR RD-H NVDEKEI ---- QK ---'4KK 





























101 	 188 charge 
imni (37) -------------------------------------------------------------------------------- +4 
HBD2(42) ----------------------- ----------------------------------------------------------------- +6 
(46) -------------- --------------------------------------------------------- - 
+11 
HBD4(51) ------------------------- --------------------------------------------------------------- +6 
HBD5(52) --------------- ------------------------------------------------------------ +2 
HBD6(46) ------------- -------------------------------------------------------------- +3 
HBD7 --------------- --------------------------------------------------------- +4 
HBD8(52) -------------------------------------------------------------------------------------- +1 
HBD9(60) ------------ ------------------------------------------------------------- +3 
RBD11(36) --------------- --------------------------------------------------------------- +2 
HBD12(82) ------------------ --------------------------------------------------------------- 0 
HBD14 ---------------------------- ------------------------------------------------- 0 
HBD18 (77) SSKKDMVEESEAGRGTETSLPNVHHSS------------------------------------------------------------- -1 
HBD19(64) -------------------- ------------------------------------------------------------------ +6 
HBD20(69) ---------------- ------------------------------------------------------------------- +6 
HBD21 -------------- ------------------------------------------------------------------- +5 
HBD23(48) ----------- ---------------------------------------------------------------------- +10 
HBD25 (78) DLITFDTTKFGETffPETNTPETTPSEATTPETTMPPSETATSETPPPSQTT 	--------------------- -------- - 7 
HBD26 (81) SMAPTPVSPTG----------- ------------------------------------------------------------------ +8 
HBD27(78) TQST------------------------------------------------------------------------------------ +5 
HBD28 - - --------- ----------------------------------------------------------------------- +6 
HBD29 (77) KHILSVLPQIKSTSFFTNFVIIPNATPMNSATISTMTPGQITYTATSTKSNTIESSATASPPPAPPPPNILPTPSLELEEEQ +5 
HBD31(49) -------------- --------------------------------------------------------------------- -1 
Figure 1.3. Sequence Alignment Showing Conserved Residues and Charge of the 3-Defensin Family. Sequences were aligned using AlignX 
before manual alignment of conserved cysteines was performed. Conserved cysteines are in red. Conserved glycines are in green. Charge is 
theoretical value at pH7.0. 3-defensin peptide has been identified in defensins coloured blue. r 
Chapter 1: Introduction 
13-defensins have been shown to be slightly larger than a-defensins, containing 
between 36 to 155 AA and a consensus sequence: x 210Cx56(G/A)xCx3 Cx3 Cx913Cx 7CCx 
[48, 49]. With the exception of DEFB 105, all -defensin genes are composed of two exons 
and one intron. 3-defensins genes encode a substantially smaller anionic pro-peptide 
compared with a-defensins which can either be cleaved once or multiple times to release the 
mature peptide (Figure 1.4). Enzymes responsible for these cleavages are currently 
unknown. 
EXONI 	 0N2 	 - 
5'UTR 	 3'UTR 
3-defensin 
EXON I - 	EXON 2 
V 
N 
5' UTR 	 3' UTR 
0-defe ns in 
EXON I 	EXON 2 	EXON 3 - 
5' UTR 	 YUTR  
HD5-6 
EXONI 	EXON2- 
5'UTR 	 3'UTR 
EXON I 	EXON 2 	EXON 3 
N' 
5' UTR 	 3' UTR 
• Signal Peptide 
Two ct-defensin-like genes 	
Pro Peptide ligate end-to-end to form a 
circular 0-defensin 	 • Mature Peptide 
Figure 1.4. Differences in Gene Structure between Members of the Defensin Family. 
Signal peptide in green, pro peptide in pale blue and mature peptide in dark blue. 
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1.2.4 - e-Defensins 
The third family of defensins to be discovered were 0-defensins, first isolated from 
the leukocytes of rhesus macaque monkeys and termed Rhesus Theta Defensin 1 (RTD-1) 
[50]. RTD-1 is encoded by two different genes with high similarity to a a-defensin gene 
apart from a premature stop codon shortly after the third cysteine of the mature peptide. Both 
genes encode a 12 AA peptide, that upon cleavage of the first three N-terminal AA are 
ligated together to form a heterodimeric, 18 AA, cyclic peptide (Figure 1.4). This defensin is 
the first cyclic peptide discovered in vertebrates and like all mammalian defensins is 
stabilized by three intramolecular disulfide bonds. The ability of each gene product to form 
homodimeric cyclic peptides was later confirmed when RTD-2 and -3 were isolated first 
from the bone marrow and then the leukocytes of rhesus monkeys [50, 51]. 
The existence of 0-defensins in modern human leukocytes is unlikely despite the 
expression of human 0-defensin (DEFT) genes that are very similar to genes encoding 
RTDs. Identification of six human DEFT genes each with a premature stop codon at position 
17 in the signal peptide identifies these genes as pseudogenes [52]. Despite the lack of 
human 0-defensin production, it has been shown recently that human promyelocytic cells 
still retain the ability to perform the novel post-translational ligation. Cotransfection of 
promyelocytic HL60 cells with constructs encoding both full length DEFT1 and DEFTI 
(R70K), with the stop codon replaced with glutamine, resulted in the isolation of the 18 AA 
heterodimer [53]. In the same study addition of aminoglycosides to cervicovaginal tissue 
allowed Retrocyclin 1 to be identified indicating the suppression of stop codon termination 
in the signal peptide and allowing 0-defensins to perform their immune roles in these cells 
[53]. 
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1.2.5 - Gene Regulation and Tissue Expression of -Defensins 
Although there are currently 32 putative 13-defensins identified in the human 
genome, only four of these have been characterised in detail using structural and functional 
methods (HBD1-4). HBD1 mRNA is most abundant in the kidney and pancreas also being 
constitutively expressed in a plethora of epithelia cells including skin, intestinal, respiratory 
tracts and urogenital tissues [36, 37, 54]. However this "housekeeping" defensin has also 
been shown to be up-regulated upon epithelial stimulation with mononuclear blood 
leukocyte stimulated supernatants and cell wall components of Mycobacterium tuberculosis 
[55, 56]. Although the individual components responsible were not identified, in the latter 
case the transcription factor NF-1L6 was shown to be important. 
In contrast to the predominant constitutive expression of HBD1, expression of the 
other defensins, HBD24 is tightly regulated and they are only highly expressed upon 
bacterial challenge or via a cytokine inflammatory response. This was unsurprising since 
both HIBD2 and 3 were originally isolated from psoriatic (inflamed) scales and the 
identification of multiple transcription factor binding sites in the promoter region of HBD2 
including nuclear factor (NF)-KB, AP-1, AP-2 and NF-1L6 [40]. Although HBD2 has a low 
basal expression in lung and trachea tissues, stimulation with proinflammatory cytokines 
including Interleukin- 1 a (IL-la), IL-1p, IL-17 and Tumor Necrosis Factor-a (TNF-a) 
identified or upregulated HBD2 expression in epithelia cells of skin, respiratory and 
gastrointestinal tract origin [40, 57-59]. Gram-negative and Gram-positive bacteria 
challenges can also upregulate HBD2 expression through PAMPs such as LPS, LTA and 
PGN. These interact with specific Toll-like receptors (TLRs) to initiate signal transduction 
pathways culminating in transactivation of NF-KB and/or API transcription factors [4]. 
Mutation, truncation or inhibitors of the two proximal NF-KB and API binding sites in the 
HBD2 gene leads to reduced or loss of RBD2 expression identifying their role in regulating 
HBD2 expression [60, 61]. 
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HBD3 has a low basal expression in both epithelial and non-epithelial cells and like 
FIBD2, its expression can be up-regulated upon proinflammatory cytokine stimulation or 
bacterial challenge [41, 421. However HBD3 expression can also be regulated via a different 
mechanism from HBD2. I-IBD3 is induced by Transforming Growth Factor alpha (TGF-a) 
and Insulin-like Growth Factor I via transactivation of Epithelial Growth Factor Receptor 
(EGFR) in a metalloprotease-directed process [56]. I-IBD4 is unique in only having a few 
sites of expression being highly expressed only in the testis and epididymis [43]. However, 
HBD4 expression in the lungs can be up regulated by phorbol 12-myristate 13-acetate, LPS 
and bacterial challenge [43]. Like HBD4, all the novel putative 3-defensin genes are 
expressed predominantly in the testis and/or epididymis where DEFB1 18-123 expression is 
down-regulated after androgen removal [45]. 
1.2.6 - Role of 13-Defensins in Innate and Adaptive Immunity 
1.2.6.1 - Antimicrobial Activity 
The 3-defensin family of cationic peptides have potent broad-spectrum antimicrobial 
activity in vitro, with each defensin having differential activity against certain bacterial 
strains. Both HBD1 and HBD2 have salt-sensitive antimicrobial activities against a plethora 
of Gram-negative bacteria, fungi and some enveloped viruses [58, 62, 631. These peptides 
have potent antimicrobial activity against only a limited number of Gram-positive bacteria 
but are only bacteriostatic against Staphylococcus aureus, a major cause of infections in 
atopic dermatitis [58]. However, HBD3 has potent salt-insensitive antimicrobial activity 
against various microbes, including the previous J3-defensin resistant Gram-positive bacteria 
S. aureus and vanomycin-resistant Enterococcus faecium [41]. A limited number of the 
newly identified 13-defensins have been functionally characterized and their antimicrobial 
activity determined. Of these, I-IBD4, HBD18 and HBD28 have all been shown to have at 
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least potent antimicrobial activity against E. coil, with only HBD27 failing to possess this 
activity [43, 64, 65]. 
Despite the increasing number of antimicrobial killing targets it was necessary to 
show defensins could kill in vivo under physiological conditions. a-defensins were first 
shown to have important antimicrobial activity in vivo when mice deficient in their 
processing enzyme matrilysin and therefore lacking mature cryptidins showed greater 
sensitivity to S. typhimurium and enhanced number of bacteria colonizing their small 
intestines compared to wild-type mice [31]. Further studies showing HD-5 had a protective 
effect on transgenic mice after S. lyphimurium challenge compared to wild-type again 
highlighted defensins in vivo activity [66]. 13-defensin killing in vivo was subsequently 
shown when E. coli injected into a HBD2 transfected tumour in immunodeficient mice 
resulted in less viable colonies upon harvesting [67]. This was an important finding as the 
HBD2 salt-sensitivity posed the question of whether HBD2 could kill under physiological 
conditions. 
Despite the potent antimicrobial activity of defensins the mechanism of action of 
defensin killing is still speculative. Using negatively-charged artificial membranes, defensins 
were shown to associate to bacteria membranes primarily via electrostatic interactions [68]. 
However, although members of both c- and 13-defensin families have been shown to 
perforate E. coli and S. aureus membranes the exact mechanism of membrane disruption is 
still the focus of much debate [69, 701. One mechanism is the pore/channel hypothesis where 
the peptides self-associate in the outer and/or inner membrane(s) to form an ion-permeable 
hole [71]. A second mechanism is the 'carpet-like' model, which is a non-specific 
mechanism where high concentrations of defensins bind to the membrane and cause changes 
in membrane fluidity and polarisation [72]. Both mechanisms cause membrane disruption 
and leakage of intracellular components. Evidence suggests however that membrane 
permeabilization is just the first step of a cascade of events that lead to bacteria killing. 
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Following permeabilization defensins have been shown to inhibit DNA, RNA and protein 
synthesis as well as cell wall biosynthesis [69, 73]. 
1.2.6.2 - Chemotactic Activity 
The focus on the functional role of defens ins in immunity soon switched to adaptive 
immunity upon the seminal finding that an a-defensin rich extract from human neutrophils 
was able to chemoattract monocytes (Figure 1.5) [74]. Since this original discovery both a-
and 13-defensin have been shown to chemoattract a host of cell types at nanomolar 
concentrations. As well as monocytes, a-defensins migrate naïve T cells, macrophage and 
immature dendritic cells (iDC) but not memory T cells, mature dendritic cells or neutrophils 
[75, 76]. The first evidence that chemotaxis was mediated by a G protein coupled receptor 
(GPCR) came when HBD2 and, to a lesser extent, HBD 1 were shown to chemoattract iDC 
and memory T cells. The chemokine receptor 6 (CCR6), expressed on the outer surface of 
MC, was transfected into I-1EK293 cells and shown to migrate towards 13-defensins in a 
concentration dependent way [77]. In combination with anti-CCR6 antibodies and pertussis 
toxin blocking iDC chemotaxis, CCR6 was identified as the chemokine receptor that f3-
defensins signal through [77]. Since this finding 3-defensins have also been shown to 
possess CCR6-independent chemotactic activity. HBD-3 and -4 have been shown to 
chemoattract non-CCR6 expressing monocytes whereas HBD2-4 have been shown to 
chemoattract both rat and human mast cells that neither CCL20 (also known as M1P-3a, the 
natural chemokine for CCR6) nor HBD1 could block [43, 78-80]. In the latter cell type, cc-
and 3-defensins have been shown to promote degranulation and therefore histamine and 
prostaglandin D2 release, leading in vivo to increased vascular permeability in skin [79, 81]. 
Interestingly, 13-defensin induced mast cell activation and chemotaxis were both mediated 
through a G protein-phospholipase C-dependent pathway [79, 80]. These salt-insensitive in 
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vitro chemotactic activities were thought to represent recruitment of circulating leukocytes 
and lymphocytes to sites of infections and this hypothesis was subsequently proven in vivo 
when subcutaneous injections of HNP 1 and 2 in BALB/c mice resulted in the recruitment of 
T lymphocytes to the site of injection [82]. 
More recent work has shown that the chemotactic properties of defensins are not 
restricted to cells implicated directly in the immune response. Defensins have been shown to 
have a role in promoting wound repair through direct recruitment of human endothelial cells 
and epidermal keratinocytes. I-IIBD2 was capable of reducing wound closure time through the 
promotion of endothelial recruitment, proliferation and capillary tube formation [83]. All 
three are essential for the formation of new blood vessels (angiogenesis) and hence wound 
repair. Defensins HBD2-4 were also shown to induce migration and proliferation of human 
keratinocytes leading to a decrease in wound closure time [84]. Moreover, inhibition of the 
13-defensin-induced phosphorylation of the signalling components EGFR, STAT-i and 
STAT-3 resulted in suppression of wound closure highlighting their importance [84]. 
However the exact mechanism for cell migration is not well understood as CCR6 expression 
was either not identified or not tested on these cell types. Therefore this migrational effect 
could be through an alternative receptor like that found in mast cell- or monocyte-induced 
migration, or could be indirect effects were the 3-defensins stimulate the release of other 
chemokines. 
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Figure 1.5. a- and -Defensins Multiple Functional Roles [85]. 
1.2.6.3 — Defensin Induced Maturation of iDendritic Cells leading to in 
vivo Immunoenhancing Activity 
Mouse 13132 (mBD2), but not mBD3, was shown to induce the maturation of murine 
iDC leading to a type I polarized adaptive immune response [86]. However this maturation 
process was negated when iDCs were isolated from TLR4 -I- mice which suggested that 
TLR4-dependent signalling as being responsible for this maturation [86]. Although CCR6 is 
not responsible for iDC maturation, it is responsible for the enhancement of the in vivo 
antigen (Ag) specific and antitumor activity. Fusion of both mBD2 and mBD3 to non-
immunogenic tumor Ag rendered this species immunogenic via antigen presenting cell 
uptake and induced production of Ag specific antibodies [87]. The inability of non 
chemotactic promBD2 and mutated CCL20 to enhance the adaptive immune response 
implicates CCR6 signalling in this role. Despite the mBD3 fusion producing a greater 
humoral immune response, only mBD2 fusions were able to remove established tumors from 
infected mice showing that the enhanced antitumor activity is due not only to humoral 
immunity but also Ag specific cellular immunity [87]. This cellular activity was identified 
later when mBD2 was fused to the generic nonimmunogenic embryonic Ag, immature 
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laminin receptor, rendering it immunogenic and producing a T cell response [88]. 
Splenocytes from immunized mice were able to specifically lyse tumours expressing this 
epitope however upon CD8 effecter cell depletion their tumour protective activity was lost 
[88]. Therefore the cellular response was determined to be tumor specific CD8 T 
lymphocytes. 
Both human a- and 3-defensins have also been shown to have immune enhancing 
("adjuvant") capabilities through simultaneous intranasal administration of ovalbumin 
(OVA) together with various defensins. Compared with OVA alone, HNP coadministration 
lead to increased OVA humoral response consisting of increased OVA specific IgG 
antibodies and cellular response from OVA specific CD4 T cells leading to increased 
production of IFN-y, IL-5,-6 and -10 [89]. HBD-1 and -2 were also able to increase OVA-
specific IgG antibodies however there were significant differences in their cytokine 
production indicating differences in their immuno-enhancing roles [90]. 
Although defensin fusions have been shown to enhance antitumor activity, it has 
been shown that defensins can have detrimental effects through enhanced tumor progression. 
Intraperitoneal injection of ovarian cancer cells transfected with mBD29 and vascular 
endothelial growth factor-A (Vegf-A) into C57BL/6 mice lead to a decreased survival time 
and greater tumor growth [91]. Tumor recruitment of iDC by mBD29 via CCR6 was 
followed by Vegf-A promoted endothelial-like differentiation and promotion of angiogenesis 
and tumor survival [91]. Therefore, although defensins have been shown to enhance both 
innate and adaptive responses, in certain circumstances it could also have a detrimental 
effect on survival. 
To summarize their functional role in immunity, defensins are expressed at sites of 
both tissue damage and infection and are therefore in an ideal location to act as modulators 
of both innate and adaptive immunity (Figure 1.6) [49]. Initially defensins are upregulated 
and secreted upon appropriate stimulation to act as non-specific antimicrobial peptides. Their 
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role becomes more specialized through attraction of both killer neutrophil/macrophage cells 
and iDC. Upon antigen uptake, mature DCs are free to interact with effector cells from the 
adaptive immune response including both B and T lymphocytes leading to a more specific 
immune response. In addition, defensins have also been found to play a role completing the 
healing process by promoting wound closure and restoration of the impermeable barrier. 
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Figure 1.6. Overview of the Role that 13-Defensins have in the Immune Response. 
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1.2.7 - Structure of 3-Defensins - 'Defensin-like' Fold 
Comparison between amino acid sequences of a- and 13-defensins revealed that only 
a few amino acids were conserved between the families (Figure 1.7 A). Therefore it was 
surprising when comparison of NMR and/or x-ray crystallographic structures of both 
defensin families revealed a structurally-conserved core motif now termed the 'Defensin-
like' fold [72, 92-96]. With the exception of 0-defensins which are cyclic [97], defensins 
contain three 3-strands constructed in an antiparallel sheet with the first 13-strand disulfide 
bonded to the 3-hairpin formed by the final two 13-strands (Figure 1.7 B) [94]. Another 
conserved structural motif is a 3-bulge, acting as a 'hinge' in the second 13-sheet. This 13-
bulge is formed between a glycine in the highly conserved Gly-X-Cys motif and the previous 
amino acid [92, 93, 96]. Stabilization is via formation of hydrogen bonds of these two amino 
acids to the fifth cysteine. However a major difference between the structures of the two 
families exists at the N-terminus with 13-defensins forming a cc-helix which is held against 
the core structure by Cysl-Cys5 [72, 92, 93, 96]. 
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Figure 1.7. Structural Analysis of a Representative from each Defensin Family Showing 
both the 'Defensin-like' Fold and Amphipathic Nature. (A) Sequence alignment of 
structurally determined defensins showing the limited primary sequence homology between 
families, except for the six conserved cysteines and the glycine involved in p-bulge. (B) (Left 
panel) Ribbon diagrams of a representative from each defensin family. Structures were 
downloaded from the protein data bank; HNP-4: 1ZMM, HBD2: 1FD4, RID-i: 1HVZ. Disulfide 
bonds are indicated in green. (Right panel) Electrostatic surface plots indicating defensiris 
amphipathic nature were adapted from [92, 95, 97]. Blue residues are basic, red residues are 
acidic and white residues are hydrophobic. 
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When a- or - defensins fold into their native state they form amphipathic structures 
with cationic residues on one face and hydrophobic on the other (Figure 1.7 B). All a-
defensins have been shown to form topologically similar dimers with hydrogen bonding 
between residues in the second n-strand on each monomer responsible [94, 951. This six-
stranded 13-sheet dimer was shown to have its hydrophobic face and cationic face at opposite 
ends and hence had the potential to form large pores in bacterial membranes [94, 95]. The 
capacity of 13-defensins to dimerize and how the individual monomers interact differs from 
one member to the next. HBD2 was first shown to dimerize when crystal studies showed an 
oligomeric formation composed of four noncovalent dimers. Hydrogen bonding between the 
second Cys of each monomer stabilized this interaction while N-terminal helix interactions 
were shown to stabilize the oligomeric structure [72]. The consequence of this dimerization 
was a burying of the hydrophobic face leaving cationic residues solvent exposed and lead to 
the carpet-like' model being proposed as cationic residues have the potential at high enough 
concentration to disrupt the bacterial membrane [72]. However whether HBD2 or HBDI 
actually dimerizes is controversial since neither NMR nor native gel electrophoresis found 
any evidence of dimerization in solution [92, 96]. It is thought that these structures could be 
artefacts and that the high peptide concentrations used in these studies may lead to formation 
of higher order multimers. HBD3 can form a dimer in solution when studied by native gel 
electrophoresis, light scattering and NMR diffusion experiments [92]. Unfortunately the 
exact interaction is unknown; although NMR studies did show that the dimer is symmetrical 
possibly interacting through the second 13-strand. Replacement of a three amino acid stretch 
Lys-Glu-Glu with the equivalent part of HBDI resulted in mutated HBD3 running as 
monomer on a native gel [70]. This was unsurprising since the second Glu had been 
proposed to form a dimer-strengthening salt-bridge with the Lys on the second 13-strand of 
the opposing monomer but what was surprising was a lack of dirnerization had little effect on 
its antimicrobial activity [70]. Therefore it was concluded that for HBD3, like HBD2, pore 
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formation was not necessary for killing and probably permeabilizes the bacterial membrane 
via the 'carpet-like' mode [70, 92]. However the importance of dimerisation has recently 
been highlighted by the finding that a 13-defensin-related peptide (Defri) forms a covalent 
bound dimer. Defri had enhanced microbial activity due to the presence of this 
intermolecular disulfide bond as compared to its six cysteine-containing analogue (Defri 
Y5C) that formed only non-covalent dimers [98]. 
1.2.8 - Structure and Functional Relationship between CCL20 and - 
Defensins 
CCL20 is the only chemokine ligand known for CCR6 which is unlike most other 
chemokine receptors that have multiple activating ligands. CCL20, also known as MIP3a, 
Liver and Activation-Regulated Chemokine (LARC) and EXODUS-1, has many similarities 
to the 13-defensin family. CCL20 is synthesized with an N-terminal signal sequence which is 
subsequently cleaved leaving a 70 AA peptide, --8 kDa soluble protein [99]. CCL20 is 
expressed constitutively in a wide range of tissues and cell types including skin, liver and the 
lung [99-101]. This constitutive expression can be significantly up-regulated e.g. CCL20 was 
upregulated in keratinocytes by proinflammatory cytokines and bacterial challenge [102]. 
Despite their similarities, the ability of 13-defensins to signal through CCR6 was surprising 
since there is little sequence similarity between any 3-defensin and CCL20 (Figure 1.8 A). 
However, the reasons for the functional overlap became clearer when both the NMR and 
crystal structures of HBD2 and human CCL20 were solved. Folded, mature CCL20 forms an 
amphipathic structure consisting of an antiparallel three strand 13-sheet followed by a C-
terminal helix [103-105]. The N-terminus is mostly random coil that has some constraints 
imposed by its two cysteines forming disulfide bonds with the core structure [103, 105]. 
Comparison between the defensin and chemokine structures revealed two main structural 
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motifs found to be similar in both structures (Figure 1.8 B). The first is a structurally 
restrained DCCL motif near the N-terminus of CCL20, which is a highly conserved motif in 
the CC chemokine family. A similar motif exists in HBD2, being DPV or DPVTCL, and is 
thought to be important in receptor activation and signalling [72, 103]. A second feature, 
which is reported to be important for the specificity of CCR6, is a groove in CCL20 formed 
by the N-loop and the P2-133 hairpin [103, 104]. This groove is —43 A wide whereas HBD2, 
which shows a similar groove on its surface, is only —9 A wide [72, 103]. This narrower 
groove, combined with the more restrained N-terminus found in HBD2, have been proposed 
as reasons for the higher affinity and activity of CCL20. 
It is of interest to note that chemotaxis is not the only functional overlap between 13-
defensins and CCL20. Recently CCL20 has been shown to possess equivalent salt-sensitive 
antimicrobial activity against certain Gram-negative and Gram positive bacteria as compared 
to 13-defensins. In fact, CCL20 possess antimicrobial activity against S. aureus, a bacterial 
strain that shows high resistance to both HBD1 and HBD2 [103, 106]. The cationic patch on 
the CCL20 chemokine has been proposed for this antimicrobial activity and the C-terminal 
cc-helix that constitutes a large proportion of this cationic patch possesses significant 
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Figure 1.8. Structural Comparison between HBD2 and CCL20 - Highlighting Two 
Functionally Important Motifs. (A) Sequence alignment showing conserved residues in 
red. Secondary elements are indicated with blue a cylinder representing a-helix and red 
arrow representing n-sheet. (B) Ribbon diagrams comparing the structures of HBD2 (1FD4) 
and CCL20 (1 M8A). The DPVTCL stretch of HBD2 and DCCL stretch of CCL20 are 
highlighted blue. The distance of the binding groove motif is also indicated. Disulfide bonds 
are highlighted in green. 
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1.2.9 - Role in Health and Disease 
Defensins have been associated with various chronic inflammatory diseases where 
deficiencies or inactivation can lead to increased and recurring bacterial colonization. Two 
chronic inflammatory skin diseases highlight the role of defensins in human health, namely 
atopic dermatitis and psoriasis. Although both involve lesions in the skin barrier, atopic 
dermatitis is highly susceptible to S. aureus skin infection whereas psoriasis has significantly 
fewer infections [107. 108]. The inability to stimulate either HBD2 or HBD3 in atopic 
dermatitis is implicated in, and has been attributed to, the upregulation of Th2 cytokines that 
have been shown to block proinflammatory cytokine induced defensin up regulation [109]. 
Psoriatic skin however contains numerous proinflammatory cytokine induced 
peptides/proteins including defensins that act as a killing barrier to invading organisms 
[109]. 
Defensin deficiency has also been implicated in Crohn's disease with reduced a-
defensin expression and lack of J3-defensin induction linked to ileal and colonic Crohn's 
disease respectively [110, ill]. Both locations of Crohn's disease are associated with an 
increased number of colonizing adhesive and invading E. co/i strains indicating that a 
breakdown in the antimicrobial protective layer could in part be responsible for this chronic 
inflammation [112]. 
An interesting point worth noting is that the 13-defensin cluster on chromosome 8 
containing DEFB4 and DEFBI03-107 has been found to be repeated up to 12 times in 
humans and this copy number varies between individuals [113]. A case study investigating 
copy number variations (CNV) of the defensin cluster in psoriasis discovered that the 
addition of only one copy compared to the median 4 copies increased an individual's 
susceptibility to the disease [114]. Likewise a case study into a link between CNV and 
Crohn's disease discovered a loss of only one copy increased an individual's susceptibility to 
colonic Crohn's disease [115]. Whether predisposition to psoriasis and Crohn's disease is 
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related to 13-defensin genomic copy number is still controversial and until gene expression 
and protein levels are shown to relate to increased copy number then this is an intriguing 
theory that merits further study. 
A third defensin-associated inflammatory disease is Cystic fibrosis (CF). This is 
characterised by recurring and increased bacterial infection of the airways and is caused by 
various mutations in the Cystic Fibrosis Transmembrane conductance Regulator gene [116]. 
Despite intensive study it is still not clear how the defective chlorine channel is involved in 
chronic lung infection. The "high salt" or "salty lung" hypothesis was proposed when an 
impaired antimicrobial activity was detected in the higher salt environment of airway surface 
liquid (ASL) in CF patients [117]. The role of defensins in this impaired activity was 
postulated when HBD1 and -2 were shown to be present in the bronchoalveolar lavage fluid 
of CF patients and possessed salt-sensitive antimicrobial activity in vitro [62, 63, 118]. 
Furthermore an ex vivo human bronchial xenograft model highlighted HBD1 as an important 
component of ASL killing activity - antisense oligonucleotide inhibition of HBD1 expression 
in ASL resulted in significantly reduced P. aeruginosa killing activity [62]. Although 
difficulties in obtaining exact salt concentrations make this hypothesis controversial, it does 
further highlight the importance of defensins in the pathogenesis of chronic inflammatory 
diseases. 
1.3- G-Protein Coupled Receptors 
1.3.1 - Introduction to G-Protein Coupled Receptors 
G-protein coupled receptors (GPCRs) represent one of the largest and most 
important families of proteins in humans [119, 120]. Over 800 GPCRs are estimated to be 
present in the human genome [121], with over 30% of current drug targets acting on only a 
small percentage of these receptors [122]. The importance of GPCRs in human health and 
pharmacology is due to the variety of ligands which activate a plethora of physiological 
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processes. Both endo- and exogenous ligands act on these seven transmembrane helical 
receptors upon binding by transducing a signal across the cell membrane using 
heterotrimeric (a, P, y) G proteins as intermediates. Exchange of GDP to GTP on the a-
subunit causes dissociation from the dimer fry.  Both of these components are capable of 
activating or inhibiting several effectors in a signalling cascade which terminates with a cell 
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The large numbers of diverse GPCRs identified by numerous studies from various 
scientific fields made it necessary for a classification system to be proposed. A commonly 
used system for both vertebrates and invertebrates was the A-F system [123, 124]. The 
largest family, family A, contains the classical rhodopsin receptor, adrenergic and 
chemokine receptors. Although these receptors have relatively low sequence homology, they 
have structurally-conserved motifs which can be used as indicators for family members. A 
classification specifically for human GPCRs was later proposed by Fredriksson in 2003. The 
GRAFS classification system, which is the acronym for the receptor families, reclassified 
human GPCRs [125, 126]. This system allowed distinctions to be made between the Secretin 
(S) and Adhesion (A) receptor families previously grouped in family B. Also, the large 
Rhodopsin family was subdivided into four main groups with 13 sub-groups [126]. Due to 
the different ligands that activate these receptors this was essential. 
The quantity and complexity of GPCRs have been extensively reviewed by Jacoby 
et al., Pierce et al. and Kristiansen et al. [127-129]. Recently, various databases have been set 
up including the RINGdb and GPdb to help categorise the interactions between the GPCR, G 
proteins and their activating ligands [130, 1311. 
1.3.2 - Expression and Purification of GPCR's 
Although GPCRs are major drug targets, structure-based drug design has been 
hampered by the lack of available structural information. This is a consequence of the 
difficulties involved in obtaining milligram quantities of homogenous protein for structural 
studies. Purification of native GPCRs from natural sources has been restricted to either 
highly abundant proteins, of which bovine Rhodopsin from rod outer segment membranes 
remains unique [132] or extreme up-scaling as exemplified by the need for 1200 porcine 
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brains to obtain a partial amino acid sequence coverage of neuropeptide Y2 [133]. Therefore 
it has been necessary to optimize heterologous expression of GPCRs. Prokaryotic systems 
such as E. co/i have been used to express GPCRs either in low yields as maltose binding 
protein fusions [134, 135] or as inclusion bodies that require subsequent refolding to produce 
functional receptors [136, 137]. A major disadvantage of expression in E. co/i, apart from the 
inefficient refolding, is an inability to perform functionally important post-translational 
modifications. To combat this, various eukaryotic expression systems such as yeast, 
baculovirus/insect, and mammalian cells have been optimized each with their own 
advantages and disadvantages. Fermentation of yeast, including S. cerevisiae, 
Schizosaccharomyces pombe and Pichia pastoris allows easy up-scale and this expression 
system can perform some of the essential post-translational modifications [138]. However, 
extraction of GPCRs from yeast is difficult due to the thick cell wall reducing the isolated 
protein yield [139]. Also the biosynthetic components of N-glycosylation in yeast are 
different than in mammalian systems potentially altering their structure [140]. Likewise 
insect cells infected with plasmid constructs encoding GPCRs within baculovirus have been 
successful in obtaining milligram quantities. However just as in yeast, insect-produced 
GPCRs have improper glycosylation modifications [139]. It must be stated that for crystal 
structure studies described later glycosylation modifications are often removed to improve 
the homogeneity of the receptor and therefore improve crystallisation [141]. Finally, 
mammalian expression systems obviously have the advantage of being capable of producing 
GPCRs fully post-translationally modified in a close to native membrane environment. 
However unlike the previous expression systems, up-scaling is extremely time-consuming 
and can produce only moderate yields. To improve both yield and up-scaling in mammalian 
expression systems a tetracycline inducible system combined with the suspension HEK293s 
cell line has been designed [142, 143]. This expression system has been applied to both 
rhodopsin and 32-adrenergic receptors, successfully producing milligram quantities [142, 
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144]. However a limitation of these cells is they lack N-acetylglucosaminyltransferase I 
activity leading to improper glycosylation modifications [142]. 
The emergence of various structural genomics consortiums, including MePNet and 
E-MeP, dedicated to GPCR expression, purification and structural characterization shows 
both the difficulties and importance of this family of receptors. Various high throughput 
studies have been performed investigating the expression levels of 100 GPCRs in E. coli, 
Semliki Forest virus/mammalian and P. pastoris cell expression systems [145-147]. Coupled 
with the increasing success of GPCR crystal studies, this is an important step forward in 
structure-based drug design. 
1.3.3 - Crystal Structure Studies 
The crystal structure of the dark state of bovine rhodopsin was the first three 
dimensional structure determined for a GPCR [148]. This seminal study revealed the 
conserved seven-transmembrane helical topology as well as providing a structural relevance 
for the family A conserved motifs. One such motif, E/DRY motif, was shown to provide an 
'ionic lock' between residues in TM3 and TM6 proposed to restrain the inactive state via 
reducing helical movements. Other conserved motifs such as the rotamer toggle switch 
tryptophan or the NPXXY motif were also shown to form important intramolecular 
interactions, with the former shown to interact with the 1 1-cis-retinal ligand [148]. The 
difficulties in obtaining GPCR crystal structures including low natural expression, 
heterogeneity, intrinsic flexibility and low numbers of surface accessible polar residues has 
forced groups to reengineer their respective GPCRs to compensate for these barriers to 
protein isolation and crystallization (Table 1.2). This effort has seen the number of GPCR 
structures in the protein databank (http://www.rcsb.org ) rise rapidly over the last two years. 
Crystal structures for human A2A adenosine, 32 adrenergic-FabS, 132 adrenergic-T4L, and 
turkey 131 adrenergic receptors have all been determined in association with either an 
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antagonist or inverse agonist [141, 149-152]. Despite the overall topology being similar to 
bovine rhodopsin there were subtle differences between all known structures especially in 
the lack of an 'ionic lock'. In the structures of both the human A2A  adenosine and turkey 131 
adrenergic receptor the EIDRY motif restrains the short helix in ICLU via hydrogen bonding 
whereas in the 132 adrenergic receptors this helix section does not exist [141, 149]. The 
resulting 132 adrenergic receptor has a more open, less restrained structure and this is thought 
to be the reason for its higher basal activity [150-152]. 
Despite the recent successes in GPCR crystal structure determination, all of these 
previous structures have been determined in their inactive state. Recently the protein 
component of rhodopsin, apoprotein Opsin, was crystallised in its active state and, in a 
separate study, the crystal structure complexed with the C terminus of Transducin Gu t  
subunit was resolved [153, 154]. These active conformations differed predominantly at the 
cytoplasmic end of transmembrane helix 6 which turned at the toggle switch tryptophan and 
moved 6 A away from the main helical structure [154]. This movement resulted in the 
E/DRY associated 'ionic lock' to be broken allowing a G protein accessible binding site to 
open up. The C-terminal of Transducin was then able to interact with the liberated Arg from 
the E/DRY motif and this open structure was further stabilized by the insertion of Tyr from 
NPXXY into the void left by TM6 [153]. In fact via a hydrogen bonded network the C-
terminal of Transducin connects these two highly conserved motifs stabilizing the active site 
even further [153]. 
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PDB NAME RESOLUTION PURIFICATION ENGINEERING STRUCTURE 
FILE  
ICL III replaced with 
T4 lysozyme. 
Antagonist bound 
Human (ZM24 135). 
3EML 
A2a 
26 A . 
Baculovirus/SF9 Acquired affinity tags. 
Adenosine insect cells Removed glycosylation 
Receptor and phosphorylation 
sites. 
Purified in presence of 
N aCI. 
ICL III replaced with 
T4 lysozyme. 
Human 32- 
Inverse agonist bound 
2RH I A drenergic 2.4 A 
BaculoviruslSF9 (Carazolol). 
insect cells Removed flexible C- 5 Receptor terminus. _ _ (phosphorylation sites). Deglycosylated. 4.&vsazv.t 
Truncation of N- 




2VT4 adrenergic 2.7 A 
Baculovirus/High phosphorylation sites. 
Receptor 




Antagonist bound.  
1F88/ 
Bovine 
Rodopsinl 2.8 Al2.9 A 
Natural - bovine 
rod outer 
I 1-cis retinal covalently 
3CAP 
Opsin membranes 
bound / none. 
Fab antibody bound to 
ICL 111. 
Human 32 Baculovirus/Sf 
Deglycosylated. 




Inverse agonist bound. 
Table 1.2. GPCR Re-Engineering - Highlighting the Difficulties of GPCR Purification and 
Crystallization. GPCRs are intrinsically unstable receptors that, with the exception of Rhodopsin/ 
Opsin, require extensive engineering to remove both areas of flexibility and heterogeneity that are 
detrimental to structural studies. Furthermore a lack of surface accessible polar molecules for 
crystal contacts has made it necessary to increase this polar surface area with either an antibody 
bound (Fab)to ICL Ill or engineering the GPCR to express another protein in place of the ICL Ill 
[149-152] 
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Using these crystal structures as templates to model other family A receptors has to 
be treated with caution since even receptors with the same ligand can have subtle 
differences. Also the crystal structure of a representative of the family A receptors, which 
use peptides for activation, has yet to be solved. Therefore much more research needs to be 
performed on a wider range of receptors before GPCR signalling is fully understood. 
1.3.4- Chemokine Receptor Family 
1.3.4.1 - Classification 
Chemokine receptors are seven-transmembrane receptors that represent the family A 
rhodopsin like receptors (Figure 1.10). Currently there are -20 signalling chemokine 
receptors known and their main role in immunity is the recruitment of leukocytes during 
both homeostatic and inflammatory trafficking [155, 156]. Chemokine receptors are 
classified as CC, CXC, CX3C or C depending on the number of residues between the first 
two cysteines of their chemokine ligand, with the exception of C receptor whose chemokine 
ligand only has two cysteines instead of the normal four [156]. Despite a low overall 
sequence homology between chemokine receptors they do contain highly conserved motifs, 
aside from the obvious seven-transmembrane topology; they have two highly conserved 
cysteines in the N-terminal and the putative ECU!, HCCXNP motif in TMVII and the DRY 
motif in cytoplasmic end of TMII. This latter motif has been shown to be very significant for 
chemokine receptor signalling as three identified chemokine receptors without this motif fail 
to signal and termed scavenger receptors [155, 157]. 
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1.3.4.2 - Human Chemokine Receptor 6 
An orphan receptor termed CKR-L3 was discovered from genomic DNA using a 
degenerate PCR strategy [158]. Almost simultaneously STLR22 was discovered from both 
genomic DNA and a tumour-infiltrating lymphocyte cDNA library [159]. These two 
receptors were shown to be almost identical and although neither study could identify the 
ligand involved these receptors did have chemokine receptor characteristics. Identification of 
the ligand became possible later upon discovery of the chemokine now known as CCL20 
(aliases are N'IIP-3(x, LARC, and EXODUS) [99]. In the same year, four different groups 
showed CCL20 had the ability to chemoattract only cells transfected with this orphan 
receptor and its binding induced calcium mobilization characteristic of chemokine signalling 
[157, 160-162]. This was the sixth functional chemokine receptor identified and was hence 
named CCR6. 
The CCR6 gene, also known in the literature as STRL22, CKR-L3, BN-1, DCCR2, 
GPR-CY4, is composed of two exons with a 96 bp intron between the third and fourth 
codons which was not identified in sequences obtained from genomic DNA and is 
uncommon for chemokine receptors [159]. The CCR6 gene was also identified on 
chromosome 6q27, removed from the main CC chemokine receptor cluster [159]. Together 
with the fact that neither CCR6 nor CCL20 can interact in any other chemokine or 
chemokine receptor combination, highlighting CCR6 as an intriguing chemokine receptor. 
CCR6 has many conserved chemokine receptor characteristics including the DRY 
motif, serine/threonine rich C-terminal and four putative extracellular conserved cysteines 
(Figure 1.11). However, little information is known about which residues are important for 
ligand affinity and receptor activation of CCR6. A study mutating all four conserved 
cysteines individually or together to serine highlighted their functional importance. Mutation 
of extracellular loop (ECL) I and II cysteines both together and individually resulted in 
reduced receptor surface expression, whereas N-terminal and ECLIII cysteine mutants had 
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near wild-type receptor surface expression (Figure 1.12) [163]. Interestingly the cysteine 
residues found in ECLI and ECLII are connected via a disulfide bond and it is therefore 
implied that reduced surface expression is due to improper folding resulting in intracellular 
accumulation [163]. Although not necessary for receptor trafficking, mutation of both N-
terminal and ECLIII cysteines did have a negative effect on receptor binding and as a 
consequence their chemotactic activity. However, at higher concentrations, these mutated 
receptors were still able to induce calcium flux indicating that they do not completely lose 
receptor function [163]. The first putative C-terminal cysteine of CCR6 has been proposed to 
enhance the stability of the receptor by post-translational modification of this cysteine with a 
palmitoyl fatty acid chain. Replacement of this cysteine with a serine resulted in both 
impaired surface expression and chemotactic ability but not to the same extent as the 
disulfide bonded cysteines on ECLI and II [163]. 
Further evidence for CCR6 specificity came from a domain swapping approach with 
CCR5. Replacement of the ECLs of CCR6 with CCR5 either individually or together 
resulted in a loss of chemotactic or calcium mobilization ability upon CCL20 stimulation 
despite similar surface expression [164]. Only the chimera CCR6/CCR5-ECLI could 
produce a reduced calcium response but was not chemotactic to CCL20 even at high 
concentrations. Interestingly a chimera was prepared were the mouse N-terminal CCR6 
domain (41% identity compared with the human CCR6) was swapped with the human 
counterpart. This chimera showed no detrimental effects when both receptor expression and 
chemotaxis were tested [164]. Identical sites of interest included the two potential N-terminal 
glycosylation sites, N-terminal cysteine as well as the YY motif shown to be important for 
CCR5 ligand binding [165]. 
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Figure 1.11. Sequence Alignment Showing the Conserved Residues Between Members of the Chemokine Receptor Family. The 
secondary motifs are highlighted with a blue cylinder representing transmembrane (TM) cx-helices. - Identical residues throughout, I -similar 
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CCR6, like most other chemokine receptors, signals through the Ga 1 G protein 
subunit, identified due to its sensitivity to the pertussis toxin [157]. A further indication of 
signalling through the Ga1 pathway came when activation of CCR6 expressing human 
intestinal epithelial cells resulted in inhibition of forskolin-stimulated cAMP production 
[166]. However it is the G13y  subunits that have been implicated in the signalling cascade 
resulting in chemotaxis due to their ability to signal through both phosphatidylinositol 3-
kinase (P13K) and phospholipase C effectors [166]. Early work on CCR6 signalling in 
leukocytes discovered that chemokine activation resulted in increased intracellular Ca 2+  
release which was reduced by a phospholipase C inhibitor (U-73122) [157]. Recently this 
[Ca 2+] increase was also identified in CCR6-expressing intestinal epithelial cells and 
blocking Ca2 release resulted in inhibition of cell migration in a wound assay [167]. This 
same in-depth study of CCR6 signalling also identified other important signalling mediators 
for migration. Both CCL20 and 13-defensin stimulation resulted in the increased production 
of F-actin at the leading edge of the cell which is the driving force for chemotaxis [167]. At 
the tail of a polarised cell, actomyosin complexes can form that contract the cell from 
behind. Ligand stimulation of intestinal epithelial cells activated RhoA; this resulted in Rho-
kinase dependent phosphorylation of myosin light chain that in turn has been shown to 
activate actomyosin contraction [167]. Finally both RhoA activation and subsequent cell 
migration was negated by P13K inhibition [167]. This is unsurprising since P13K signalling, 
like phospholipase C, has been implicated as a major pathway in chemokine receptor 
signalling [168]. This is a very limited review of a multitude of components involved in both 
in vitro and in vivo cell signalling however it does show that both CCL20 and 13-defensins 
have the ability to activate multiple components of these pathways from an extracellular 
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Transmembrane 
Figure 1.12. Ribbon Diagram representing a Theoretical Model of CCR6. CCR6 
predicted structure was downloaded from http://cssb.biology.gatech.edu/skolnick/files/gper  
and ribbon diagrams generated using DS Viewer Pro [169]. Cysteines mutated as part of the 
CCR6 biochemical analyses are shown [164]. Extracellular cysteines are highlighted blue, 
Intracellular cysteines are highlighted yellow and transmembrane cysteines are highlight 
green. Disulfide bond between ECLI and ECLII cysteines is represented by a yellow bond in 
the top view structure (Right panel). 
1.3.4.3 - Tissue and Immune Cell Expression 
A number of studies have explored the tissues where CCR6 expression occurs. 
Northern blot analysis identified CCR6 mRNA transcripts mostly in secondary lymphoid 
tissues, with expression greatest in the spleen, lymph nodes, appendix and fetal liver [58, 
160]. Furthermore CCR6 was shown initially to be expressed in various leukocytes including 
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lymphocytes instigating a role in immune cellular trafficking [158, 160]. However this 
expression pattern was further complicated upon the realization that subtle changes in cell 
maturation status and subtype effected this expression. Due to the low natural abundance of 
DCs, in vitro stimulation of CD34 hematopoietic progenitor cells or monocytes with an 
appropriate cytokine cocktail were used for immature DC expression studies. CCR6 has been 
shown to be expressed in both myeloid and lymphoid derived immature DCs as well as the 
skin-homing Langerhan cells [157, 170, 171]. Upon antigen uptake and their activation, 
iDCs undergo a maturation process which results in the down-regulation of CCR6 mRNA 
and upregulation of other chemokine receptors including CCR7 [172]. 
Both northern blot and RT-PCR analysis found CCR6 to be expressed on CD4 
(Helper) and CD8 (Cytotoxic) T cells as well as CD19 B cells [173, 174]. Surface 
expression of CCR6 on T cells was identified later when FACS analysis identified CCR6 
expression more predominantly on CD4 cells than CD8 cells [174]. The exact subtype of 
these CD4 cells were identified as memory T cells as CCR6 positive cells also expressed 
the memory specific surface marker CD45RO [174]. Interestingly CCR6 expression is not 
restricted to one type of memory T cell. A recent study has shown both TO and the recently 
identified TO 7 memory T cells express CCR6, and have implicated these CCR6 expressing 
T cells in the clearance of both intracellular pathogens and C. albicans [175]. In another 
study, surface expression analysis of CCR6 expressing CD8 cells also identified co 
expressing surface markers of the memory or effector memory subset [176]. These memory 
T cells were also found to express either skin or mucosa homing specific receptors, 
indicating their role in immunity where 13-defensins and CCL20 are highly expressed upon 
pathogenic challenge [174]. With CCR6 also being expressed on mature memory B cells it 
has been proposed that CCR6 ligands direct these cells to the appropriate compartments so 
that they can efficiently interact to link the innate and adaptive immune response. 
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1.3.4.4 - Role of CCR6 in Normal and Diseased Immunity 
The role that human CCR6 performs in immunity has been inferred by using either 
knockout or CCR6-GFP knock-in mice. CCR6 -I- mice do not display any developmental 
abnormalities in any major organ but specialised intestinal lymphoid structures such as 
Peyer's Patches, known to accumulate CCR6 expressing iDCs have been shown to be 
abnormal in size in some cases [177]. However, mice deficient in CCR6 do have differences 
in cellular recruitment under both homeostatic and inflammatory responses. Analysis of 
specific subsets of lymphocytes resulted in differences in concentration under homeostatic 
conditions and a reduced humoral response to both antigen and Rotavirus infection [178]. 
One reason for this defect could be a breakdown in antigen presentation because of defective 
accumulation of CCR6 expressing iDCs. This impaired iDC accumulation in CCR6 -I- mice 
has been identified in the three major areas of 3-defensin or CCL20 expression being the 
lung BAL fluid, skin and intestinal associated Peyer's patches upon activation of the immune 
response [178-180]. In both the skin and Peyer's patches this resulted in a failure to activate 
pathogen-associated T Imphocytes as performed in the wt mice and as such provides direct 
in vivo evidence for a role of CCR6 in adaptive immunity [180, 181]. 
Identification of CCR6-mediated inflammatory diseases has also been inferred from 
CCR6 deficient mice. Chronic Obstructive Pulmonary Disease (COPD) is characterised by 
increased infiltration of DC, neutrophils and T lymphocytes [182]. Comparison of the 
accumulation of these leukocytes in the lungs of CCR6 -I- mice compared to wt upon 
cigarette smoke inhalation resulted in reduced numbers of both iDCs and T lymhocytes 
[183]. These CCR6 -I- mice were more protected against chronic smoke-induced 
emphysema [183]. The role for CCR6 in human COPD has subsequently been shown with 
increased accumulation of both CCL20 and DC in affected patients [182]. In fact as the 
disease gets progressively worse the accumulation of CCR6 expressing DCs increases [182]. 
This is just one of many inflammatory diseases CCR6 has been linked to. Mice deficient in 
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CCR6 have been shown to offer protection against experimental induced sepsis, onset of 
experimental autoimmune encephalomyelitis and allergic pulmonary inflammation [184-
186]. Together these studies indicate the important role that the CCR6 and - 
defensinlCCL2O interaction has in controlling the inflammatory response and the severe 
consequences of its dysfunction. 
1.4 -Overall Aim 
Difficulties in expressing and purifying both 13-defensins and CCR6 have been a 
major bottleneck in the elucidation of their structural-functional relationship. Certain 
intrinsic properties of both 13-defensins and CCR6 are responsible and these problems must 
be circumvented in order for their interaction to be investigated fully. Therefore the major 
aim of this thesis was to optimize the expression and purification of both these difficult 
targets so as to provide a platform for future structural-functional studies. 
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2.1 - Production of Human 3-Defensins 
2.1.1 - Introduction 
Although a number of defensins have been isolated from natural sources, the 
difficulty in obtaining the required amount of tissue or fluid, coupled with the labour-
intensive, low-yielding isolation steps has led to the use of recombinant DNA technology to 
provide material for study. This bottleneck in studying the structure-function activity 
relationships of 3-defensins has been overcome to an extent by the success of large scale 
solid-phase synthesis of both a- and 3- defensins [1-3]. However, it has been discovered that 
due to their innate amphipathic properties defensins often form aggregates resulting in 
formation of both deletion and truncated products. As an alternative, extensive investigation 
into appropriate expression systems has been carried out. Early work centred around utilizing 
both Escherichia co/i (E.coli) and Baculovirus/insect cells as suitable hosts in expression 
systems that have resulted in moderate expression of defensins [4-7]. The problems 
associated with recombinant production are the obvious toxicity of defensins and their low 
expression yields. These problems have been circumvented by using a fusion partner 
expression system. Both soluble fusion expression using thioredoxin and insoluble fusions 
using a portion of the E. co/i tryptophan operon have been successful [8-10]. The former 
strategy has now been used to purify both wild-type (wt) and GFP-labelled HBD2-4 using 
either a batch or a continuous exchange E. coli cell-free system [9, 11, 12]. However this 
purification strategy only obtained moderate concentrations of fusion protein and 
concentrations of cleaved, functional active 3-defensins were never revealed. Furthermore, 
neither the purity nor disulfide bond connectivity were addressed and whether it is possible 
to reduce and chemically oxidize 3-defensins without affecting the functionality of the GFP 
is currently unknown. 
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To produce various defensins suitable for structural and functional analyses 
purification of HBD2 was optimized as part of this study. Prior to the studies discussed in 
this thesis, a codon-optimised, synthetic HBD2 gene had been cloned into the expression 
plasmid pET-3 lb (Helen Fielder, Masters student, Edinburgh University, 2005). However, 
this plasmid contained multiple copies of this gene including a mutated version. Therefore 
this plasmid is unsuitable for subsequent HBD2 mutational studies. Thus, the codon-
optimized l-IBD2 gene was re-designed for expression in E. coli and amplified using 
overlapping primers by recursive PCR. The expression strategy combined a ketosteroid 
isomerase (KS!) fusion and poly-histidine tag. This allowed the protein to be expressed in an 
insoluble form within inclusion bodies and then be isolated using immobilized metal affinity 
chromatography (IMAC). Cost-effective chemical cleavage was achieved using cyanogen 
bromide (CNBr) and the mature peptide was further purified using RP-HPLC. 
Our aim was to isolate purified forms of HBD1, HBD2 and three single disulfide 
H13D2 mutants - each was produced using this procedure allowing routine production of 
defensins for structure-function studies. 
2.1.2 - Synthesis of HBD2 Gene 
Six overlapping primers (see Materials and Methods) with codons optimized for 
expression in E. coli were designed to synthesize the HBD2 gene using a recursive PCR 
reaction [13]. The furthermost 5' and 3' primers coded for the restriction sites A1wNT, used 
for cloning into a linear expression vector pET3 lb thereby utilizing KSI as a fusion partner. 
To separate the mature HBD2 from the KS! fusion in a cost-effective way, a single 
methionine (Met) was engineered in between the 5'AlwNI site and the start of HBD2 gene, 
enabling chemical cleavage using CNBr. Cloning directly into pET-3 lb would have allowed 
us to utilize a C-terminal 6X His-tag. However, due to a C-terminal encoded Met, our 
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released HBD2 would contain a C-terminal homoserine lactone [14]. Therefore a stop codon 
was incorporated upstream of the 6X His-tag. 
Using high fidelity Herculase Hotstart DNA polymerase the recursive PCR 
generated a major band at 147 bp corresponding to the newly engineered HBD2 gene (Figure 
2.1 A). The HBD2 gene was then subjected to a final PCR amplification reaction and 'A' 
overhangs were added to allow ligation into the linear cloning vector pGEM-T easy vector. 
Positive clones were sequenced to confirm the fidelity of the PCR reaction. Sequencing of 
the HBD2 gene revealed a single nucleotide had been mutated in the first position of glycine 
at position 34 (G34S). Consequently, megaprimer mutagenesis was undertaken to correct the 
mutation. 








1 CAGGCGCTCATGGGTATCGGTGACCCGGTTACCTGCCTGAAATCCGGTGCTATCTGCCAC 60 
GTCCGCGACTACCCATAGCCACTGGGCCAATGGACGGACTTTAGGCCACGATAGACGGTG 
ProVal PheCys ProArgArgTyrLysGlnl leGlyThrCysGlyLeuProGlyThrLys 
61 CCGGTTTTCTGTCCGCGTCGTTACAAACAGATCGGTACCTGCGGTCTGCCGGGTACCAAA 120 
GGCCAAAAGACAGGCGCAGCAATGTTTGTCTAGCCATGGACGCCAGACGGCCCATGGTTT 
CysCysLysLysPro* * * A1wNI 
121 TGCTGCAAAAAACCGTGACAGATGCTG 147 
ACGACGTTTTTTGGCACTGTCTACGAC 
Figure 2.1. Cloning of Codon-Optimized Synthetic HBD2. (A) Synthesis of optimised 
HBD2 gene by recursive PCR. Lane M, 1 kb DNA Hyperladder I (Bioline); lane 1, recursive 
HBD2 PCR product, The band indicated by an arrow is synthesised 147 bp codon-optimised 
HBD2 gene. (B) Sequence of synthetic, codon-optimized HBD2 gene (147 bp) after 
mutational correction, 5' and 3' AIwNI restriction sites (yellow) allowed cloning into plasmid 
pET-31b and expression of HBD2 as a KSI-HBD2 fusion, The engineered Met (cyan) and 
stop (***) codons are indicated. 
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2.1.3 - Construction of the Expression Plasmid using Megaprimer 
M utagenesis 
Removal of the PCR-induced mutation in the gene-synthesized HBD2 gene was 
performed using the megaprimer mutagenesis method [15]. The first PCR reaction is 
responsible for the synthesis of the mega primer and involves the mutagenic primer and the 
plasmid specific primer on the complementary strand. This is subsequently used in a second 
PCR along with the opposite plasmid specific primer to the one used in the first reaction. 
Using pGEMII-IBD2 (G34S) as the template, the mutagenic primer (S34G primer 
For) and plasmid specific primer (pGEM Rev Mutagenesis) were used to synthesize the 
megaprimer, now incorporating the corrected nucleotide. A second PCR reaction including 
the megaprimer and plasmid specific primer (pGEM For Mutagenesis) generated the full 
length HBD2 gene still including the 5' and 3' A1wNI restriction sites. As before, this gene 
was cloned into pGEM and verified by DNA sequencing (Figure 2.1 B). 
A1wNI restriction digested HBD2 was cloned into the expression plasmid pET3 lb. 
Furthermore, to replace the 6X His tag lost by inserting a stop codon, KSI-HBD2 fusion 
gene was cloned into the expression plasmid pET28a via NcoI and XhoI restriction sites. 
Thus, a 6X His tag was engineered upstream of the KSI gene producing a HISKSI-14BD2 
fusion gene (Figure 2.2). 
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AIwNI 	AIwNI 














HIBD2 	i)(s P 
Figure 2.2. Schematic Representation of the Construction of the Expression Plasmid. 
This fusion gene was then subjected to two site-directed mutagenesis steps. Both the 
5' Ndel site and 3 A1wNI site flanking the fusion gene contain an ATG Met codon that will 
reduce the efficiency of CNBr cleavage. Therefore using megaprimer mutagenesis as before, 
Met was replaced with Alanine (Ala), removing the NdeI site but leaving the A1wNI 
restriction site intact for cloning different defensin genes (Figure 2.3 A). 
The final expression plasmid pET28aJHISKSI-HBD2 was used for all further studies 
on I-IBD2 (Figure 2.3 B). 
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A 
1 MGSSHHHHHH SSGLVPRGSH AHTPEHITAV VQRFVAALNA GDLDGIVALF 
51 ADDATVEDPV GSEPRSGTAP IREFYANSLK LPLAVELTQE VRAVNEAAF 
101 AFTVSFEYQG RKTVVAPIDH FRFNGAGKVV SIRALFGEKN IHACQALMGI 
151 GDPVTCLKSG AICHPVFCPR RYKQIGTCGL PGTKCCKKP 
B 
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Figure 2.3. HISKSI-HBD2 Fusion Gene. (A) Sequence of HISKSI-HBD2 fusion gene (189 
AA). Mature HBD2 peptide highlighted in bold. Met-Ala mutations in KSI (M1A and M126A) 
are underlined. (B) Schematic representation of expression vector pET28a HISKSI-HBD2. 
2.1.4 - Over Expression of HBD2 Fusion Protein in E.coli 
The ability of pET28aJHISKSI-HBD2 to express the fusion protein at high levels in 
E. coil was tested in the E. co/i host strain 131_21 (DE3) on a small scale (10 ml LB). 
Transformed E. co/i was either induced with 1 mM IPTG or left to replicate un-induced for 6 
hours. Protein analysis by SDS-PAGE clearly showed an induced protein band 
corresponding to a mass of-23 kDa (Figure 2.4) indicating the fusion protein had been over 
expressed. Due to the high expression level of the induced protein band no further 
optimization of expression conditions were necessary. Therefore large scale expression 
studies were carried out to produce large quantities of fusion protein. Typically, six litre 
cultures produced large, creamy white cell pellets (.-12 g) indicative of overexpression of 
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fusion proteins. Cell pellets were either stored at -20 °C until needed or lysed to isolate the 
fusion protein. 










Figure 2.4. Expression of HISKSI-HBD2. 12% Bis-Tris acrylamide gel analysis before and 
after induction with IPTG. Lane M, SeeBlue 2 protein marker (Invitrogen); lane 1, total crude 
lysate before induction; lane 2, insoluble fraction after induction. The band indicated by arrow 
is expected mass of HISKSI-HBD2. 
2.1.5 - Purification of Recombinant HBD2 Fusion Protein 
Accumulation of insoluble HISKSI-HBD2 as inclusion bodies allowed 
centrifugation to be used as a purification step. The resuspended cell pellet was subjected to 
enzymatic, chemical and physical cell wall disruption before the pelleted inclusion bodies 
were resuspended in denaturing Ni 2 -NTA binding buffer. Single step IMAC purification 
using nickel resin yielded a highly pure fusion protein. 
2.1.6 - CNBr Cleavage of Recombinant HBD2 Fusion Protein 
Efficient cleavage of the mature recombinant HBD2 (rHBD2) from its hydrophobic 
fusion partner requires an appropriate reaction buffer. The isolated fusion protein was either 
dissolved in 70% formic acid or dissolved in acidified 6 M Guanidine HCI, 25 mM Tris-HCI 
reN 
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buffer and the efficiency of cleavage was investigated. Recently it has been shown that 70% 
TFA cleavage efficiency is low for amphipathic peptides and was thus not tested [16]. 
Complete CNBr cleavage was observed in 18-22 hrs in both reaction mixtures. An advantage 
of using 70% formic acid is that excess water and excess CNBr can be removed by rotor 
evaporation and lyophilization. Mature rHBD2 was then extracted from the fusion mixture 
using 0.01% acetic acid and analysed by ESI-MS. Unfortunately mass spectrometric analysis 
showed evidence for the presence of mono- and bis-formylated peaks, in addition to the 
expected in/z peaks for HBD2 (Appendix Al). Although formylation was partially reversed 
by hydrolysis under basic conditions, due to the lowering of the overall yield using these 
steps, 6 M GdnHCI was used for all future purifications. Again unreactive CNBr and 
hydrogen cyanide, which are by-products in the presence of HCI, were removed by rotor 
evaporation. Taking advantage of the inherent insolubility of KS!, dialysis against a slightly 
basic reducing buffer caused the cleaved KSI to form a precipitate negating the need for a 
chromatography step. Centrifugation allowed the cleaved, soluble, mature, rHBD2 to be 
separated from its fusion partner and analysis by SDS-PAGE showed the majority of HBD2 
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Figure 2.5. CNBr Chemical Cleavage of HBD2 Fusion Protein. 12% Bis-Tris acrylamide 
gel analysis of HISKSI-HBD2. Lane M, SeeBlue 2 protein marker (Invitrogen); lane 1, 
insoluble HISKSI-HBD2 before chemical cleavage; lane 2, soluble fraction after chemical 
cleavage. The band indicated by the arrow is the expected mass of mature rHBD2. 
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2.1.7 - Purification and Oxidation of Mature Recombinant HBD2 
The original purification of reduced rI-IBD2 was carried out using a reverse phase 
Poros column attached directly to an AKTA Purifier. Unfortunately the peptide isolated from 
this step was not of high enough purity to allow for oxidative refolding to the three disulfide 
bond-containing form. Therefore subsequent purifications utilized a semi-preparative RP -
HPLC strategy to purify both reduced and oxidized HBD2 to homogeneity. 
A necessary step in production of both synthetic and recombinant defensins is the 
correct refolding of the peptide. Although the correct folding is problematic for defensins, 
there are established methods including DMSO oxidation and using redox partners [1, 3, 17]. 
To optimize refolding, small scale refolding experiments were performed on lyophilized 
reduced peptide under the following reaction conditions: (1) DMSO oxidation; (2) redox 
reagents GSH and GSSH; (3) cysteine and cystine in presence or absence of a denaturing 
agent (Figure 2.6). DMSO oxidation led to extensive precipitation of the peptide and 
subsequently only a low yield of oxidized HBD2 was recovered. Denaturing agent GdnHCl 
has been shown to assist in the oxidation process [3]. However using the redox pair 
cysteine/cystine under both denaturing and non denaturing conditions, the latter was found to 
be more efficient at producing oxidized HBD2. This is in agreement with Chino et al. who 
when optimizing the oxidation of HBD1-4 found GndHCI actually interfered with the 
folding process [17]. GSHIGSSH at a ratio of 1:100:10 (peptide:GSH:GSSG) was found to 
be as efficient as cysteine/cystine however due to the significant extra cost of glutathione the 
latter was chosen for all large scale oxidation reactions. 
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Figure 2.6. Oxidation Efficiency of HBD2 Analyzed by RP-HPLC. Reduced and oxidized 
HBD2 peaks labelled with * and respectively. 
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2.1.8 - Characterization of Oxidized Recombinant HBD2 
Although there was clearly a shift to a longer retention time for oxidized I-IBD2 
compared to the reduced form as previously described [3], an accurate mass of oxidized 
HBD2 was required to show all three disulfide bonds had formed. Using the HBD2 empirical 
formula (oxidized HBD2, C 188H305N55050S6; reduced HBD2, C 188H311N55050S6) the intensity 
and isotopic distribution can be predicted for both oxidized and reduced forms (Figure 2.7). 
High resolution FT-ICR mass spectrometry analysis of the [M+4H] 4 charge state clearly 
shows the isotopic distribution and masses fit extremely well to that for oxidized HBD2. 
£ 
1080 	 1083 	 1086 
m/z 
Figure 2.7. FT-ICR Isotopic Envelope of Oxidized rHBD2. Isotopic envelope of the 
[M+4H]4 charge state of oxidized rHBD2. Triangles represent the isotopic distribution 
expected for oxidized HBD2. Circles represent the isotopic distribution expected for reduced 
H BD2. 
The crystal structure of HIBD2 implicated the potential for HBD2 to form oligomeric 
structures [18]. Neither dimeric nor higher order oligomeric charge states were observed by 
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FT-ICR analysis, indicating I-IBD2 is in a monomeric state under these conditions (Appendix 
A2). This conclusion was supported by results from native gel electrophoresis analysis where 
both the reduced and oxidized forms of HBD2 migrated at the same monomeric mass as seen 
previously (Figure 2.8) [19]. 




Figure 2.8. Native Gel Analysis of Monomeric HBD2. 16% Tricine gel analysis of HBD2. 
Lane M, SeeBlue 2 protein marker (Invitrogen); lane 1, HBD2 reduced; lane 2, HBD2 
oxidized. 
Before functional analysis, the disulfide bond connectivity and folded state were 
analyzed. Using one dimensional (ID) 'H NMR spectroscopy, it was observed that rHBD2 
displayed well dispersed chemical shifts in the amide region as compared to the unstructured 
Defb14 [20], suggesting the presence of secondary structures in the folded defensin. 
Although characterization of the disulfide connectivity for natural, isolated HBD2 was never 
carried out it is assumed that HBD2 possess the 3-defensin disulfide connectivity Cysi-
Cys5, Cys2-Cys4, Cys3-Cys6 based on studies with synthetic material [3, 18]. Along with 
the refolding process, determination of the correct disulfide connectivity is the most 
technically difficult step in production of active 3-defensins. Since residues Cys5 and Cys6 
are consecutive in the linear sequence, trypsinlchymotrypsin digest alone can not decipher 
between a disulfide bond connectivity linked to Cys5 or to Cys6. There are two methods 
used after enzymatic digest: (1) Edman degradation; (2) Collision-induced dissociation 
(CID). Using a synthetic biotinylated HBD2 (BioHBD2) as a test peptide. 
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trypsinlchymotrypsin digest yielded two major peptide fragments (Table 2.1). The first 
peptide fragment represented the peptide connected by the Cys2-Cys4 disulfide bond found 
in both a and 13-defensins. The second peptide fragment contained two disulfide bonds with 
unknown connectivity. Separating these two fragments was achieved using LC-MS and on-
line CID, using argon gas, was applied to the second fragment. A parent ion was fragmented 
by collision with the inert gas and fragment ions were analyzed. Unfortunately, although N-
terminal sequencing was achieved, the fragment ion that we hoped to observe to enable us to 
decipher between the a— and 13—  connectivites could not be found. In parallel work carried 
out by Dr Emily Seo, Edman degradation was performed on the HPLC purified second 
fragment of the rHBD2. Phenylisothiocyanate reacted with uncharged N-terminal amino 
group of Cys5 to yield a final phenylthiohydantoin (PTH) Cys derivative which formed a 
disulfide bound with the Cysi fragment and this was identified by mass spectrometry (Table 
2.1). 
Therefore the conclusion from these combined analyses was that the rHBD2 has the 
13-defensin disulfide pairings Cysl-Cys5, Cys2-Cys4, Cys3-Cys6. 
Me 
Chapter 2: Purification and Functional Characterization of Human -defensins 







[SGAIC2HPVF] [QIGTC4GIPGTK] 2002.4 2002.5 
[GIGDPVTC'L] [C3PR] {C 5C6KIa 1823.0 1823.5 
Expected fragments from rHBD2 
trypsin/chymotrypsin digest 
[SGAIC2HPVF] [QIGTC GIPGTK] 2002.4 2002.5 
[GIGDPVTC'L] [C3 PR][C5 C6K]t 1596.1 1596.4 
Expected fragments from Collision Induced 
Dissociation  
[PVTC'L] [C3  PR]  [CIC6  K] 9 1255.9 1254.8 
[VTC'L] [C3PR] [C5C6K] ® 1158.5 1157.7 
[TC 1 L] [C3PR] [C 5 C6K] 1059.3 1058.7 
[C 1 L] {C3 PR] [C5CoK]e 958.2 957.6 
[GIGD] 6 569.2 569.5 
[GIG]" 454.2 4545 
[GI]' 397.2 397.4 
[G]6 284.1 284.2 




[IGDPVTC1L] 	[C6 K] 1065.0 Not observed 
Table 2.1. Analysis of Disulfide Connectivity using CID and Edman Degradation. 
a [M+3H]3 charge state of[GIGDPVTC 1 L] [C3 PR] [C C6K] (mlz 608.46) was subjected to 
CID. 
b [GIGDPVTC1L] [C3  PR][C5C6 K] was subjected to Edman Degradation. 
® y ions 
A b ions 
[G] Biotin modified Glycine (+226.3 Da) 
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2.1.9 - Antimicrobial Activity 
13-defensins role in innate immunity involves the direct killing of invading 
pathogens. To test rHBD2 for this activity in vitro, an antimicrobial assay was performed 
using a method published previously by our group that was based on a procedure used by 
Prof. Bob Hancock and coworkers [21]. A wide range of microbes were tested incorporating 
Gram-negative bacteria, Gram-positive bacteria and fungal species. In brief, varying 
concentrations of rHBD2 were incubated with the test organism and the surviving organisms 
were allowed to grow on nutrient agar. The concentrations of peptide required to kill 50%, 
90% and 99.99% (LD50, LD90 and MBC99.99 respectively) were calculated and compared 
to a control solution containing no peptide (Table 2.2). 
ORGANISM STRAIN SOURCE MBCAIMICB LD90C LD50D 
Gram-negative 
E. coil MG1655 Thesis 
<20A 1.5-3.0 <1.5 
ML-35 24 17B  
Unspecified 23  —10 
ML-35p 22  4.25-12.25 
F 
P. aeruginosa PAO1 Thesis 
<25A 1.5-3.0 <1.5 
ATCC 27853 24 
 
Unspecified 23  —10  
ATCC 9027 22  4.25-12.25
F 
Gram-positive 
S. aureus ATCC 25923 Thesis >50 
A 12.5-25 1.5-3.0 
710A 24 
3570B  
Unspecified 23 100 
E 
ATCC 6341 22 N.DE  
Yeast _____  
C. aibicans J2922 Thesis 
>50A 3.0-6.0 1.5-3.0 
Unspecified 24 70 B 
Unspecified 23 1 25  
820 22 1 1 	4.25-12.25 
F 
Table 2.2. Antimicrobial Activity of Oxidized rHBD2 Against a Panel of Micro-
organisms. All values stated are in ig/ml. 
A MBC values are the minimum concentration required to kill 99.99% of initial inoculum. 
B MIC values are the lowest concentration required to inhibit microbial growth. 
C LD90 values are the minimum concentration required to kill 90% of initial inoculum. 
D LD50 values are the minimum concentration required to kill 50% of initial inoculum. 
E Bacteriostatic Effect 
F Bactericidal Effect 
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We found that rHBD2 exhibited MIBCs against the Gram-negative bacteria E. co/i 
and P. aeruginosa at <20 and <25 p.g/ml respectively. rHBD2 displayed antifungal activity 
with an LD90 in the range 6-12.5 .tgIml, however the peptide is clearly not as potent an 
antimicrobial peptide against Gram-positive S. aureus. Direct comparison of the 
antimicrobial values found for our HBD2 preparation and previous literature values are 
difficult. Firstly, there is more than one type of antimicrobial assay being performed 
including radial diffusion assay and microbroth dilution assays making direct comparisons 
impossible [22, 23]. Even when the same method is used variations in micro-organism 
strains can have an effect on the concentration of peptide needed to kill efficiently (Table 
2.2). However analysis of the literature values does reveal a trend that indicates that our 
rHBD2's antimicrobial specificity is similar to that of natural purified HBD2. Comparison of 
four separate studies, including this thesis, clearly identifies HBD2 as being a more potent 
antimicrobial agent against Gram-negative bacteria and C.albicans than against Gram-
positive S.aureus [22-24]. Therefore in conclusion it was shown that the purification process 
has had no detrimental effects on rHBD2 antimicrobial properties. 
2.1.10 - Chemotactic Activity 
Another important role for 3-defensins is the recruitment of cells involved in 
adaptive immunity to sites of infection via the chemokine receptor CCR6. Yang et al. were 
the first to show that both 1-IBD 1 and HBD2 were able to chemoattract immature dendritic, 
memory T cells and CCR6 transfected HEK293 cells [25]. Since this finding, CCR6 has 
been shown to be a promiscuous GPCR with various human and mouse 3-defensins been 
shown to activate this receptor including certain linear analogues of these peptides [3, 20]. 
Using a previously published method, in collaboration with Julia Dorin, rHBD2 
chemotactic activity was analysed using CCR6 transfected HEK293 cells and was found to 
chemoattract in a concentration dependent way with an optimal concentration of 100 ng/ml 
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(Figure 2.9). This is in good agreement with the optimal concentrations of 100 ng/ml and 
1000 ng/mI for the natural CCR6 chemokine CCL20 (M[P-3(x) and HBD2 respectively that 
were published previously [25]. The chemotaxis assay depends on the concentration 
dependent movement of CCR6 expressing cells to the under surface of a collagen coated 
polycarbonate filter. Any assay involving growing, living cells is difficult to reproduce 
because of differing surface expression of the ligand inducing functional receptor and each 
cells differing ability to bind to the filter. Therefore each peptide concentration was tested in 
triplicates in three separate experiments meaning a total of nine data points were collected 
for each peptide concentration. Each assay performed must also be carried out with both 
positive and negative control peptides to access the assays viability. To prove the results are 
statistically relevant a paired, two-tailed, student's t test must be carried out comparing the 
results to the number of cells migrated by media alone. 
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Figure 2.9. Chemotaxic Activities of Oxidized rHBD2 of CCR6 Transfected HEK293 
cells. Migration by CCL20/N4IP-3ct (light purple) and HBD3 IC (yellow) were positive 
controls, DEFBI4aIa (dark purple) was negative control. The numerical data (number of 
cells per high power field) was recorded as an average of three separate experiments in 
triplicate and error bars indicate the Standard Error (SE). Statistical significance (p<0.05) is 
indicated with a * as compared to the number of cells per HPF of culture media alone. 
2.1.11 - Purification of Oxidized HBDI 
Having prepared the rHBD2 by our new method we wanted to also apply it to the 
production of another defensin and the 'housekeeping' 3-defensin HBDI was chosen as a 
target. The HBDI gene was synthesized in a similar manner as to that described for HBD2 
with AIwNI sites flanking both the 5' and 3'ends of the gene. However, upon restriction 
analysis of the pET/HISKSI-HBD2 plasmid it was found that replacing the Met codon with 
an Ala codon in the A1wNI recognition site resulted in a Dcm methylase recognition site, 
resulting in blocking the cleavage site for the restriction enzyme [26]. Despite efforts to 
transform the methylase mutant E. co/i K 12 strain (ER2925) which is both Dcm and Dam. 
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HBD2 gene could still not be isolated from the expressing plasmid. Therefore a fusion gene 
incorporating both KSI and HBDI was purchased from Codon devices replacing the 
upstream A1wNT site with a HindlII restriction site. This change allowed all future defensin 
genes synthesized with flanking upstream HindIII and downstream A1wNT restrictions sites 
to be cloned into the pET28A expression plasmid. The expressing plasmid pET28a RISKS!-
HBD1 was used to transform E. coli BL21 (DE3) cells and large scale purification was 
carried out. Purification of HBD1 was performed essentially as described for HBD2. One 
step Ni2tNTA chromatography was applied to isolate the HBD1 fusion protein prior to 
CNBr chemical cleavage in acidified 6 M GndHCl buffer. RP-HPLC was applied to isolate 
highly pure reduced rHBD1 before chemical oxidation using the cysteine/cystine redox pair 
in Tris-UCI buffer was performed. Following RP-HPLC purification of oxidized rHBDI, 
SDS-PAGE analysis clearly identifies a highly pure single band with the correct mass for 
oxidized rHBD1 (Figure 2.10). Furthermore, ESI-MS analysis revealed HBD1 had a 
deconvoluted mass of 3928.27 Da (theoretical mass 3928.56 Da) suggesting the presence of 
only oxidized 1-IBD1 containing three disulfide bonds (Figure 2.11). 
We did not carry out a full antimicrobial or chemotactic analysis of the rHBDI 
because a paper was published which investigated >20 HBDI site-directed mutants [27]. 
Instead the purified rHBD1 was gifted to Dr E. Seo within the group for structural studies 
with N 15 labelled HBD2. Here, we wished to identify any possible interaction between 
HBD1 and HBD2 using NMR (E. Seo, personal communication). 
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Figure 2.10. Purification of rHBDI. 12% Bis-Tris acrylamide gel analysis of rHBD1. Lane 
M, SeeBlue 2 protein marker (Invitrogen); lane 1 soluble rHBD1; lane 2, soluble rHBD2 The 
band indicated by arrow is expected mass of mature rHBD1. 
+5 
mlz 
Figure 2.11. rHBD1 Analysis by ESI-MS. The spectrum shows the +4 to +6 charge 
states for HBDI. Inset, deconvoluted data resulting in a mass of 3928.27 ±0.8 Da 
(theoretical mass 3928.56 Da). 
2.2 - Single Disulfide Bond Mutants of HBD2 
2.2.1 - Introduction 
Despite recent improvements in the production of defensins, in-depth 
structure/function relationships of specific peptides are lacking. Investigations have focused 
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mainly on the antimicrobial function of defensins, with chemotactic effects mostly ignored. 
Our collaborators, along with various other groups, have focused on HBD3 or its mouse 
ortholog Defb14 [3, 28, 29]. Disulfide connectivity, peptide length and charge have all been 
investigated with respect to its antimicrobial activity. Linearized HBD3, achieved by 
cysteine amino acid replacement or by carboxyaminomethyl derivitization, was found to be 
as potent as oxidized HBD3 containing three disulfide bonds [3]. Therefore the antimicrobial 
potency of a defensin (and AMPs in general) appears to be dependent on a combination of 
hydrophobicity and charge rather than the spatial arrangement of the charged and/or 
hydrophobic residues imposed by the disulfide bonded framework. This amphipathic nature 
of antimicrobial peptides has been used as a template to design novel "unnatural" peptides 
with potent activity [30]. 
However there is evidence that some defensins do require their structurally-
constrained motifs to maintain their antimicrobial potency. For example, linear HBD2, in 
artificial lipid vesicle permeabilization experiments, was ineffective at releasing the 
intracellular marker when compared to the oxidized HBD2 indicating that disulfide bonds 
are indeed needed [18]. Addition of only a single disulfide bond between the third and sixth 
disulfide bond in a N-terminal truncated HBD2 did display antimicrobial activity against 
Gram-negative microbes, implicating a structurally restrained 3-strand motif as playing an 
important role [31]. Although this conclusion was strengthened by the loss of antimicrobial 
activity upon deletion of this motif, a second structural motif, an N-terminal a-helix has also 
been implicated. Removal of the (x-helix stabilizing Asp4 reduced the efficiency of (-
D)HBD2 in permeabilizing E. co/i cytoplasmic membranes [24, 32]. 
The role played by the structural constraint imparted by the conserved defensin 
disulfide motif is even less well understood with respect to chemotactic activity. However, it 
is not surprising that specific structural motifs are required for a peptide to be an active 
chemokine since this process requires a specific receptor/peptide ligand interaction. Using 
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solid phase peptide synthesis, coupled with an elegant orthogonal cysteine protection 
strategy, Wu et al. prepared a series of six I-IBD3 isoforms of known disulfide bond 
connectivity. Each isoform was tested for antimicrobial and chemotactic activity and a 
control, linear peptide was also prepared where each the of six cysteines were replaced with 
a-aminobutyric acid (abu) [3]. It was found that the six defensins with disulfide bonds and 
the abu-FI1BD3 were potent antimicrobial peptides but the chemotactic activity varied, with 
the cysteine-free peptide being inactive. Although this study appeared to confirm the 
essential nature of the disulfide bonds for a defensin to display chemotactic activity, a recent 
paper has challenged this view. Taylor et al. showed that not only does a linear HBD3 
peptide with iodoacetamide treated cysteines display chemotactic activity but also a linear 
HIBD3 peptide were the cysteines are replaced with alanines except for a single cysteine 
residue at position five (FIIBD3-lcys 5) [20]. This latter peptide was shown to form a covalent 
dimer upon DMSO oxidation, however treatment of the free cysteine with iodoacetamide 
failed to inhibit this chemotactic ability revealing that dimerization is not essential for this 
activity. Furthermore neither a N-terminal truncated version of I{BD3-lcys 5 nor a }{BD3 
peptide with only a single cysteine at position one (HBD3-lcys') could display chemotactic 
activity [20]. Together this implies that HBD3 chemotactic ability is not dependent on the 
disulfide bonded structural framework imposing a certain spatial arrangement but rather on 
individual residues throughout the sequence that include the cysteine at position five. In the 
study of 26 site-directed mutants of HBD 1, non cysteine residues were evaluated to discover 
the important residues for both antimicrobial and chemotactic activity [27]. Using charge 
swapping or neutralization mutations, C-terminal cationic residues were shown to be 
important for antimicrobial activity as previously seen with other defensins. Chemotactic 
data indicated that the N-terminal a-helix was important, as was hypothesized from 
structural comparisons between CCL20 and HBD2 [33]. This binding epitope was also 
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extended to include three residues (Lys22, Arg29, Lys33) which are spread out along the 
length of the peptide but are only adjacent in the folded 13-defensin isoform ofHBD1. 
Although the pET28/HISKSI-HBD2 plasmid was ideal for a similar mutagenesis 
study on HBD2s structure-function activity, the conflicting results obtained with regard to 
the importance of disulfide bonds, especially with respect to chemotactic activity, 
highlighted the need for further investigation. Furthermore it was our groups understanding 
that a similar study on HBD2 had already been performed and was awaiting publication 
(personal communication). Therefore using the method optimized for rHBD2, three HBD2 
mutants were prepared and purified with each containing a single, canonical disulfide bond 
with the other four cysteine residues replaced with alanines (HBD2 1-5, HBD2 2-4 and 
HBD2 3-6, Figure 2.12). The structure of each mutant was analyzed using 1D 1 1-1 NMR and 
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1 	 43 
HBD2 0 GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP 
HBD2 1-5 0 GIGDPVTcLKsGAI; HPVF-PRRYKQIGT.GLPGTKC KKP-- 
HBD2 2-4 0 GIGDFVTLKSGAICHPVFJPRRYKQIGTCGLPGTK •.KKP-- 
HBD2 3-6 0 GIGDPVTLKSGAI.HPVFCPRRYKQIGT/GLPGTKCKKP 
HBD2 (-d) 28,29 GIG-PVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP 
I-iBD2 5-41 	29 ---- PVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP - 
HBD2 (-N) 27 -------- ---------- FCPRRYKQIGTG-LPGTKCK----- 
HBD2 BREVI 29 GIGDPVTCLKSG ------------------- LPGTKCRRKKP 
A 
B 
13-strand 	 a-helix 
/ 
HBD2 
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Figure 2.12. Single Disulfide Bond HBD2 Mutants. (A) Sequence Alignment of wt HBD2 
and Mutated Peptides. ° indicates peptides purified as part of this study. (B) Ribbon 
Diagrams Representing the 3D Structure of HBD2 with each Individual Disulfide Bonds 
Indicated. Structure was downloaded from the protein data bank; HBD2: 1 FD4. Structural 
motifs are labelled and the disulfide bonds are indicated in yellow. 
2.2.2 - Construction and Purification of Single Disulfide Mutants 
Single disulfide mutant genes were synthesized using the same procedure as 
described for rHBD2 except for the replacement of A1wNI restriction site at the 5' end of the 
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gene for a HindlIl restriction site. Mutant genes were then cloned into the expression 
plasmid using the restriction sites HindIlI and XhoI (pET28aIHISKSI-HBD2 1-5, 2-4, and 3-
6) (Figure 2.13). Following the same purification procedure as with both HBDI and HBD2, 
the three separate HBD2 mutants were over-expressed and reduced HBD2 mutants were 
purified using RP-HPLC after CNBr cleavage of the fusion protein. 
Iii (55"4) 
HISKSI.H8D214 	 HISxSl.H9022-4 
Kan 	 Kan 	 Kan 
pET28A/HISKS1-F(6D2/1-5 	 pET28a/FIISKSI-H602/2-4 	 2ET28A/HISKSI-IIBD2J 3-6 
5800 bp 	 5800 hp 
	 5800 bp 
Lad L-- 	 LacL 	 Lad. 
'1 
Figure 2.13. Schematic Representations of the Expression Vectors pET28a/HISKSI-
HBD2/1-5, 2-4, and 3-6. 
Single disulfide bond mutant 3-defensins have been shown to oxidize efficiently in 
20% DMSO [31]. Therefore instead of using the redox pairs (e.g. cysteine/cystine) as with 
HBD2 and HBDI, the HBD2 mutants were oxidized using 20% DMSO and the reaction was 
monitored by LC-ESI-MS. Oxidized HBD2 mutants were purified again using RP-HPLC 
(Figure 2.14). Interestingly, from the UV trace the retention time for all three mutants was 
less than that for wt I-IBD2 (l-IBD2 1-5, 26 mm; HBD2 2-4, 31 mm; HBD2 3-6, 27 mm; 
HBD2 38 nun). This could be due to the hydrophobicity of the alanines replacing the normal 
cysteines. However this can not explain the differences between the retention times for 
HBD2 2-4 compared to the other two mutants (HBD2 1-5 and HBD2 3-6), — 3-4 minutes, 
which all have the same charge and hydrophobic residues. This suggests that the HBD2 2-4 
mutant has a different structure than the other two peptides and a possible explanation could 
be that the folded conformation of HBD2 2-4 may have more hydrophobic residues exposed 
to the surface. 
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Oxd. HBD2 Cys 3-6 
Oxd. HBD2Cys2-4 
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Oxd. HBD2 Cys 1-5 
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Time (mm) 
Figure 2.14. HPLC Analysis of Oxidized HBD2 and its Single Disulfide Bond Mutants. 
Using SDS-PAGE analysis all three HBD2 mutants were shown to be pure and 
migrated with a mass of —4 kDa in comparison to wt HBD2 (Figure 2.15). Due to their 
identical masses, trypsin digestion was performed on the oxidized HBD2 single disulfide 
bond mutants and analyzed by LC-ESI-MS. The peptide fragments identified were unique to 
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each individual peptide and corresponded to their predicted trypsin fragment masses (Table 
2.3) 




Figure 2.15. Purification of Oxidized HBD2 and its Single Disulfide Bond Mutants. 12% 
Bis-Tris acrylamide gel analysis of oxidized HBD2 and its single disulfide mutants. Lane M, 
SeeBlue 2 protein marker (Invitrogen); lane 1, purified oxidized HBD2; lane 2, purified 
oxidized HBD2 1-5; lane 3, purified oxidized HBD2 2-4; lane 4, purified oxidized HBD2 3-6. 
PEPTIDE TRYPTIC FRAGMENTS EXPECTED OBSERVED 
MASS (DA) MASS (DA) 
HBD2 




1-5 1222.4 ±_3.89 
HBD2 
[SGAIC 2 IHIPVFAPR] [QIGTC4GLPGTK] 2326.19 
2-4 2326.8 ±_0.48 
HBD2 
[GIGDPVTALK] 969.92 
2-4 970.1 ± 0.14 
HBD2 
[SGAIAHPVFCPR1 [A 	K] 1572.9 Not observed 
3-6 
HBD2 [GIGDPVTALK] 970.1 970.34 
3-6 ± 0.45 
HBD2 [QIGTAGLPGTK] 1041.77 
3-6 1042.2 ±1.08 
Table 2.3. Protease Digestion and Peptide Analysis by Electrospray Mass 
Spectrometry. Oxidized HBD2 single disulfide bond mutants were digested with trypsin and 
identified peptides are shown. Expected masses from a tryptic derived digest were compiled 
using PAWS software. 
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2.2.3 - Characterization of HBD2 Mutants 
The oxidization and oligomeric state were analysed using high resolution FT-ICR 
mass spectrometry. Due to the small mass difference between the reduced (C 1881-1 31 1 N55050S 29  
Avg. mass 4206.01 Da) and oxidized state (C 188H309N55050S 2 , Avg. mass 4204.00 Da), high 
resolution mass spectrornetry as needed to confirm the extent and efficiency of the 
oxidization reaction. Clearly, in all three cases, the HBD2 mutants had been converted into 
the oxidized form (Figure 2.16). A second observation from the ion envelopes was a lack of 
dimerization or higher order oligmerization, suggesting that each peptide contained a single 




06' 	 , • 	HBD2 
I 	HBD2 	 S 	 2-4 1-5 04 .  
02 	H 02 S 




1050 	 JC5i 	 1052 	 1053 	1054 	 10151 	1052 	1053 	1054 







1050 	 051 	 1052 	 Cs. -3 	 1054 
Figure 2.16. FT-ICR Isotopic Envelope of Oxidized HBD2 Single Disulfide Bond 
Mutants. Isotopic envelope of the [M+4H] 4 charge state of oxidized HBD2 mutants. Green 
circles represent the isotopic distribution expected for oxidized HBD2 mutants. Red circles 
represent the isotopic distribution expected for reduced HBD2 mutants. 
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ID 'H 600 MHz NMR was used to compare the structure of the HBD2 mutants to 
that of the wt HBD2. The wt HBD2 has highly resolved, well dispersed resonances in the 
amide region indicating a folded state. Resolution of I-IBD2 mutants are not as well dispersed 
indicating a less structured peptide (Figure 2.17). Based on the resonances resolution both 
HBD2 1-5 and 2-4 are slightly more structured compared to HBD2 3-6. This could be a 
consequence of the different secondary structural elements imposed by each disulfide bond. 
Analysis of both the crystal and solution structures of wt 14BD2 (PDB accession no: IE4Q, 
1FQQ, 1FD4) revealed that the N-terminal cc-helix is connected to the third 13-sheet by the 
disulfide bond 1-5 and results in the cc-helix being held against the 13-sheet in a rigid 
structure (Figure 2.12B) [18, 34]. Residue Cys5 not only forms a disulfide bond with Cysl 
but is also involved in multiple hydrogen bonds with the second 13-sheet forming a conserved 
13-bulge which appears to be a signature structural motif in the 13-defensin family. The 
disulfide bond Cys2-Cys4 is involved in stabilizing the anti-parallel 13-sheets through 
bonding between the first 13-sheet and the start of the 13-hairpin. Residue Cys4 is also 
involved in a hydrogen bond holding the 13-hairpin in a rigid structure and bringing the third 
13-sheet closer [34]. Disulfide bond 3-6 holds the third 13-sheet to the first type IV turn after 
the first 13-sheet. This 13-turn between the first two 13-sheets was shown to be highly flexible 
indicating the possible reason for.the lack of structure in HBD2 3-6 [18]. 
85 














Figure 2.17. ID 1 H NMR Spectrum of Oxidized HBD2 and its Single Disulfide Mutants. 
Amide region of the proton NMR spectrum of HBD2 1-5 (red), HBD2 2-4 (blue), HBD2 3-6 
(green), wt HBD2 (purple). 
2.2.4 - Antimicrobial Activity 
It was shown in Section 2.1 .9 that wt 1-IBD2 possessed antimicrobial activity against 
Gram-negative bacteria at micromolar concentrations. Using the same protocol as before 
HBD2 single disulfide mutants were tested against this standard E. coli strain (MG1655) 
(Table 2.4). HBD2 single disulfide bond mutant concentrations as high as 100 .ig/ml were 
not able to kill 99.99% of bacteria. Clearly the canonically folded HBD2 is more potent an 
antimicrobial peptide with an MBC of <20 .tg/ml. 
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PEPTIDE MBC A LD90  B LD50 C 
HBD2 <20 1.5-3.0 <1.5 
HBD2 1-5 >100 50-100 12.5-25 
HBD2 2-4 >100 25-50 6-12.5 
HBD23-6 >100 50-100 12.5-25 
Table 2.4. Antimicrobial Activity of Oxidized wt HBD2 and its Single Disulfide Bond 
Mutants Against a Gram-negative E. coil (MG1655) strain. All values stated are in pg/ml. 
A MBC values are the minimum concentration required to kill 99.99% of initial inoculum. 
B LD90 values are the minimum concentration required to kill 90% of initial inoculum. 
C LD50 values are the minimum concentration required to kill 50% of initial inoculum. 
Inclusion of a single disulfide does however recover antimicrobial activity found to 
be lost by Hoover et al. when I-IBD2 was reduced [18]. All three mutants can kill 90% of E. 
co/i with LD90 values of 25-50 .tg/ml for HBD2 2-4 and 50-100 Wml for HBD2 1-5 and 3-
6. The difference in potency for HBD2 2-4 could be a consequence of a non-native fold 
causing more solvent exposed hydrophobic residues as could be implicated from the 
extended retention time by HPLC. A further discovery of note was the recovery of 
antimicrobial activity that was lost in studies with Brevi HBD2. Brevi HBD2 is HBD2 1-5 
with most of the antiparallel 3-sheet removed (Figure 2.12A). Morgera et al. found that 
removing a stretch of 19 amino acids containing Cys2, Cys3 and Cys4 inactivated its 
antimicrobial activity against a reference E.coli ML-35 strain [32]. However antimicrobial 
activity of the full length peptide with only the single disulfide bond Cysl-Cys5 was never 
tested. In this present study the inclusion of this antiparallel 13-sheet has resulted in partial 
antimicrobial activity as compared to wt HBD2. Furthermore, Nagaraj et al tested an N-
terminal truncated H13D2 peptide that contained the defensin conserved 13-hairpin motif 
constrained with disulfide bond Cys3-Cys6 (Figure 2.12A) [31]. This peptide displayed 
antimicrobial activity against an E.coli (W 160-37) strain; unfortunately comparisons with 
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wt HBD2 were not tested. These results together, indicate that the highly-conserved, 
antiparallel 13-sheet "platform", as well as charge and hydrophobicity, are important in 
generating a 13-defensin with potent antimicrobial activity and a single disulfide bond is not 
sufficient to provide this specific structural framework. 
2.2.5- Chemotactic Activity 
It was important that wt HBD2 had been previously shown to be able to 
chemoattract HEK293 cells transfected with the chemokine receptor CCR6 (Figure 2.9). To 
determine the role of the disulfide bonds on the ability of HBD2 to act as a chemokine we 
performed chemotactic assays with each of the single disulfide bond HBD2 mutants (Figure 
2.18). The lack of a classical bell-shaped curve indicates that the three single disulfide 
mutants are not chemoattractants for CCR6 transfected HEK293 cells. In fact, in the 
concentration range tested the three disulfide mutants are never significantly better 
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Figure 2.18. Chemotactic Activities of Oxidized wt HBD2 and Single Disulfide Bond 
Mutants for CCR6 Transfected HEK293 Cells. Migration by MIP-3a (light purple) and wt 
HBD2 (yellow) were positive controls. Migration by HBD2 1-5 (light green), HBD2 2-4 (dark 
purple) and HBD2 3-6 (pink) are indicated. The numerical data (number of cells per high 
power field) was recorded as an average of three separate experiments in triplicate and error 
bars indicate the SE. Statistical significance (pz0.05) is indicated with a * as compared to the 
number of cells per HPF of culture media alone. 
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Comparisons of the crystal and solution structures of human 3-defensins with the 
chemokine MIP-3ct/CCL20 indicated that two structural motifs are conserved and implicated 
as being important (Figure 2.19) [33, 35-37]. The N-terminal motif DCCL and DPVTCL in 
CCL20 and HBD2 respectively, are thought to be held in a rigid conformation and required 
for receptor activation. This structural rigidity was proposed to be conserved in HBD2 1-5. 
Its inability to chemoattract could imply that either this is not the case or that both structural 
motifs are essential. The wide, shallow groove formed between the N-terminal a-helix, loop 
connecting l3-f32 strands and C-terminal residues of HBD2 is also implicated in receptor 
recognition [33, 371. Positioning of this loop towards the C-terminus is conferred in part by 
the disulfide bond Cys3-Cys6. However, the inability of HBD2 3-6 to chemoattract suggests 
that without the disulfide bond Cysl-Cys5 this groove is not maintained and this peptide is 
not recognized or cannot activate the receptor. It appears that the structural requirements for 
HBD2 to be a potent chemoattractant are defined by its rigid structure imposed by its 
disulfide bonds. Such structural requirements appear to depend on the individual defensin 










Figure 2.19. Ribbon Diagram Highlighting the Structural Important Motifs of CCL20. 
Structure was downloaded from the protein data bank; CCL20: 1 M8A. Structural motifs are 
labelled and the disulfide bonds are indicated in green. DCCL motif is highlighted in blue and 
the distance of the putative binding groove is also indicated. 
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2.3 - Production of Human 3-defensins in Mammalian Cell Lines 
2.3.1 - Introduction 
Many mammalian cell lines have been used to dissect the complicated issue of 
defensin expression. These cell lines, for example CaCo2 cells and primary keratinocytes, 
have the potential to be used for defensin isolation. CaCo2 cells are human caucasian colon 
adenocarcinoma epithelial cells and have been used as models for intestinal epithelial cells in 
cell culture [38, 39]. O'Neil et al. has shown that it is possible to isolate HBD1 and HBD2 
from these intestinal epithelial cells [38]. Using one step, weak cationic exchange 
chromatography, two HBD1 isoforms and a HBD2 isoform (migrated slower than a standard 
rHBD2 on acetic acid urea gel) were purified [38. 39]. Although the relative concentrations 
of the two isoforms were low, HBDI (-45 ng/ml) and HBD2 (5 ng/ml), more stringent 
chromatography should increase the concentration to a more workable level. Therefore 
initial experiments were performed on these cells to isolate sufficient levels of HBD2 for 
proteomic and sequencing analysis. 
2.3.2 - Expression, Cloning and Attempted Isolation of 13-defensins 
To determine whether unstimulated CaCo2 cells constitutively express HBDI, cells 
were grown until they were confluent and RNA was extracted for analyses by RT-PCR and 
gel electrophoresis (Figure 2.20). A DNA band at 204 bp is representative of the full length 
transcript of signal-pro-HBDI - the l-IBD1 gene containing the signal sequence and pro-
sequence. The lack of a distinct band in the reactions without reverse transcriptase (-RT) 
indicates that this positive result is due to gene expression rather than DNA contamination. 
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Using the same protocol we found that full length signal-pro-HBD2 was not expressed. As 







Figure 2.20. Expression of HBDI in Unstimulated CaCo2 Cells. Defensin gene 
expression was analysed by RT-PCR using primers specific for HBD-1 and -2. Lane 1-6, 
extracted RNA subjected to RT-PCR analysis - RT. Lane 7, HO subjected to RT-PCR 
analysis - RI. Lane 8-13, RNA subjected to RT-PCR analysis +RT. Lane 14, H 20 subjected 




Figure 2.21. Expression Analysis of HBD2 from Stimulated CaCo2 Cells. Expression 
was analysed by RT-PCR using primers specific for HBD-2. Lane 1-6, extracted RNA 
stimulated for 0, 0 (with H 20), 15, 30, 60 and 360 min with IL-1P were subjected to RT-PCR 
analysis. 
We added the pro-inflammatory cytokine, interleukin-113 (IL-13) to the CaCo2 cells 
and RT-PCR analysis was carried out at different time points for up to 6 hrs. Clearly, after 6 
hrs induction with IL- 13, a RT-PCR product at 255 bp is observed, consistent with the size 
predicted for the signal-pro-1 ­113132 (Figure 2.21). Despite the correct size being observed for 
both defensin genes, confirmation was required by gene sequencing the RT-PCR product. 
Cloning of both products into the plasmid pGEM followed by transformation into E. co/i 
JM 109 generated a number of colonies. A number of plasmids were isolated and the insert 
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sequenced. Both HBDI and HBD2 wt sequences were identified. Interestingly, half of the 
HBD2 clones contained a single nucleotide polymorphism (SNP), resulting in the 
substitution of a lysine residue with a glutamic acid in the mature HBD2 peptide (K25E) 
(Appendix A3). This SNP could result from a PCR induced mutation; however a high 
fidelity polymerase was used in the RT-PCR reaction suggesting that this was not the case. 
Rather, it appears that CaCo2 cells may express two different HBD2 isoforms. The CaCo2 
cells have undergone an unknown number of replications so it is not clear whether this 
mutation was present when these cells were originally immortalized. It would be interesting 
to prepare the HBD2 K25E mutant and analyse its antimicrobial and chernotactic activity - 
this was outwith the scope of this study. This is not the first SNP identified in 13-defensin 
genes, with multiple SNPs in both the DEFBI and DEFB4 genes been identified throughout 
the gene including the S'UTR. 3'UTR, promoter region, exon 1 and exon 2 [40, 41]. These 
SNPs have been found to have an effect on transcriptional activity. A SNP in the NF-11-6 
consensus sequence of the DEF134 promoter region increased its transcriptional activity and 
it was hypothesized that it could have an effect on disease susceptibility [42]. An association 
between SNP and disease susceptibility has now been shown with DEF131. The C-G SNP at 
position -44 in the 5'UTR of DEFB1 has been shown to provide protection against Candida 
oral infection, Chronic Obstructive Pulmonary Disease and Crohn's Disease [43-45]. A 
number of recent studies have begun to analyse the impact of defensin copy number 
variations and their linkage to disease susceptibility. For example, both a- and - defensins 
are thought to play a role in chronic inflammatory diseases such as Crohn's disease and 
inflammatory bowl disease [46]. However, it is important that the defensin sequence, and not 
simply copy number variation, be analyzed to fully understand these issues. 
Preliminary work on the purification of mature HBD2 from CaCo2 cells was carried 
out as part of this study. CaCo2 cells were initially grown in serum medium before 
undergoing differentiation in ITS serum free media for 21 days. Cell supernatant was 
92 
Chapter 2: Purification and Functional Characterization of Human 13-defensins 
collected 6 hrs post IL-l3 induction and cationic exchange used for purification. Western 
blot analysis using an HBD2 antibody was unable to detect any mature peptide. The lack of 
detectable levels could be due to a combination of factors: (I) low expression; (2) salt levels 
in media (although diluted) interfered with chromatography; (3) the excreted HBD2 in the 
cell supernatant was not extractable possibly because it was bound to other proteins, lipids 
etc. Optimization of these factors could result in detectable levels of HBD2 and allow for 
sequence analysis of mature HBD2 peptide using high-resolution mass spectrometry. 
2.4 - Functional Analysis of Synthetic Biotinylated HBD2 
A major technical difficulty in the identification of any possible interacting partners 
of a defensin is an inability to "fish-out" the peptide efficiently before, during or after they 
perform their important role. An N-terminal biotinylated HBD2 (BioHBD2), which could be 
used in streptavidin pull-down experiments, was synthesized (AlbaChem) and its ability to 
perform the same functional roles as unmodified HBD2 was tested. 
The chemotactic activity of BioHBD2 was analysed using CCR6 transfected 
HEK293 cells and was found to chemoattract in a concentration dependent way with an 
optimal concentration at I ng/ml (Figure 2.22). This indicates that the biotin tag does not 
interfere with the functionally important N-terminus of HBD2. 
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Figure 2.22. Chemotaxic Activity of BIoHBD2 for CCR6 Transfected HEK293 Cells. 
Migration by MIP-3a (light purple) and sHBD2 (yellow) were positive controls. The numerical 
data (number of cells per high power field) was recorded as an average of three separate 
experiments in triplicate and error bars indicate the SE. Statistical significance (p< 0 . 05) is 
indicated with a * as compared to the number of cells per HPF of culture media alone. 
A second functional role recently proposed for 13-defensins is its anti-inflammatory 
properties [47, 481. An important part of the mammalian innate immune system is the ability 
to detect and react to virulence factors. One of the most important activators is the bacterial 
outer membrane component lipopolysaccharide (LPS), also known as endotoxin. The 
important receptor that recognises LPS/endotoxin is the Toll-like receptor 4 (TLR4); a 
member of a the large family of receptors involved in recognition of virulence factors [49]. 
A working model of this recognition and activation involves the lipid A domain of bacterial 
LPS, along with LPS binding protein and CD 14, interacting with TLR4 to trigger a 
complicated signalling transduction pathway within a number of cells in the immune system 
[49]. Up-regulation of the pro-inflammatory cytokine Tumor-Necrosis Factor-cc (TNF-a) is 
one consequence of this interaction and I-IBD2 was shown previously to block LPS-induced 
TNF-a production by macrophages [47]. We tested the ability of BioHBD2 to block TNF-a 
production by primary human monocyte cells after stimulation using Kd0 2-lipid A, a 
chemically defined truncated LPS, isolated from a deep-rough strain of E. coli [50] (Figure 
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2.23). The results clearly show an increase in TNF-a production upon stimulation with 
Kd02-lipid A as compared with media alone. A mixture of BioHIBD2 (50 p.g/ml) with Kd0 2-
lipid A (10 ng/ml) resulted in a decrease in TNF-a production compared to Kd0 2-lipid A 
stimulation only. However there was no significant difference between the TNF-a levels 
when the Kd02-lipid A concentration was increased (100 ng/ml). It has been previously 
shown that stimulation of TNF-ct production in macrophages with Kd0 2-lipid A in the range 
of 50-100 jig/ml results in very similar TNF-ci levels [50]. This lack of significant reduction 
in TNF-cc production after addition of BioHBD2 could be a result of a high concentration of 
uncomplexed Kd0 2-lipid A. Subsequently an increase in concentration of BioHBD2 (100 
tgIml) mixed with Kd0 2-lipid A resulted in a significant decrease in TNF-ci production as 
compared to Kd0 2-lipid A alone and reveals that BioHBD2, like unmodified HBD2, has anti-
inflammatory properties. Together with its chemotactic properties, this indicates the addition 
of a N-terminal biotin tag does not have a negative effect on }IBD2 function and therefore is 












Figure 2.23. Inhibition of LPS-induced TNF-a Production by BioHBD2. Varying 
concentrations of BioHBD2 (jtg/ml) and Kd0 2-lipid A (ng/ml) were mixed for 30 min prior to 
stimulation of primary human monocyte cells and production of TNF-a measured by ELISA. 
Data represent the mean and standard error of two independent experiments performed in 
triplicate, except stimulation with the BioHBD2 (100 tg/ml) and Kd0 2-Lipid A (100 ng/ml) 
mixture was only performed once in triplicate. 
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3.1 - Production of Human Chemokine Receptor 6 (CCR6) 
3.1.1 - Introduction 
Despite the increasing number of heterologous expression systems available for 
chemokine receptor production, relatively few receptors have been purified to homogeneity 
and/or analyzed biochemically. The two HIV-1 coreceptors, CCR5 and CXCR4, along with 
the decoy chemokine receptor D6, are the most extensively analyzed receptors and 
purification has been achieved using both E. co/i and/or mammalian cell systems [1-4]. 
The goal of this project was to optimize the purification of CCR6 to produce 
sufficient quantities of the protein for proteomic and biochemical analysis. Despite the low 
yields and time-consuming methods, mammalian cells were chosen as the expression system 
because of their closeness to the native environment and ability to perform post-translational 
modifications (PTM5). Furthermore, cells expressing CCR6 were available in our laboratory 
to assay the activity of various defensin peptides. The CCR6 gene was engineered with both 
N-terminal and C-terminal specific tags to aid both solubilization and purification before 
generation of a stable cell line expressing CCR6 was obtained. Successful solubilization 
followed by optimization of purification yielded sufficiently pure CCR6 to allow for both 
mass spectrometry and biochemical analysis. Although further optimization is required to 
increase the yield and purity, this is the first occasion that CCR6 has been purified and 
provides a platform for further characterization. 
3.1.2 - Expression of Epitope-Tagged CCR6 in Mammalian Cell Lines 
The CCR6 transfected HEK293 cells used in all previous chemotactic assays was an 
ideal expression system for initial purification studies. The expression plasmid 
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pcDNA3.1/CCR6, used to transfect the original l-1EK293 cells, was obtained from Dr De 
Yang. Although the CCR6 gene had an enterokinase cleavable N-terminal FLAG tag, to 
increase stability and facilitate purification of CCR6, the addition of a C-terminal tag was 
deemed necessary. Using the original vector as a template, mega-primer mutagenesis was 
carried out to add a C-terminal HIS 10 tag. Although mutagenesis was successful, as revealed 
by DNA sequencing, subsequent cloning back into pcDNA3.1 was unsuccessful because 
large-scale restriction digestion of pcDNA3.1 resulted in multiple non-specific cleavages. 
Therefore a CCR6 gene incorporating the C-terminal HIS 10 tag was designed and purchased 
from Codon devices (Figure 3.1 A). This epitope-tagged CCR6 gene was cloned into 
pcDNA3.1 and was used as an expression plasmid for transfection of mammalian cells 
(Figure 3.113). 
A 
1 MDSKGSSQKG SRLLLLLVVS NLLLCQGVVS 
51 YFVSVNTSYY SVDSEMLLCS LQEVRQFSRL 
101 VITFAFYKKJ\ RSMTDVYLLN MAIADILFVL 
151 CKLLKGIYAI NFNCGMLLLT CISMDRYIAI 
201 CLVVWGLSVI ISSSTFVFNQ KYNTQGSDVC 
251 ELLFGFFIPL MFNIFCYTFI VKTLVQAQNS 
301 IPHNMVLLVT AANLGKNNRS CQSEKLIGYT 
351 FIGQKFRNYF LKILKDLWCV RRKYKSSGFS 







KRHKAI RVI I AVVLVFLACQ 
KTVTEVLAFL HCCLNPVLYA 
CAGRYSENIS RQTSETADND 








NEO 	Ncol (3148) 
Figure 3.1. Epitope-Tagged CCR6 (A) Full Length Sequence of CCR6 (417 AA). Histidine 
tag (Red) and FLAG tag (Blue) is indicated. (B) Schematic Representation of Expression 
plasmid pcDNA3. 1 /FGCCR6H 10. 
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Expression plasmid pcDNA3.1/FGCCR6HIO was transfected into two different 
mammalian cell lines, Human Embryonic Kidney (HEK) 293 and LI .2 murine pre-B cells. 
The HEK293 cells had been shown to express active CCR6 and insert the protein into its 
membrane in an orientation that allowed it to be chemoattracted by its natural ligands, 
CCL20 (also known as MIP3-a) and 3-defensins [5]. Unfortunately. HEK293 cells are 
adherent cells and scaling-up the cell culture to facilitate purification of large amounts of 
protein is expensive and time-consuming. As an alternative, Li .2 cells are suspension cells 
and therefore scaling-up in large bioreactors was an attractive alternative. Although Li .2 
cells had not been tested for CCR6, another receptor in the same GPCR family, the non-
signalling chemokine receptor D6, had previously been shown to express high levels upon 
sodium butyrate treatment [1]. We used the same plasmid, pcDNA3.1/FGCCR6H1O, to 
transfect the L1.2 cells but unfortunately, despite growth of transfected LL2 cells in killing 
media, flow cytometric analysis determined there was no surface expression of the receptor 
even after sodium butyrate treatment (Figure 3.2 A-D). The difference between surface 
expression of D6 and CCR6 could be due to the lack of a N-terminal hemagglutinin (HA) tag 
present in D6. This signal peptide from influenza HA has been shown to increase the surface 
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Figure 3.2. CCR6 Expression in Transfected Mammalian Cells. 1-1.2 control cells (A and B) or Epitope-tagged Human CCR6 transfected 1-1.2 cells 
(C and D) were examined for specific binding by flow cytometry after sodium butyrate treatment using either lgG2b-FITC negative control antibody (A 
and C) or an anti-CC R6-FITC antibody (B and D). 
HEK293 control cells (E and F) or Epitope-tagged Human CCR6-expressing HEK293 cells (G and H) were examined for specific binding by 
flow cytometry using either lgG2b-FITC negative control antibody (E and G) or an anti-CCR6-FITC antibody (F and H). Previously confirmed CCR6 
expressing HEK293 cells were used as positive control (I) [5]. 
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Highly-expressing stable transformants of CCR6 in 1-1EK293 cells were confirmed 
using both RT-PCR and FACS analysis. Using CCR6 specific primers, RNA extracted from 
both HEK293 control and F1EK293 transfected cells underwent RT-PCR analysis. CCR6 
gene expression was confirmed in only transfected HEK293 cells were reverse transcriptase 
had been added to the reaction (Figure 3.3, Lane 8). The lack of a CCR6 band in the reaction 
without reverse transcriptase indicated that this gene expression was not due to DNA 
contamination. It was also found that this CCR6 expression could not be detected in the 
control HEK293 cells. This result was confirmed by the identification of 13-Actin expression 
indicating that both RNA extraction and RT-PCR analysis had been performed correctly. 
This result agrees with a previous microarray profiling study of HEK293 cells that revealed 
CCR6 was not expressed in this cell line and as such HEK293 cells could be used as a 
negative control for future investigations [7]. RT-PCR analysis only detects gene expression 
and does not reveal whether the CCR6 protein was being properly trafficked to the cell 
surface therefore FACS analysis was performed. FACS analysis using an anti-CCR6-FITC 
conjugated antibody was performed on both H1EK293 control and HEK293 transfected cells. 
Comparison between the relative fluorescence of }1EK293 control and I-1EK293 transfected 
cells confirms the RT-PCR analysis that only HEK293 transfected cells are expressing 
CCR6. Furthermore this shows that CCR6 was successfully inserted in the outer membrane 
in a topologically correct orientation (Figure 3.2 E-I). Comparison of the relative 
fluorescence between CCR6 expressing cells with and without a C-terminal HIS1O tag 
suggested that the affinity tag had no detrimental effect on surface expression (Figure 3.2 H 
and I). 
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Figure 3.3. Expression of CCR6 in Transfected HEK293 Cells. CCR6 gene expression 
was analyzed by RT-PCR with 3-Actin acting as house-keeping gene. Lanes 1-2, 3-Actin 
expression in HEK293 cells, without and with reverse transcriptase. Lanes 3-4, CCR6 
expression in HEK293 cells, without and with reverse transcriptase. Lanes 5-6, 3-Actin 
expression in CCR6 transfected HEK293 cells, without and with reverse transcriptase. Lanes 
7-8, CCR6 expression in CCR6 transfected HEK293 cells, without and with reverse 
transcriptase. The band indicated by arrow is correct size for CCR6 gene fragment. 
Initial protein analysis of epitope-tagged CCR6 was performed on a small scale. The 
intrinsic hydrophobic properties of membrane proteins, along with their association with 
membrane lipids make visualization by SDS-PAGE analysis difficult due to their tendency 
to aggregate [8]. Therefore a temperature dependent SDS/DTT solubilization step was 
carried out prior to SDS-PAGE separation. Using anti-CCR6 antibody western blot analysis, 
epitope-tagged CCR6 was identified predominately as a dimeric species at temperatures 
above 50 °C (Figure 3.4). Below this temperature there was a slight increase in the 
monomeric form and reduction in the dimeric form. Reducing the temperature even further 
to 4 °C at the same time as increasing solubilization time allowed predominately monomeric 
epitope-tagged CCR6 to be visualized by western blot analysis and these conditions were 
therefore used in all future analysis. The effect of sodium butyrate treatment on CCR6 
expressing l-1EK293 cells was also tested. Unfortunately treatment of these cells resulted in 
increased cell toxicity revealed by cell detachment from the culture flask and less CCR6 
expression identified by anti-CCR6 antibody western blots analysis (Figure 3.5). 
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Figure 3.4. Western Blot Analysis Revealing the Effects of Temperature on CCR6 
Protein Expression. Lane 1, 90 °C, Lane 2, 80 °C, Lane 3, 70 °C, Lane 4, 60 °C, Lanes 5, 
50 °C, Lane 6, room temp. The black and red arrows indicate monomeric CCR6 and dimeric 
CCR6 respectively. 







Figure 3.5. Western Blot Analysis Revealing the Effects of Sodium Butyrate on CCR6 
Protein Expression. Lane M, SeeBlue 2 protein marker; Lanes 1-3, CCR6 transfected 
HEK293 cells with 10 mM sodium butyrate treatment; Lanes 4-6, CCR6 transfected HEK293 
cells without sodium butyrate treatment. The arrow indicates monomeric CCR6. 
3.1.3 - Solubilization of Epitope-Tagged CCR6 
Removal of membrane proteins from their natural environment is both a necessary 
and problematic step in their purification. Instability and insolubility in aqueous buffers 
necessitates the use of either mild detergent extraction or, if the proteins have been expressed 
in a bacterial system, isolation from inclusion bodies and subsequent refolding. Due to the 
additional problems associated with refolding functional membrane proteins, epitope-tagged 
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CCR6 was extracted using mild, non-ionic detergents. Studies where chemokine receptors 
were subjected to systematic detergent screens have highlighted that a general method 
cannot be applied and even GPCRs from the same family require individual assessment and 
optimization [2, 3, 9]. Therefore initial solubilization of epitope-tagged CCR6 from HEK293 
crude membrane extracts were performed using a combination of n-dodecyl-13-maltoside 
(DDM) and cholesteryl hemisuccinate ester (CHS), previously shown to be effective in 
solubilization of chemokine receptor CXCR4 [10]. A mixture of solubilizied epitope-tagged 
CCR6, other membrane proteins and mixed micelles of phospholipids and detergents were 
then subjected to various chromatographic techniques to optimize CCR6 purification. 
3.1.4 - Immobilised Metal-Affinity Chromatography Purification of 
Epitope-Tagged CCR6 
Solubilized epitope-tagged CCR6 was purified using two-step immobilized metal-
affinity chromatography (IMAC) using resin as opposed to a packed column. SDS-PAGE 
and western blot analysis after Ni 2 -NTA purification revealed that epitope-tagged CCR6 
was indeed soluble and that the deca-HIS tag was accessible to bind the affinity resin 
efficiently. In fact, anti-HIS antibody western blot analysis revealed the possible presence of 
proteolyzed, monomeric and higher-order forms of CCR6 (Figure 3.6 A). Whether 
proteolysis and aggregation is a result of the extended purification protocol and/or excessive 
incubation time in the denaturing SDS-PAGE loading buffer is unclear. This does however 
emphasize the natural instability of membrane proteins once they are removed from their 
native environment. 
Although single-step IMAC chromatography had been previously shown to result in 
the purification of other GPCRs to near homogeneity, SDS-PAGE analysis clearly showed 
the presence of multiple non-CCR6 proteins necessitating another purification step. Fractions 
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containing proteins that were anti-HIS antibody positive were pooled, diluted and applied to 
pre-equilibrated cobalt affinity resin (Talon). SDS-PAGE analysis after Talon purification 
showed that this step led to increased purity of epitope-tagged CCR6. However western blot 
analysis shows an increasing number of cleavage products at --24 and —30 kDa with a loss of 
the —47 kDa band thought to represent the full length monomeric epitope-tagged CCR6 
(Figure 3.6 B) (47475.42 Da). Comparison of both SDS-PAGE and western blot analysis 
also reveals protein bands non-reactive to the anti-HIS antibody. These could represent C-
terminal cleavage products of epitope-tagged CCR6 and also membrane associated proteins 
that bind non-specifically to either CCR6 or lipids still associated in the micelle. However, 
purification using only one affinity tag increases the probability that these protein bands are 
non-specifically bound contaminants. Therefore the second step using Talon resin was 
replaced with a size-exclusion chromatography step. 
Identification of monomeric, full length, epitope-tagged CCR6 is also problematic 
by SDS-PAGE analysis alone. Using molecular mass estimates based on amino acid 
sequence is difficult since membrane proteins migrate faster than the soluble low molecular 
weight calibration proteins, however addition of purification tags and post-translational 
modifications, e.g., glycosylation, can retard this migration [Ll]. Therefore SDS-PAGE 
analysis alone can not used to identify full length CCR6. Moreover, anti-HIS antibody 
western blot analysis alone is also unable to identify full length CCR6 but together with an 
anti-FLAG antibody, full length CCR6 would be identifiable. Therefore all future 
purification analysis was performed using both antibodies. 
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Figure 3.6. IMAC Purification of Epitope-Tagged Human CCR6 from HEK293 Cells. (A). Left hand side; SDS-PAGE of Ni 2 -NTA purification of 
FLAG-CCR6-HIS10. Lanes A - I, 10 mM imidazole wash, 300 mM imidazole elution and 500 mM imidazole elution fractions in triplicates. Right-hand 
side, western blot analysis of Ni 2 -NTA purification of FLAG-CCR6-HIS10. Lanes J - S, 10 mM imidazole wash, 300 mM imidazole elution and 500 mM 
imidazole elution fractions in triplicates analyzed with anti-HIS antibody. (B) SDS-PAGE and western blot analysis of Talon resin purification of FLAG-
CCR6-HIS10. Left hand side, lane 1-4, 500 mM imidazole elution fractions and concentrated 500 mM imidazole elution fractions in duplicate analyzed 
by SDS-PAGE. Right hand side lane 5, flow through fraction; lane 6, 10 mM imidazole wash fraction; lanes 7-8, concentrated 500 mM imidazole elution 
fractions analyzed with anti-HIS antibody. 
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3.1.5 - Metal-Affinity followed by Size Exclusion Purification of Epitope- 
Tagged CCR6 
Size exclusion chromatography is often used as a final purification step, useful in 
removing small molecules used as elutants or large non-specific binders in affinity 
chromatography. Its capability of resolving monomeric and dimeric chemokine receptors 
also emphasized its usefulness in the purification of epitope-tagged CCR5 [4]. Ni 2 -NTA 
purification again yielded multiple HIS-containing proteins revealing proteolytic cleavage 








Figure 3.7. Western Blot Analysis of Ni 2 -NTA Purification of FLAG-CCR6-HISI0. Lanes 
1-3, 10 mM imidazole wash; lanes 4-6, 300 mM imidazole elution fraction; lanes 7-9, 500 
mM imidazole elution fraction. FLAG-CCR6-HIS10 was separated by SDS-PAGE and 
identified using an anti-HIS antibody. 
Separation of cleavage products was attempted using a calibrated Superdex 200 size 
exclusion column. The elution profile was monitored at 280 nm and clearly shows separation 
of protein peaks (Figure 3.8 A). Unfortunately, anti-HIS antibody western blot analysis 
shows that separation of full-length CCR6 from cleavage products was not successful 
(Figure 3.9). Interestingly, anti-FLAG western blot analysis indicates the presence of two 
FLAG containing proteins. These two proteins also reacted with the anti-HIS antibody 
indicating the presence of full-length epitope-tagged CCR6. The difference in their migration 
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suggests a possible difference in their patterns of PTMs, although these differences are not 
known at present. Intriguingly, cleavage products of CCR6 did not react with the anti-FLAG 
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Figure 3.8. Size Exclusion purification of epitope-tagged CCR6. (A) FLAG-CCR6- 
HIS1 0 elution profile from Superdex 200 size exclusion column analyzed at wavelength 280 
nm. (B) Calibration curve for column. 
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Using the calibration curve (Figure 3.8 B), it was estimated that CCR6 solubilized in 
the detergent DDM migrated with a mass> 230 kDa. This increase in mass is a consequence 
of the CCR6 being incorporated into a detergent micelle and as such the fractionation range 
of the column was not optimal for ideal separation. Future purifications should use Superdex 
300 size exclusion chromatography which has higher resolution for large proteins. 
Furthermore, more stringent chromatography prior to size exclusion would be needed as 
SDS-PAGE analysis showed a mixture of proteins eluting together with the CCR6. 
Consequently a third purification was performed taking advantage of the N-terminal FLAG 
tag. 
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Figure 3.9. Western Blot Analysis of Superdex 200 Purification of FLAG-CCR6-HISIO. 
Lane 1, elution fractions 1310-136; lane 2, elution fractions 135-131; lane3, elution fractions C11- 
C5; lane 4, elution fractions 06-CO; lane 5, elution fractions C11-D10; lane 6, elution 
fractions D9-D5; lane 7, elution fractions D4-E1; lane 8, elution fractions E2-E6; lane 9, 
elution fractions E7-E11. FLAG-CCR6-HIS1 0 was separated by SDS-PAGE and identified 
using an anti-HIS antibody. Lanes 10-18, elution fractions 139-131 analyzed with an anti-FLAG 
antibody. 
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3.1.6 - Metal-Affinity followed by Immuno-Affinity Purification of 
Epitope-Tagged CCR6 
Purification utilizing both the N-terminal and C-terminal tags is advantageous in 
isolating full-length CCR6 because only proteins with both tags will be isolated. In an 
attempt to avoid proteolysis of CCR6 which we observed with the methods described above, 
batch purification using loose Ni 2 -NTA resin was replaced with IMAC chromatography on 
a packed column attached to an AKTA Purifier. In addition, purification of CCR6 was 
performed without a previous freeze-thawing step between solubilization and metal-affinity 
chromatography. 
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Figure 3.10. Western Blot Analysis of His-trap Ni 2 Purification of FLAG-CCR6-HISI0. 
Lane 1, elution fractions 14-20; lane 2, elution fractions 21-27; lane 3, elution fractions 28-34; 
lane 4, elution fractions 35-41; lane 5, elution fractions 42-48; lane 6, elution fractions 49-56; 
lane 7, elutions fractions 57-62. Proteins were eluted with an increasing imidazole gradient 
ranging from 30 mM to 500 mM and identified using an anti-FLAG antibody. 
Analysis of the IMAC chromatography elution profile of purified epitope-tagged 
CCR6 was complicated by the inherent spectroscopic properties of imidazole. Imidazole 
absorbance at 280 nM increased the possibility of eluted CCR6 fractions being concealed 
especially at the higher concentrations. Therefore elution fractions were combined and anti-
FLAG antibody western blot analysis was performed (Figure 3.10). Clearly this revealed the 
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existence of two proteins that reacted with the N-terminal epitope specific antibody. This 
would indicate two different forms of full-length CCR6, migrating at -47 kDa and -56 kDa 
respectively. These two proteins are identical in size to that previously isolated using size-
exclusion chromatography (Figure 3.9). Further purification using immuno-affinity 
chromatography specific to the FLAG peptide tag resulted in a significant improvement in 
the purity of full-length CCR6. SDS-PAGE analysis with the extremely sensitive silver stain 
reveals a strong band at --47 kDa with a major contaminating protein at -62 kDa (Figure 
3.11). Subsequent mass spectrometric analysis of the 62 kDa band following in-gel tryptic 
digestion revealed this contaminating band to be the heavy chain of monoclonal anti-FLAG 
antibody. The protein migrating at -47 kDa clearly reacts strongly with both anti-HIS and 
anti-FLAG antibodies suggesting that it is the full length epitope-tagged CCR6 (predicted 
mass 47,475 Da, Figure 3.11). The protein migrating at -56 kDa reacts with the anti-HIS 
antibody but only reacts weakly with the anti-FLAG antibody indicating that if it is an 
alternatively modified form of CCR6 then this it is less abundant. However another 
explanation could be that CCR6 is not fully denatured and/or reduced and therefore SIDS 
binding is affected which alters its migration pattern for the same protein. Again this 
highlights the problems associated with GPCRs and their analysis by SDS-PAGE. 
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Figure 3.11. Anti-FLAG Affinity Purification of FLAG-CCR6-HISIO. Lane 1, silver stained 
SDS-PAGE gel of purified FLAG-CCR6-HIS10. Lane 2, purified FLAG-CCR6-HIS10 
analyzed with anti-HIS antibody and lane 3, anti-FLAG antibody. The band indicated by a 
black arrow is the correct size for full length FLAG-CCR6-HIS10 (47,475 Da). The band 
indicated with a red arrow was subsequently identified as the heavy chain of the monoclonal 
anti-FLAG antibody. 
3.2 - Characterization of Purified Epitope-Tagged CCR6 
3.2.1 - Nanospray LC-MS/MS Analysis of Epitope-Tagged CCR6 
To confirm the identity and further characterize the purified CCR6 isolated by the 
metal-affinity steps, nanospray (nano) LC-MS/MS analysis was performed on peptide 
fragments from proteolysis of CCR6. Detergents necessary for GPCR purification have 
detrimental effects on the quality of MS analysis through: 1) sample ionization suppression; 
2) adduct formation; 3) detergent ionization signals concealing sample signals [12]. Two 
methods were performed to circumvent the detrimental effects of detergents. First, in-gel 
tryptic digestion of CCR6 separated by SDS-PAGE was performed. Extraction of peptide 
fragments into a MS-compatible buffer was attempted before nanospray LC-MS/MS 
analysis. Unfortunately no tryptic peptide fragments corresponding to CCR6 were identified. 
Successful trypsin digestion of CCR6 would yield two types of fragments. The first type is 
insoluble in mass spectrometry compatible buffers and hence could not be detected. This 
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group is composed of large, hydrophobic transmembrane helical domains of CCR6 and is a 
result of a low number of arginines and/or lysines present. In contrast, it was hoped that the 
hydrophilic N- and C-terminal regions, in addition to the loop regions, constituting the 
soluble MS-detectable fragments would be detected. The inability to detect the latter 
fragments is likely a result of inefficient enzymatic cleavage of CCR6, resulting in large, 
hydrophobic peptides which were extracted from the gel matrix in an extremely low yield. 
The second method used to remove detrimental detergents was to precipitate CCR6 
prior to in-solution chemical and enzymatic cleavage, with the detergents remaining in the 
organic solvent. It was found that precipitated CCR6 subsequently dissolved more readily in 
acidic conditions necessary for chemical cleavage. CNBr cleaves peptide bonds C-terminal 
to methionine residues often found in hydrophobic helical domains. Together with tryptic 
digestion, peptide fragments are shorter, more soluble and therefore more conducive to better 
mass spectrometry analysis after both chemical and enzymatic digestion. To further improve 
the efficiency of trypsin cleavage, chemically-digested fragments were dissolved in RapiGest 
(Waters), a MS-compatible detergent shown previously to improve enzymatic digestion and 
mass spectrometry analysis of neurotensin [13]. 
Gratifyingly, nanoLC-MS/MS analysis of CCR6 subjected to this procedure yielded 
a total of three sequenced peptide fragments corresponding to CCR6 (Table 3.1). Sequences 
from MS/MS analysis include peptides derived from N-terminal extracellular domain, 
intracellular loop 2 and extracellular loop 3 connected to part of transmembrane helix 6. A 
representative tandem mass spectrum reveals the sequencing of intracellular loop 2 (Figure 
3.12). Although sequence coverage is <10%, this provides a good basis for further, more 
comprehensive MS analysis. Improvements in optimization of protein purification would 
undoubtedly improve sequence coverage as a contaminating protein, Cytoskeleton-
associated protein 4 (63 kDa membrane protein) was identified and likely suppressed CCR6 
peptide fragment ionization. 
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PEPTIDE SEQUENCE POSITION IN CCR6 
1 34 LLCSLQEVR 42 N-terminal to first transmembrane helix 
2 144 YIAIVQATK 152 Intracellular loop 2 (ICL2) 
3 273 VLLVTAANLGK 283 Part of transmembrane helix 6 connected to 
extracellular loop 3 (ECL 3) 
Table 3.1 CCR6 Peptide Fragments Resulting from Both Chemical and Enzymatic 
Cleavage. Numbers indicated are the positions of the fragments in the context of the mature 
full-length hCCR6 sequence starting at the N-terminal. The MS/MS data for peptide 2 is 
shown in Figure 3.12 below. 
A major reason for expressing CCR6 in the heterologous mammalian expression 
system was their ability to correctly post-translationally modify the protein of interest. Mass 
spectrometry has been successfully shown to identify previously putative post-translational 
modifications of GPCRs [14, 151. NanoLC-MSIMS analysis of trypsin digested purified 
Histamine H 1  receptor not only identified an N-linked glycosylation site but also the 
individual components that constituted this modification [14]. Phosphorylation sites have 
also been identified using a similar strategy in the V2 Vasopressin receptor (V2R). NanoLC-
MS/MS analysis of IMAC enriched trypsin digested V2R revealed a novel intracellular 
phophorylation site [15]. However even complete sequence coverage can not guarantee their 
identification, therefore a biochemical analysis of CCR6 PTMs was carried out in 
conjunction with MS analysis. 
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Figure 3.12. MS/MS Spectrum of a Peptide Fragment of Purified CCR6. Inset, Peptide 
sequence corresponding to a section of ICL 2. Observed monoisotopic mass was 1005.55 
Da and calculated monoisotopic mass was 1005.59 Da. 
3.2.2 - Post-translational Modification Analysis of CCR6 
Biochemical methods have been used to identify a range of post-translational 
modifications (PTMs) in numerous chemokine receptors [16-18]. In general, proper 
intracellular trafficking (N-linked glycosylation), improved ligand binding (tyrosine sulfation 
and 0-linked glycosylation), receptor stability (palmitoylation), and receptor 
densensitization and internalization (phosphorylation) are just some of the roles PTMs play 
in proper chemokine receptor functioning. 
Due to a lack of CCR6 biochemical analysis, preliminary bioinformatic sequence 
analysis was performed to identify putative PTM sites. Results obtained using PROSITE; a 
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database of functional motifs [19], revealed CCR6 has five putative N-glycosylation sites 
(Figure 3.13). Only three are predicted to be extracellular with one being on the N-terminus. 
Results obtained using a combination of PROSITE and NetPhos revealed a plethora of 
putative phosphorylation sites for multiple GPCR kinases throughout the CCR6 sequence 
[20]. In general it is accepted that phosphorylation of the C-terminus is a first step in 
densensitization followed by internalization of the receptor, however the cluster of putative 
tyrosine and serine phosphoiylation sites in the N-terminus could have a role in attracting 
positively-charged ligands, such as defensins, to CCR6. A similar role has already been 
shown for tyrosine sulfation in CCR5, CCR2b and CXCR4 [17, 21, 221. Although an exact 
functional motif has not been identified for tyrosine sulfation it is implied that a tyrosine 
followed or preceded by a negatively charged amino acid could be sulfated [23]. Although 
the CCR6 N-terminal contains a conserved YY motif at position 26-27, in which the 1st 
tyrosine is sulfated in the corresponding residues in both hCCR5 and mCCR8 [16, 21], and a 
tyrosine at position 18 preceded by an aspartic acid, these residues are both putative sites for 
phosphorylation and further analysis is needed to confirm the PTM. Finally, putative sites for 
covalent modifications of cysteine residues with fatty acids were revealed with a N-
myristoylation site on ECL2 and two palmitoylation sites bordering the putative extracellular 
side of transmembrane helix 7. 
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Figure 3.13. Snake-like Diagram Representing the Possible Topology and Post-Translational Modifications for 
Epitope-Tagged CCR6. Deca-HIS tag ( een) and FLAG tag (Red) are indicated. Putative glycosylation and 
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PTM analysis by comparative metabolic labeling is routinely carried with great 
success [1, 17]. Unfortunately this method of analysis was not available; therefore analysis 
was performed using a combination of enzymatic methods and fluorescent staining. Metal-
and immuno-affinity purified epitope-tagged CCR6 was analyzed for both N- and 0-linked 
glycosylation. Initially purified CCR6 was purified on a SDS-PAGE gel and stained with a 
glycosylation-specific stain, however although CCR6 has five putative N-linked 
glycosylations sites no band was observed. This was probably a consequence of low 
concentrations of epitope-tagged CCR6 in the gel matrix. Therefore a gel-shift assay 
followed by anti-FLAG western blot probing was carried out. Purified CCR6, denatured in 
SDS, was subjected to both N- and 0- specific deglycosylation enzymes. N-glycosidase F 
digestion of purified CCR6 resulted in an increase in electrophoresis mobility with CCR6 
shifting from -47 kDa to -38 kDa (Figure 3.14). This suggests that N-linked 
oligosaccharides were contributing greatly to the mass of CCR6. Although this method 
cannot specify which asparagines are glycosylated, a shift of 9 kDa is strong evidence that 
more than one amino acid is glycosylated. Digestion of purified CCR6 with 0-linked 
deglycosylating enzymes did not result in a band shift. Although 0-linked oligosaccharides 
are smaller in size removal of sialic acid by a2-3, 6, 8, 9-Neuraminidase would still result in 
an observable mass shift. Being the third CC chemokine receptor identified as being N-
glycosylated indicates that this modification is common in the family and most likely has a 
functional role. 
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Figure 3.14 Glycosylation Analysis of Purified Epitope-Tagged CCR6. Epitope-tagged 
CCR6 without (lane 1) and with (lane 2) N-Glycosidase F. 
Phosphorylation analysis of purified CCR6 was performed using a phosphoprotein 
specific fluorescent stain. Prior to gel staining, western blot analysis performed with both 
anti-tyrosine and anti-serine specific antibodies revealed a lack of reactivity with purified 
CCR6. Although at a basal level chemokine receptors are phosphorylated, it has been shown 
that they become hyper-phosphorylated upon stimulation with their natural ligand [24]. 
Since purified CCR6 was isolated without ligand stimulation it is possible that not enough of 
the putative sites were phosphorylated and therefore would not reactive with the antibodies. 
Purified CCR6 was separated on a SDS-PAGE gel and stained with a phosphoprotein 
specific fluorescent stain resulted in a faint band corresponding to the correct mass of CCR6 
(Figure 3.15). An intrinsic problem associated with this method was the low abundance of 
purified CCR6 in the gel matrix. Consequently over-exposure was required to identify the 
fluorescent CCR6 band leading to proteins that are not known to be phosphorylated being 
identified. Therefore it is impossible to determine whether CCR6 is phosphorylated at a 
basal level. 
122 
Chapter 3: Purification and Biochemical Analysis of CCR6 
Figure 3.15 SDS-PAGE Analysis of Purified CCR6 Stained with Phosphoprotein Gel 
Stain. Lane M, protein marker, Lane 1, purified CCR6. The band indicated by a black arrow 
is the correct size for full length FLAG-CCR6-HIS10 
3.3 - N-terminal Truncation of Epitope-Tagged CCR6 
To begin to elucidate the functional role of the N-terminal domain of CCR6, site-
directed mutagenesis on the wild-type expressing plasmid was performed to remove the first 
27 AA from the N-terminal while keeping the N-terminal FLAG-tag for FACS analysis 
(Figure 3.6). Truncation of the first 27 AA removes putative phosphorylation, glycosylation 
and possible sulfation sites. In a similar study, removal of the corresponding section of 
CCR5 resulted in impairment of ligand binding but still enabled cell surface expression [2]. 
1 MDSKGSSQKG SRLLLLLVVS NLLLCQGVVS 
51 QEVRQFSRLF VPIAYSLICV FGLLGNILVV 
101 AIADILFVLT LPFWAVSHAT GAWVFSNATC 
151 ISMDRYIAIV QATKSFRLRS RTLPRSKIIC 
201 YNTQGSDVCE PKYQTVSEPI RWKLLMLGLE 
251 KTLVQAQNSK RHKAIRVIIA VVLVFLACQI 
O1 QSEKLIGYTK TVTEVLAFLH CCLNPVLYAF 
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Figure 3.16. Sequence of N-terminal Truncated CCR6 (396 AA). HIS tag (Red) and FLAG 
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HEK293 cells were transfected with pcDNA3.1IN-trunc/CCR6 and surface 
expression was analyzed by FACS analysis using anti-FLAG-FITC conjugated antibody. 
FACS analysis revealed there was no surface expression of the N-truncated receptor when 
compared to the full length CCR6 transfected HEK293 cells (Figure 3.17). To confirm that 
the N-trunc CCR6 had been successfully transfected HEK293 cells were lysed before 
running the crude extract on a SDS-PAGE gel and western blotting with an anti-HIS 
antibody. Analysis of this data revealed the presence of both monomeric and dimeric N-trunc 
CCR6 reacting with the antibody and indicated that N-trunc CCR6 was being expressed but 
not properly trafficked to the cell surface (Figure 3.18). 
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Figure 3.17. N-terminal Truncated CCR6 Expression in Transfected HEK293 cells. 
HEK293 control cells (A and B) or Epitope-tagged Human CCR6-expressing HEK293 cells 
(C and D) were examined for specific binding by flow cytometry using either lgG-CFS 
negative control antibody (A and C) or an anti-FLAG-FITC antibody (B and D). N-terminal 
truncated CCR6-expressing HEK293 cells (E and F) were examined for specific binding by 
flow cytometry using either lgG 1 -CFS negative control antibody (E) or an anti-FLAG-FITC 
antibody (F). 
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The differences in cell surface expression between N-terminal truncated CCR6 and a 
similar CCR5 mutant could be a result of CCR6 having a N-terminal putative N-
glycosylation site, which has been shown to be important for surface expression of some 
GPCRs and irrelevant for others [25]. Additionally, a YS motif has been shown to be 
important in intracellular trafficking for a2-ARs which has been removed in the N-truncated 
CCR6 [26]. Removal of this motif retains the receptor in the Golgi apparatus. The exact 
intracellular location and N-terminal motif responsible for surface expression of CCR6 
remains to be identified but these results indicate the importance of the N-terminus and are a 
good starting point for further analysis. 
kDa 
30 
Figure 3.18. Western Blot Analysis of N-terminal Truncated CCR6. The feint band 
indicated by the black arrow is the correct size for N-terminal truncated epitope-tagged 
CCR6 (45,008 Da). The band indicated by the red arrow is possibly dimeric N-terminal 
truncated epitope-tagged CCR6. 
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4.1 - Materials 
4.1.1 -General Reagents 
All chemicals and solvents were of the appropriate quality and unless stated were 
purchased from Bio-Rad, Fisher, GE Healthcare, Gibco BRL, Invitrogen and Promega. 
Synthetic Biotinylated (Bio) HBD2 was purchased from Albachem as a custom synthetic 
peptide. Synthetic genes HBD1 and CCR6 were purchased from Codon Devices, Inc. 
Human embryonic kidney (HEK) 293 and CCR6 transfected HEK293 cell lines were 
a kind gift from Dr De Yang (National Cancer Institute, Frederick). Murine L1.2 pre-B cells 
were a kind gift from Prof. G Graham (Glasgow Biomedical Research Centre, University of 
Glasgow). 
4.1.2 - General Buffers 
TAE buffer - Tris-HCI (40 mM), acetic acid (20 mM), EDTA (1 mM), pH 8.3. 
SDS sample buffer - Tris-HC1 (0.5 M), 30% glycerol, 10% SDS, 2- 13-mercaptoethanol, 
0.05% bromophenol blue, pH 6.8. 
SDS running buffer - Tris-HC1 (25 mM), glycine (192 mM), 1% SDS, pH 8.3 or 20 x MES 
buffer was diluted to I x with deionised water. 
Western blot transfer buffer - Tris-HC1 (25 mM), glycine (150 mM), 10% methanol, pH 
8.3. 
Western blot washing buffer - Dissolved 10 PBS tablets in I litre of deionised water and 
autoclaved at 121 °C for 20 mm. Upon cooling, 0.1% tween was added. 
Digestion buffer - Tris-HCI (50 mM), CaC1 2  (20 mM), 0.005% triton X-100, pH 8.3. 
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4.1.3 - Bacterial Growth Media and Antibiotics 
All media was autoclaved for 20 min at 121 °C and all antibiotics were sterile 
filtered through 0.22 jtM filters. 
2YT - Bacto-tryptone (16 g), bacto-yeast extract (10 g) and NaCl (5 g) were dissolved in 1 
litre of deionised water and adjusted to pH 7.5. 
Soc - Bacto-tryptone (20 g), bacto-yeast extract (5 g), NaCl (0.5 g), MgC1 2 (5 g) and 
glucose (3.2 g) were dissolved in 1 litre of deionised water and adjusted to pH 7.5. 
Luria Bertani (LB) - Bacto-tryptone (10 g), bacto-yeast extract (5 g) and NaCl (10 g) were 
dissolved in I litre of deionised water and adjusted to pH 7.5. 
Ampidilhin - a stock solution (100 mg/ml) is filtered (0.2 tM) and used at a final 
concentration (100 pg/ml) in various media. 
Kanamycin - a stock solution (30 mg/ml) is filtered (0.2 M) and used at a final 
concentration (30 pg/ml) in various media. 
LB Agar plates - Bacto-agar (15 g) was dissolved in 1 litre of LB to prepare agar plates. 
S-Gal/LB/amp plates - a sachet of S-Gal TM/LB Agar Blend without IPTG was dissolved in 
deionised water (500 ml) and autoclaved for 20 min at 121 °C. Once cooled ampilicillin 
(final conc. 100 jtg/ml) was added to the solution to prepare plates. 
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4.2 - DNA Manipulation 
4.2.1 - Oligonucleotide Primers 
The following oligonucleotide primers have been used in the various aspects of the 
study. 
NAME SEQUENCE (5' - 3') 
pGEM For TAATACGACTCACTATAGGG 
pOEM Rev ATTFAGGTGACACTATAGAA 
pET For CCCCTATAGTGAGTCGTATTA 
pET Rev GGATATAGTTCCTCCTFTCAGC 
pcDNA3. 1 For CGACTCACTATAGGGAGACCCAAG 
pcDNA3.1 Rev TAGAAGGCACAGTCGAGG 
HBD2 Primer I 
CAGATGCTGATGGGTATCGGTGACCCGGTTACCTGCCTGAAA 
TCC 
HBD2 Primer 2 
CGGACAGAAAACCGGGTGGCAGATAGCACCGGATTTCAGGC 
AGOT 
HBD2 Primer 3 
CCGGTTTTCTGTCCGCGTCGTTACAAACAGATCGGTACCTGCG 
GT 
HBD2 Primer 4 GCAGCATTTGGTACCCGGCAGACCGCAGGTACCGAT 
HBD2 Primer 5 ACCAAATGCTGCAAAAAATGACAGATGCTG 













HBD2 Met NdeI For GCGGCAGCCATGCGCATACCCCAGAACACATC 
HBD2 Met Nc/el Rev GATGTGTTCTGGGGTATGCGCATGGCTGCCGC 
CCR6 For GTTITCAGCAATGCCACGTGCAAG 
CCR6 Rev AAAGAAACCAAAGAGTAGCTCAAG 
131 
Chapter 4: Materials and Methods 
Internal CCR6 Rev GGCTGCAAATTTGGGTAAAA 
HBD2 S34G For CTGCGGTCTGCCGGGTACCAAATGCTG 
HBD2 S34G Rev CAGCAT'TTGGTACCCGGCAGACCGCAG 
Human 3-Actin For TGCAAGGCCGGCTFCGCGGGCGAC 
Human -Actin Rev GAAGCATfl'GCGGTGGACGATGGA 
Mutant HBD2 Primer AAGCTTATGGGTATCGGTGACCG 
HBD2 1-5 Primer 2 
CGCGGAGCGAAAACCGGGTGAGCGATAGCACCGGAmCAG 
GCAGGTAAC 
14BD2 1-5 Primer 3 
CGGTTFT'CGCTCCGCGTCGTTACAAACAGATCGGTACCGCTGG 
TCTGCCG 
HBD2 1-5 Primer 4 CTCGAGTITCACGGTTVVVFAGCGCATYT'GGTACCCGGCAGACC 
AGCGGTA 
HBD2 2-4 Primer 2 CGCGGAGCGAAAACCGGGTGGCAGATAGCACCGGATCAG 
AGCGGTAAC 
HBD2 2-4 Primer 3 CGGTTTTCGCTCCGCGTCGTI'ACAAACAGATCGGTACCTGCGG 
TCTGCCG 
HBD2 2-4 Primer 4 CTCGAGTTCACGGTTTTI'TAGCAGCTTTGGTACCCGGCAGACC 
GCAGGTA 
HBD2 3-6 Primer 2 ACGACGCGGACAGAAAACCGGGTGAGCGATAGCACCGGATT 
TCAGAGCGG 
HBD2 3-6 Primer 3 GTTTTCTGTCCGCGTCGTTACAAACAGATCGGTACCGCTGGTC 
TGCCGGG 
HBD2 3-6 Primer 4 CTCGAGTTCACGGTTTTTTGCAAGCTTTGGTACCCGGCAGACC 
AGCG 
HBD1 For ATGAGAACTTCCTACCTTCTGCTG 
HBD1 Rev CTTGCAGCACTTGGCCTTCCCTCT 
HBD2 For CCAGCCATCAGCCATGAGGGTCTT 
HBD2 Rev GGAGCCCTTTCTGAATCCGCATCA 
Table 4.1. Oligonucleotide Primer Sequences used in this Study. 
4.2.2 - Electrophoresis of DNA 
Agarose (1-2% w/v) was dissolved in 1 x TAE buffer upon heating (100 °C). Upon 
cooling (50-60 °C), ethidium bromide (0.5 p.g/ml) or GelRed TM (Cambridge BioScience) 
was added, mixed and immediately poured into the casting mould. After solidifying at room 
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temperature, DNA samples were mixed with 5 x loading buffer (Bioline) and electrophersed 
at 100 volts (V) until good resolution was observed between the bands. 
4.2.3 - Purification of DNA from Agarose Gel 
The appropriate DNA band was excised using a clean scalpel identified by UV 
illumination. Excess agarose was removed prior to purification of the DNA using QiAquick® 
Gel Extraction Kit (Qiagen) carried out in accordance with the manufacturer's instructions. 
DNA was eluted in a final volume of 20 jtl deionised water. 
4.2.4 - Ligation into pGEM Cloning Vector 
T4 DNA ligase (1 jtl) was added to a mixture already including purified DNA (3 jtl), 
pGEM-T Easy Vector (1 l) and 2 x T4 ligation buffer (5 jil). Ligations were incubated 
either for an hour (hr) at room temperature or overnight at 4 °C. Subsequently an aliquot (2 
l) of the ligation reaction was used to transform JM 109 E. coil competent cells as described 
in section 4.2.6. 
4.2.5 - Ligation into Expression Vector 
Generally, T4 DNA ligase (1 j.tl) was added to a mixture already including purified 
DNA cut with appropriate restriction enzymes (13 j.tl), expression plasmid cut with 
appropriate restriction enzymes (4 p.1) and 10 x T4 ligation buffer (2 p.1). Ligations were 
incubated overnight at 4 °C and an aliquot (2 p.1) of the ligation mixture was used to 
transform Top 10 E.coli competent cells as described in section 4.2.6. 
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4.2.6 - Transformation of Competent Cells with Plasmid DNA 
Competent cells were thawed at 4 °C for 5 minutes (mm) before 2 jtl of plasmid 
DNA (-40 ng) was added and gently mixed. Incubation proceeded at 4 °C for 30 min before 
being subjected to heat shock for 30 seconds (see) at 42 °C. Cells were then returned to 4 °C 
for 2 mm. Soc (250 tl) was added under sterile conditions and shaken at 200 rpm for 1.5 
hrs at 37 °C. Subsequently, the cell suspension was spread to dryness on selective agar and 
incubated overnight at 37 °C. 
4.2.7 - Purification of Plasmid DNA 
Plasmid DNA was purified using the QlAprep ® Spin Miniprep Kit (Qiagen) 
following the manufacturer's instructions and DNA was eluted in a final volume of 100 jtl 
deionised water. Plasmid DNA was identified by restriction endonuclease analysis as 
described in section 4.2.8. 
4.2.8 - Small Scale Restriction Enzyme Digestion of DNA 
Generally, 8 tl purified plasmid DNA (-1 tg) was treated with the appropriate 10 x 
buffer (1 pi) and restriction endonucleases (1 1.11) (New England Biolabs). After incubation 
for 2 hrs at 37 °c, loading dye was added to stop the reaction and was analysed by agarose 
gel electrophoresis. Agarose gels were viewed by trans illumination using UV-light. 
4.2.9 - Large Scale Restriction Enzyme Digestion of DNA 
Generally, 43 pi purified plasmid DNA (-4 p.g) was treated with the appropriate 10 
x buffer (5 p.1) and restriction endonucleases (1 p.1 of each). After incubation for 2 hrs at 37 
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°C, loading dye was added to stop the reaction and was analysed by agarose gel 
electrophoresis. Agarose gels were viewed by trans illumination using UV-light. 
4.2.10 - General PCR Reaction 
Normally PCR reactions were carried out using a Perkin Elmer 480 Thermal Cycler. 
Template DNA (3 p.1) was added to a PCR tube already containing 2 x puRe Taq Ready-To-
Go PCR beads, deionised water (37 j.tl), forward primer (5 p.1, of a 10 p.M stock, to give a 
final concentration of I p.M) and reverse primer (5 p.1 of a 10 p.M stock) and covered with 
nujol oil. After a hot start (5 mm, 94 °C) the reaction was generally subjected to 30 cycles: 
PROCESS TEMPERATURE (°C) TIME (SEC) 
Denaturation 94 60 
Annealing 60 30 
Elongation 72 60 
A further elongation step (72 °C, 10 mm) was included for addition of A-overhangs to 
produce a product which can be ligated into the linear pGEM cloning plasmid with 'T' 
overhangs. The PCR reactions are then prepared and electrophoresed as described in section 
4.2.2. Generally the annealing temperature is set to -5 °C less than the primer's melting 
temperature. 
4.2.11 - Gene Synthesis 
Recombinant defensin genes were constructed using recursive PCR performed on an 
eppendorf ® Mastercycler Personal. Using HBD2 as a typical reaction, six overlapping 
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primers with codons optimized for expression in E. coli were designed using the mature 
HBD2 amino acid (AA) sequence. The reaction contained in a final volume of 100 tl; 10 p.1 
(100 pmol) of the outermost 5' primers (HBD2 Primer 1 and HBD2 Primer 6) of each strand, 
10 p.1(10 pmol) of the internal primers (1-IBD2 Primer 2 - HBD2 Primer 5), 4 p.1 DMSO, 10 
p.110 x Herculase reaction buffer (Stratagene), 4 p.1 25 mM dNTPs, 21 p.1 dH 20 and finally I 
p.! Herculase Hotstart DNA polymerase (Stratagene). This reaction mixture was subjected to 
30 PCR cycles of 95 °C for 2 mm, 40 °C for 3 min and 72 °C for 30 sec. A general PCR 
reaction was performed to confirm annealing of all six primers in a final volume of 50 p.!; 5 
It! HBD2 Primer 1 (50 pmol), 5 p.1 HBD2 Primer 6 (50 pmol), 2 p.! template, 38 p.1 dH 20 and 
2 puRe Taq Ready-To-Go PCR beads were subjected to 30 PCR cycles of 95 °C for 2 mm, 
40 °C for 3 mm, 72 °C for 30 sec and a final extension of 72 °C for 10 min to add 'A' 
overhangs. The PCR product containing the codon optimized gene preceded by a methionine 
(Met) and flanking A1wNI recognition sites was purified by agarose gel electrophoresis, 
extracted and ligated into pGem T Easy vector as described previously. Each of the HBD2 
single disulfide mutant genes were also synthesized using this method. 
Dr David Clarke constructed HBD2 1-5 and HBD2 3-6 
4.2.12 - Megaprimer Mutagenesis 
The megaprimer mutagenesis method used was adapted from a method previously 
described [1]. A standard PCR reaction was performed as described in section 4.2.10, 
including a forward mutagenic primer (5 p.1, of a 10 p.M stock) and reverse plasmid primer (5 
p.d of a 10 1iM stock). The PCR products were separated by 1% agarose gel electrophoresis 
and the DNA band representing the 'megaprimer' was excised, purified and 5 p.1 was used in 
a second PCR reaction using forward plasmid primer (5 p.1 of a 10 p.M stock). 
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4.2.13 - Site-Directed Mutagenesis PCR 
Site-directed mutagenesis was performed using the Quickchange Site-Directed 
Mutagenesis kit (Stratagene) and was performed as described in the manufacturer's 
instructions. DpnI treated PCR product was transformed into ToplO E.coli competent cells 
as described in section 4.2.6. 
4.2.14 - DNA Sequencing 
Sequencing reactions contained the following: DNA template (5 tl); primer (1 pi); 5 
x Big Dye Sequencing buffer v3.1 (2 p.!); and Big Dye v3.1 (2 p.1). All sequencing reactions 
were carried out on an E ppendorf® Mastercycler Personal and the program consisted of: 
STEP TEMPERATURE (°C) TIME 
Step 1 94 30 sec 
Step 2 94 30 sec 
Step 3 45 30 sec 
Step 4 60 4 mm 
Steps 2-4 
x 30 cycles 
All sequencing was performed on an ABI prism 377 DNA sequencer using the Sanger 
dideoxy chain termination method. 
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4.3 - Cell Culture 
4.3.1 - Culture of CaCo2 Cells 
The human colonic epithelial cell line, CaCo2, were grown to confluency in 
Dulbecco modified Eagle's medium (DMEM), supplemented initially with 2% fetal calf 
serum (FCS), and 1% antibiotic agent (Penicillin/streptomycin). Since cells did not attach 
directly to the 75 cm 2  flasks when seeded with ITS (insulin, selenium and transferrin) 
supplemented media, 2% FCS was used initially and then replace with ITS once CaCo2 cells 
had attached. Cells were maintained at 37 °C in a water saturated incubator with 5% CO2 and 
media changed every 3 days. Once confluent, cells were washed twice with PBS (5 ml) and 
incubated at 37 °C with trypsin (3 ml, 0.075%) until cells detached from the surface. The 
reaction was stopped with addition of media (9 ml) and cells were centrifuged (5,000 rpm, 5 
mm). The pellet was subsequently resuspended in 1 ml media and transferred (250 j.tl) to a 
new culture vessel. Alternatively cells were grown for up to 3 weeks, with media replaced 
every 3 days. The harvested supernatants were subsequently stored at -20 °C for future 
protein analysis. 
4.3.2 - Stimulation Protocols 
Confluent CaCo2 cells in six well tissue culture plates (Gibco BRL) were stimulated 
at time points up to 6 hrs with IL-fl3 (10 nglml) (Peprotech 
EC) Afterwards, supernatants 
were removed and the cells were used for RNA extraction and RT-PCR analysis as described 
below. CaCo2 cells grown in 75 cm2  culture flasks were stimulated with IL-i 3 for 6 hrs and 
supernatants were harvested and stored at -20 °C prior to I-IBD2 purification. 
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4.3.3 - Purification of Mature HBD2 from CaCo2 Cells 
IL-l13 stimulated CaCo2 supernatants were diluted 4-fold in 10 mM HEPES buffer 
(pH 8.1) to reduce the salt concentrations before being incubated with 1 ml Fractogel EMD 
s03- -650 (Merck), pre-equilibrated with 10 mM HEPES, 50 mM NaCl (pH 8. 1), for 2 hrs at 
4 °C. The Fractogel resin was then centrifuged (500 x g, 5 mm), and washed with 5 column 
volumes (CV) of pre-equilibration buffer. Fractions were then eluted with 1 CV of 10 mM 
HEPES containing 125 mM, 250 mM, 500 mM, and I M NaCl. Elution fractions were 
analyzed for HBD2 production using SDS-PAGE and anti-HBD2 western blot analysis. 
4.3.4 - Culture of HEK 293 and HEK 293 CCR6 Cells 
Both HEK293 and CCR6 transfected HEK293 cells were maintained in DMEM, 
supplemented with 10% FCS, 1% antibiotic agent (Penicillin/streptomycin) and sodium 
pyruvate (1 mM). H1EK293/ CCR6 cells were also supplemented with G418 Geneticin. Cells 
were maintained at 37 °C in a water saturated incubator with 5% CO2 and media changed 
every 3 days until cells needed. 
4.3.5 - Culture of Murine LI .2 pre-13 Cells 
Both murine LI .2 pre-B control and transfected cells were maintained in RPM! 
1640, supplemented with 10% FCS, 1% antibiotic agent, 13-mercaptoethanol (50 jtM) and 
glutamine (5 mM). Transfected L1.2 pre-B cells were also supplemented with G418 
Geneticin. Cells were maintained at 37 °C in a water saturated incubator with 5% CO2 and 
media changed every 3 days until cells needed. 
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4.3.6 - Linearization and Purification of pcDNA3.1/CCR6 
The vector pcDNA3.1/CCR6 was linearized prior to transfection into HEK293 cells. 
Large scale digestion was performed, as described in section 4.2.9, using the unique PvuI 
restriction site in pcDNA3 . l/CCR6. DNA was purified by gel extraction after separation by 
agarose gel electrophoresis. An equal volume of phenollchloroformlisoamyl alcohol 
(25:24:1) was added to the purified DNA, vortexed and centrifuged (13,000 rpm, 1 mm). In a 
new eppendorf, the upper phase was added and mixed with an equal volume of 
chloroformlisoamyl alcohol (24:1), vortexed and centrifuged (13,000 rpm, 1 mm). Upper 
phase was moved to a fresh tube were sodium acetate (3 M, 10% v/v) and ethanol (200% 
v/v) were added before precipitating at -20 °C. Precipitated DNA was centrifuged (13,000 
rpm, 15 mm), washed twice with 75% ethanol and resuspended in an appropriate volume of 
dH2O. 
4.3.7 - Transfection into Mammalian Cells 
Plasmid DNA transfection was carried out according to the Lipofectamine 2000 
(Invitrogen) or Superfect (Qiagen) manufacturer's instructions. In brief, DNA transfection 
into 1-1EK293 mammalian cells was carried out in 24 well plates at a ratio of DNA to 
LipofectamineTM 2000 of 1:2.5. Linearized DNA (0.8 jig) was diluted in Opti-MEM 
Reduced Serum Medium (50 p.1) with no additional FCS added and mixed gently. 
Lipofectamine (2 p.l) was diluted in the same media and incubated at room temperature for 5 
mm. Both components were then incubated together for 20 min at room temperature before 
being added to the confluent cells which one day before transfection were subcultured and 
plated at 1 x 106  cells in growth media without antibiotics. Cells were incubated at 37 °C, 5% 
CO2  for 24 his before being passaged into fresh media at 1:10. 24 his later reduced serum 
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medium was replaced with selective media and cells were cultured as before until control 
cells without linearized plasmid DNA were killed. 
DNA transfection into murine L1.2 preB-cells was carried out in 60 mm cell culture 
dishes at a ratio of DNA to Superfect of 1:4. DNA (5 tg) was diluted in serum free media 
(150 ltl) with no additional FCS or antibiotics added, and mixed gently. Superfect (20 pi) 
was incubated with the DNA for 10 min at room temperature before being added to L1.2 
cells which one day before transfection were subcultured and seeded in growth media 
without selective antibiotics. 48 hrs later, L1.2 cells were passaged and grown in selective 
media in 96 well plates until control cells were killed. 
4.3.8 - Isolation of Monocytes 
Monocytes were isolated from human donor blood preparations. Freshly extracted 
blood was added to sodium citrate (3.8%) before centrifugation (12,000 rpm, 20 mm, brake 
off). Supernatent (Supernatent A) was removed with an aliquot (25 ml) centrifuged (3,000 
rpm, 15 mm) and this supernatant collected (Supernatent B) and stored till needed. 10 ml 
aliquots of supernatant A were placed in glass tubes containing CaC1 2 0  M) and incubated at 
37 °C until blood clot formed. Dextran (6%) was added to the remaining cells and made up 
to a final volume of 50 ml with NaCl (0.9%) and allowed to mix for 15-30 min until red 
blood cells settled. Supernatent was subsequently centrifuged (1000 rpm, 6 mm) and the 
pellet resuspended in 2 ml supernatant B. White blood cells were then separated using 42% - 
51 % Percoll gradients. Carefully 42% Percoll gradient (840 tl 90% Percoll and 1 160 p.1 
supernatant B) was added to resuspended the pellet followed by the addition of 51% Percoll 
gradient mixture (1020 p.1 90% Percoll and 980 p.1 supernatant B), mixed and centrifuged 
(1000 rpm, 10 mm, brake off). Monocytes (upper layer) were removed and resuspended in 
IMDM serum free media (PAA) before centrifugation (12,000 rpm, 5 mm). This step was 
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repeated twice more until monocytes were resuspended at a concentration of 4 x I 0 6/ml and 
seeded in a 96 well plate. After 2 hrs IMDM serum free media was replaced with 10% 
autologous serum supplemented media and monocytes were allowed to age for 7 days before 
LPS stimulation experiments. 
Method was optimized and performed by Katherine Miles. 
4.3.9 - LPS Solubilization 
Kd02-lipid A (1 mg/ml) was dissolved in sterile PBS and sonicated for 5 min in a 
bath sonicator. After centrifugation (13,000 rpm, 1 mm) the stock solution was transferred to 
a clean eppendorf and stored at -20 °C until needed. 
4.3.10 - LPS Stimulation 
24 hrs before LPS stimulation IMDM media with 10% autologous serum was 
replaced with serum free IMDM media. Kd0 2-lipid A was incubated for 30 min at room 
temperature either alone or in combination with different concentrations of BioHBD2 or 
polymyxin B (final volume of 200 p.1 made up with IMDM serum free media). 24 hrs after 
stimulation supernatant was removed and used directly for TNF-a ELISA analysis. 
4.3.11 - RNA Extraction from Mammalian Cells 
Total cellular RNA was extracted from confluent cells in six well plates using 
RNAzol B (1 ml, Biogenesis). Lysed cells we transferred to a screw-cap tube containing 
chloroform (10% w/v), shaken vigorously (15 sec) and placed on ice for 5 mm. After 
centrifugation (15,000 rpm, 15 mm, 4 °C), the upper phase containing RNA was transferred 
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to a sterile tube. The RNA was precipitated with an equal volume of isopropanol and 
incubated for 15 min at 4 °C. After centrifugation (15,000 rpm, 15 mm, 4 °C), the pellet was 
washed with 75% ethanol (2 ml) and centrifuged again (15,000 rpm, 5 mm, 4 °C). This step 
was repeated before the pellet was dried and finally resuspended in diethylpyrocarbonate 
(DEPC) treated water. The quantity and purity of RNA was assessed by spectrophotometry. 
4.3.12 - Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
First strand cDNA synthesis was accomplished using a first-strand cDNA synthesis 
kit for RT-PCR (Roche). RNA (2 jtg) resuspended in 7.8 jil DEPC-treated water was used as 
the template. RNA samples were denatured for 15 min at 65 °C, before being returned to ice. 
A reaction mixture containing 2 tl 10 x PCR buffer, 4 tl MgCl 2 (5 mM final concentration), 
2 ti dNTPs (1 mM final concentration), 0.4 p.! Gelatin (0.01 mg/mi final concentration), 2 p.1 
random p(dN)6 primer (3.2 p.g), 1 p.1 RNase inhibitor (50 units final concentration), and 0.8 
p.! Avian Myeloblastosis Virus - reverse transcriptase (AMV-RT) (20 units final 
concentration) was then added to denatured RNA. Duplicate samples were prepared without 
AMV-reverse transcriptase. Samples were incubated at room temperature to allow primers to 
anneal before incubating for 60 min at 42 °C. To deactivate, the RT samples were incubated 
for 5 min at 95 °C before being returned to ice. These samples were then used as the 
template for second strand synthesis. 
4.3.13 - Chemotaxis Assay 
Chemotaxis assays were carried out as previously described [2]. Multiwell 
Chemotaxis Chamber assays were performed using HEK 293 cells overexpressing CCR6 
and synthetic CCL20 (PeproTech) used as a positive control. Chemotactic index value was 
143 
Chapter 4: Materials and Methods 
calculated for the optimal chemotactic concentration. All experiments were performed in 
triplicate and each experiment repeated three times. The number of cells per high power field 
(HPF) were counted for each concentration of peptide and the mean calculated for all three 
experiments. A sample data set is shown below. To assure the results are statistical relevant a 
paired, two tailed Student's t-test is performed using the t test statistical program on 
Microsoft Excel (=TTEST(data set 1, data set 2,2, 1). When performing the t test, data set 2 
was always the media control values. With the statistical significance set at p  <0.05, any 
value less than this can be identified as statistically relevant. In the example below this is 




0.1 1 10 100 1000 MEDIA 
CONTROL  
1 60 103 99 61 65 73 
2 64 117 119 52 89 80 
3 57 88 93 96 59 76 
4 70 118 109 109 84 108 
5 75 105 113 91 65 87 
6 102 113 100 97 84 108 
7 106 118 98 75 87 80 
8 93 97 113 79 78 111 
9 76 111 110 104 76 107 
Mean 78.11111 107.7778 106 84.88889 76.33333 92.22222 
S.D. 6.035645 3.475221 2.910708 6.496675 3.636237 5.306646 
pvalue 0.046115 0.025906 0.026494 0.205606 0.014765 
Method was optimized and performed by Uday Pathania and Fiona Kilanowski. 
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4.4 - Protein Expression and Purification 
4.4.1 - Defensin Purification 
All wild-type and single disulfide bond mutant 13-defensins were expressed and 
purified using identical protocols until the chemical oxidation step. 1-IBD2 expression and 
purification method will be described below as an example. 
4.4.1.1 - Defensin Purification Buffers 
Resuspension buffer - Tris-HC1 (50 mM), 25% sucrose, EDTA (1 mM), 0.1% sodium 
azide, DTT (10 mM), pH 8.0. 
Lysis buffer - Tris-HC1 (50 mM), 1% triton X-100, NaC1 (100 mM), 0.1% sodium azide, 
DTT (10 mM), pH 8.0. 
Wash buffer - Tris-HC1 (50 mM), 1% triton X-100, NaCl (100 mM), EDTA (1 mM), 0.1% 
sodium azide, DTT (1 mM), pH 8.0. 
1 M Guanidine HCI buffer - GdnHCl (1 M), Tris-HCL (50 mM), 1% triton X-100, NaCl 
(100 mM), EDTA (1 mM), 0.1% sodium azide, DTT (1 mM), pH 8.0. 
6 M Guanidine HCI buffer - GdnHC1 (6 M), Tris-HC1 (50 mM), imidazole (10 mM), NaCl 
(500 mM), 3-Mercaptoethanol (5 mM), pH 8.0. 
Elution Buffer - GdnHC1 (6 M), Tris-HC1 (50 mM), imidazole (120 mM), NaCl (500 mM), 
3-mercaptoethanol (5 mM), pH 8.0. 
Reducing buffer - Tris-HC1 (25 mM), TCEP (20 mM), pH 8.0. 
Wild type oxidation buffer - Tris-HC1 (50 mM), cysteine (3 mM), cystine (0.3 mM), pH 
8.0. 
Mutant oxidation buffer - Sodium phosphate (50 mM), 20% DMSO, pH 8.0. 
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4.4.1.2 - Ketosteroid Isomerase (KSI)43-defensin Expression in E.coli 
One freshly transformed BL2 1 (DE3) colony containing the pET-28aIHISKSI-
HBD2 plasmid was used to inoculate 250 ml of 2YT medium, containing 30 tg/ml 
kanamycin. This was grown at 37 °C on an orbital shaker for 12 hrs and then an appropriate 
volume was added to 3 litres of 2YT, containing 30 g/m1 kanamycin to give a final 0D 600 of 
0.1 and divided equally into six one litre flasks, with approximately 500 ml in each flask. 
Cells were grown at 37 °C until an 0D 600  of 0.5, induced with a final concentration of 1 mM 
(IPTG), and incubated for a further 6 hrs. Cells were 
subsequently harvested by centrifugation (8000 x g, 10 mm, 4 °C). The cell pellet was stored 
at -20 °C until needed for protein extraction. 
4.4.1.3 - Isolation of KSI-13-defensin Inclusion Bodies 
All centrifugation steps were carried out for 20 min at 11000 x g and 4 °C. The cell 
pellet was suspended in 5 mL resuspension buffer per gram of wet pellet, before addition of 
50 mg/ml lysozyme, 500 MM MgCl 2  and 10 pi DNase. After incubation for 30 min at room 
temperature, 5 ml/g wet weight pellet of lysis buffer was added and incubated for 45 min at 
room temperature. To this extract, 1 mM EDTA (500 mM stock) was added and the sample 
was snap-frozen in liquid N 2, before being thawed for 30 min in a 37 °C water bath. To this 
extract 1 mM MgC1 2  (500 mM stock) was added and the sample left at room temperature for 
1 hr to allow a decrease in viscosity before another 1 mM EDTA was added and immediately 
centrifuged. The pellet was washed in an appropriate volume of wash buffer, sonicated for 4 
x 30 sec blasts on ice and centrifuged. The pellet was then washed in 1 M Guanidine HC1 
buffer, sonicated for 4 x 30 second blasts on ice and centrifuged. The resultant pellet was 
resuspended in 6 M GdnHCl buffer and added to pre-equilibrated nickel-nitrilotriacetic acid 
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(Ni-NTA) agarose affinity chromatography (Qiagen). Mixture was incubated for 1 hr at 4 °C 
in an end-over-end rotator, before being washed 3 x with 5 column volumes of 6M GdnHC1 
buffer. Protein was eluted 3 x with 5 column volumes of elution buffer and subsequently 
dialyzed against 25 mM Tris buffer, pH 8.0 overnight at 4 °C which formed a precipitate of 
partially pure KSI-HBD2. 
4.4.1.4 - Cyanogen Bromide (CNBr) Cleavage of KSl-3-defensin Fusion 
Protein 
Precipitated fusion protein was centrifuged and the pellet resuspended in either 
degassed 6 M GdnHCl, 25 mM Tris-HC1 buffer pH 8.0 and acidified with droplet additions 
of HC1 (5 M) until pH -1 or resuspended in degassed 70% formic acid. Solid CNBr (final 
concentration 250 mM) was added and cleavage proceeded for 24 hrs in the absence of light 
and under nitrogen. The cleaved mixture was evaporated at 42 °C using a rotary evaporator 
to remove any unreacted CNBr, and the concentrated sample was either precipitated by 
dialysis against 25 mM Tris-HC1 buffer, pH 8.0 overnight at 4 °C (GndHC1 cleavage) or 
freeze-dried (70% Formic acid cleavage). Precipitated KSI was removed by centrifugation 
(11000 x g, 20 mm, 4 °C) and the aqueous phase containing impure HBD2 was filtered and 
purified by RP-HPLC as described in section 4.4.1.6. HBD2 was extracted from the freeze-
dried mixture of KSI and HBD2 with 0.01% acetic acid. HBD2 formylation was partially 
reversed upon dialysis against 25 mM Ammonium acetate, pH 9.5, overnight at 4 °C and 
was monitored using positive electrospray ionisation mass spectrometry (ESI-MS) described 
in section 4.8.5. 
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4.4.1.5 - Reverse phase-High Pressure Liquid Chromatography 
(RP-HPLC) Purification of 3-defensins 
RP-I-IPLC on a JupiterTM Proteo column was performed on a Waters 600 control 
pump with a photo diode array 996 detector instrument using Millenium 32 software. Impure 
HBD2 was loaded into a 5 ml loop and injected onto the JupiterTM Proteo column at a flow 
rate of 3 ml/min. The proteins were eluted using a gradient of 5-55% acetonitrile over 50 mm 
at a flow rate of 3 ml/min. Protein fractions containing 3-defensin were identified by SDS-
PAGE and positive ESI-MS. A mixture of partially reduced and oxidized peptides identified 
were pooled together and freeze-dried. Freeze-dried peptides were resuspended in reducing 
buffer and purified on RP-HPLC as described above. Fractions containing only reduced 13-
defensins were identified as before and were freeze-dried prior to chemical oxidation. 
4.4.1.6 - Chemical Oxidation of 13-defensins 
All reactions were carried in sealed containers under N 2  and using degassed buffers. 
Freeze-dried, reduced, wild-type peptides (400 g) were dissolved in wild-type oxidation 
buffer and stirred for 4 hrs at room temperature. All reduced single disulfide mutant HBD2s 
(400 g) were dissolved in mutant oxidation buffer and the reaction was allowed to proceed 
for 3 days at room temperature with gentle stirring. The reactions were followed by RP-
HPLC and analyzed by positive ESI-MS, to confirm the completion of the oxidation 
reaction. 
In addition, freeze-dried, reduced HBD2 (400 g) was dissolved in three additional oxidation 
buffers to identify the optimal HBD2 oxidation conditions: Sodium phosphate (50 mM), 
20% DMSO, pH 8.1; GdnHCl (1 M), NaHCO 3  (100 mM), cysteine (3 mM), cystine (0.3 
mM), pH 8.1; Tris-HC1 (25 mM), ammonium acetate (100 mM), GSH (100 mM),GSSG (10 
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mM), pH 7.8. Reactions were allowed to proceed for 4 hrs at room temperature and reactions 
were monitored as before. 
4.4.2 - Chemokine Receptor 6 (CCR6) Purification 
4.4.2.1 - Crude Protein Extraction from CCR6 Expressing HEK293 
Mammalian Cells 
CCR6 expressing HEK293 cells were maintained as described above in six well 
tissue culture plates (Gibco BRL) and cells were grown until confluent. Cells were lysed 
using CelLyticTM-M (Sigma-Aldrich) with protease inhibitor cocktail (Sigma-Aldrich) 
added. Mammalian cell lysis was performed according to the manufacturer's instructions and 
was carried out at 4 °C to reduced proteolysis. Protein containing supernatants were either 
stored at -80 °C or analyzed by SDS-PAGE and western blot. 
CCR6 expressing HEK293 cells were treated with sodium butyrate (10 mM) at 
—80% confluency for 18 hrs prior to cell lysis and analyzed as described previously. 
4.4.2.2 - Buffers used in CCR6 Purification 
Buffer A - FIEPES (20 mM), EGTA (1 mM), pH 7.4. 
Buffer B - HEPES (20 mM), EGTA (1 MM), MgCl 2 (5 mM), 20% glycerol (v/v), 2% DDM 
(w/v) and 0.25% CHS (wlv), pH 7.4. 
Buffer C - HEPES (20 MM), MgC12 (5 mM), NaCl (300 mM), imidazole (20 mM), 20% 
glycerol, 2% DDM (wlv) and 0.25% CHS (w/v), pH7.4. 
Buffer D - HEPES (20 mM), NaCl (150 mM), imidazole (10 mM), 20% glycerol, 2% DDM 
(w/v) and 0.025% CHS (w/v), pH 7.4. 
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Buffer E - HEPES (20 mM), NaCl (150 mM), imidazole (300 mM), 20% glycerol, 0.2% 
DDM (w/v) and 0.025% CHS (w/v), pH 7.4. 
Buffer F - HEPES (20 mM), NaCl (150 mM), imidazole (500 mM), 20% glycerol, 0.2% 
DDM (w/v) and 0.025% CHS (w/v), pH 7.4. 
Buffer G - HEPES (20 mM), NaCl (150 mM), 20% glycerol, 0.2% DDM (w/v) and 0.025% 
CHS (w/v), pH 7.4. 
Buffer H - HEPES (20 mM), NaCl (150 mM), imidazole (30 mM), 20% glycerol, 0.2% 
DDM (w/v) and 0.025% CHS (w/v), pH 7.4. 
Buffer I - HEPES (20 mM), NaCl (150 mM), imidazole (500 mM), 20% glycerol, 0.2% 
DDM (w/v) and 0.025% CHS (w/v), pH 7.4. 
Buffer J - HEPES (20 mM), NaCl (150 mM), 3 x FLAG ® peptide, 20% glycerol, 0.2% 
DDM (w/v) and 0.025% CHS (w/v), p1-I 7.4. 
4.4.2.3 - HEK293/CCR6 Membrane Isolation 
Membranes were prepared as previously described for the human T-cell line, CEM 
cells [3]. Briefly, cells were scrapped into ice cold PBS and centrifuged (1000 rpm, 5 mm, 4 
°C) to collect all unbroken cells. Cell pellet was washed twice more before being 
resuspended in buffer A containing an EDTA-free protease inhibitor cocktail (Roche). Cells 
were lysed by physical disruption using 40 strokes of a tight pestle in a Dounce 
homogeniser. Cell lysate was firstly, centrifuged (1000 rpm, 10 min at 4 °C) before being 
ultracentrifuged (30,000 rpm, 30 mm, 4 °C) to form the crude membrane pellet. Crude 
membrane was then washed by resuspension in buffer A and then ultracentrifuged (30,000 
rpm, 30 mm, 4 °C). Finally the HEK293ICCR6 membrane preparation was resuspended in 
buffer A and either frozen in liquid N 2, and stored at -80 °C or solubilized as described 
below. 
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4.4.2.4 - Solubilization Protocol 
HEK293 membrane preparations were solubilized in buffer B containing an EDTA-
free protease inhibitor cocktail. Membranes were incubated in solubilization buffer B for 2 
hrs at 4 °C in an end-over-end rotator. Insoluble material was removed by ultracentrifugation 
(30,000 rpm, 30 mm, 4 °C). 
4.4.2.5 - HIS Tag Purification of CCR6 
All purification steps were carried out at 4 °C unless stated otherwise. Solubilized 
membranes were diluted 2-fold in buffer C and incubated with buffer D pre-equilibrated Ni-
NTA resin overnight in an end-over end rotator. Resin was poured into a 5 ml disposable 
column and allowed to settle under gravity. Resin was washed (1 CV, 3 x) in buffer C before 
being first eluted (1 CV, 3 x) with buffer E, then eluted (1 CV, 3 x) with buffer F. Fractions 
containing CCR6, identified by western blot were pooled together and diluted in buffer G till 
a final buffer concentration of 20 mM imidazole was obtained. CCR6 was further purified 
using lml pre-equilibrated Talon Cobalt resin (BD Clonetech, Oxford, UK) and eluted using 
buffer F. imI fractions were collected and analyzed for CCR6 using SDS-PAGE and western 
blot. 
4.4.2.6 - HIS Tag followed by Gel Filtration Chromatography Purification 
of CCR6 
Purification was carried out exactly as above except the Talon Cobalt resin step was 
replaced with a calibrated Prepacked Tricorn Superdex 200 10/300 GL (GE Healthcare) 
gel filtration step. Fractions containing CCR6 after Ni-NTA purification were identified as 
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above and were concentrated by ultrafiltration (VivaSpin concentrator, 30 kDa molecular 
weight cut-off). Filtered (0.45 jim) CCR6 samples were loaded into a 1 ml sample loop and 
injected onto a pre-equilibrated Superdex 200 10/300 GL gel filtration column using FPLC 
(AKTAexplorer 10, GE Healthcare). Column was run at an isocratic flow rate of 0.4 ml/min  
using buffer G as the mobile phase. Fractions containing CCR6 were identified as before. 
4.4.2.7 - Gel Filtration Calibration 
Prepacked TricornTM  Superdex 200 10/300 GL was calibrated using a protein 
mixture consisting of Aldolase, Ovalbumin, Ribonuclease A, and Aprotinin dissolved in 
buffer E. A sample volume of 0.5% total column volume (TCV) was loaded onto a 100 jtl 
loop and injected onto the preequilibrated column. Column was run at an isocratic flow rate 
of 0.4 ml/min using buffer G as the mobile phase and calibration curve was calculated 
according to the manufacturer's instructions. Void volume had previously been calculated 
using Blue Dextran (1 mg/ml, 0.5% TCV). 
4.4.2.8 - HIS Tag followed by FLAG Immuno-Affinity Purification of 
CCR6 
All purification steps were carried out at 4 °C unless stated otherwise. Filtered (0.45 
jim) solubilized membranes were diluted 2-fold in buffer C and loaded into a 10 ml 
superloop and injected onto a pre-equilibrated 5 ml HisTrap TM  column (GE Healthcare) 
using FPLC (AKTABasic 100, GE Healthcare). Protein fractions were eluted with a linear 
irnidazole gradient (100% buffer H to 100% buffer I) over 20 CV and eluted proteins were 
monitored at A 280 . CCR6 containing fractions were determined by SDS-PAGE and western 
blot analysis as described before. CCR6 containing fractions were concentrated by 
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ultrafiltration (VivaSpin concentrator, 30 kDa molecular weight cut-off) and were incubated 
with washed and pre-equilibrated Anti-Flag M2 affinity gel (Sigma-Aldrich) for 2 hrs at 4 
°C. The affinity gel had previously been washed 3 x with 0.1 M glycine HCl, pH 3.5, 3 x 
with PBS and pre-equilibrated with 3 washes of buffer G. Resin was then poured into a 1 ml 
disposable column and allowed to settle under gravity. After 5 x 1 CV washes with buffer G, 
the protein was eluted using buffer J. 1 ml fractions were collected and analyzed for CCR6 
using SDS-PAGE and western blot. 
4.5 - Enzymatic Digestion of Proteins 
4.5.1 - Protease Digestion of -defensins 
Enzymatic digestion of peptides (1 mg/ml) with chymotrypsin (500 jig/ml) and/or 
trypsin (500 jxgIml) and was performed at 37 °C in digestion buffer and allowed to proceed 
overnight. After addition of 0.05% TFA to terminate reaction, cleavage products were 
analyzed by Liquid chromatography (LC)-ESI-MS as described in section 4.8.6. 
4.5.2 - In-Gel Digestion 
Excised protein gel bands were placed in sterile 1.5 ml eppendorf tubes and dried in 
a GyroVap for 30 min prior to treatment. Dried gel pieces were washed with 50% 
acetonitrile (ACN) twice and dried in GyroVap for 15 mm. Protein disulfide bonds were then 
reduced with DTT/EDTA (100 niM Ammonium Bicarbonate, 10 mM DiT, 0.2% EDTA) for 
30 min at 56 °C and cysteines alkylated, upon cooling to room temperature, with 
iodoacetamide (100 mM Ammonium Bicarbonate, 50 mM iodoacetamide) in the dark for 30 
min at room temperature. Gel pieces underwent three cycles of washing (100 mM 
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Ammonium Bicarbonate) for 10 min at room temperature and dehydration (50% ACN) for 
10 min at room temperature before being GyroVap for 15 mm. Trypsin was added directly to 
the gel piece until completely absorbed before ammonium bicarbonate (50 mM) was added 
and incubated for 12-16 hrs on an orbital shaker at 37 °C. Alternatively, prior to trypsin 
digest, the gel piece was incubated with CNBr (5 M, 5 tl). Digested peptide solution was 
evaporated in the GyroVap and stored at -20 °C. 
4.5.3 - Protein Precipitation 
Purified CCR6 was precipitated with a mixture of chloroform, methanol and TFA. 
Methanol (150 tl) and chloroform (100 j.il) were added to the protein solution (50 jil at 0.88 
mg/ml) and vortexed. Addition of 10% TFA (100 p1) was followed by centrifugation (13,000 
rpm, 20 mm) to separate the two phases. Protein precipitated at the interface was carefully 
isolated and the methanol (150 p1) was added. Protein was pelleted and methanol removed 
using a pipette. Protein pellet was then air dried prior to chemical or enzymatic digestion. 
4.5.4 - In-solution Digestion of CCR6 
Protein was initially chemically cleaved using CNBr before undergoing 
trypsinization. Initially the protein was resuspended in 90% formic acid. CNBr (5 M, 5 jil) 
was added and mixed for 2 hrs at room temperature in the dark. The cleaved mixture was 
freeze-dried to remove any unreacted CNBr, and the protein mixture was acidified overnight 
in 0.5% TFA (500 Ml).  After another freeze-drying step, peptides were dissolved in 0.2% 
RapiGest (Waters) and incubated with DYE (4 mM) for 30 min at 55 °C. Reduced peptides 
were alkylated with iodoacetamide (10 mM) for 30 min in the dark before being digested 
further with Trypsin Gold (promega) at a ratio of 1:5 trypsin:CCR6 overnight at 37 °C. Prior 
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to mass spectrometric analysis RapiGest was hydrolysed by addition of formic acid (30%) 
for 30 min at 37 °C. Peptides were centrifuged (13,000 rpm, 10 mm) and supernatant 
transferred to clean microcentrifuge tube. Digested peptides were stored at -20 °C until 
needed for mass spectrometric analysis. 
4.6 - Molecular Immunology 
4.6.1 - Antibodies 
11 	TYPE 	[ 	 NAME 	 [ 	COMPANY 	11 
Primary Biotinylated Anti-HBD-2 Autogen Bioclear 
Primary! Secondary Streptavidin-HRP BD Biosciences, Pharmingen 
Primary Mouse Anti-His GE Healthcare 
Secondary Goat anti-mouse-HRP Cell Signalling 
Primary Anti-human CCR6-FITC R & D systems 
Control Mouse IgG 1 -CFS R & D systems 
Primary ANTI-FLAG M2-FITC Sigma 
Primary Mouse ANTI-FLAG M2 Sigma 
Control Mouse IgG2 -FITC BD Biosciences, Pharmingen 
Primary Rabbit Anti-human CCR6 AbCam 
Secondary Goat Anti-rabbit-HRP AbCam 
Table 4.2. Antibodies used in this Study. 
4.6.2 - Fluorescence-Activated Cell Sorting (FACS) Analysis 
Adherent mammalian cells were either trypsinized or scrapped into PBS and 
centrifuged (500 x g, 5 mm). Cells were resuspended in PBS and washed (3 x) to remove any 
residual growth factors from the culture media. Washed cells (1 x 10) were transferred to a 
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new tube and blocked with human IgG (1 tg) for 15 min at room temperature. Fluorescein-
labelled monoclonal antibodies (0.5 p.g/ml) were incubated in the dark with the blocked cells 
for 45 min at 4 °C. Cells were washed (3 x) in PBS to remove any unbound antibody and 
finally resuspended in PBS for FACS analysis. FACS analysis was performed on a BD 
FACS Aria TM  System using a 488 nM excitation laser and 530/30 bandpass filter. Analysis 
was performed using FACS Diva software. 
FACS analysis was performed by Dr Lois Alexander. 
4.6.3 - Western Blot 
Proteins separated on SDS-PAGE were equilibrated in transfer buffer for 20 mm 
along with an equal sized Hybond-ECL nitrocellulose membrane (0.2 jim, Amersham). 
Proteins were then transferred and immobilized onto the equilibrated membrane by 
electroblotting at 15 V for 30 min using a Trans blot SD Semi-Dry Transfer cell. Membranes 
were blocked to avoid non-specific antibody binding. Membranes were shaken overnight at 4 
°C in either 5% non-fat milk or Super Block (Pierce). Excess blocking solution was then 
removed by washing with PBS-T (0.1%). All washing steps were carried out at room 
temperature and consisted of 3 x 10 min washes unless stated. Blocked membranes were 
then incubated in primary antibody with blocking solution for 60 min at room temperature. 
Excess antibody was then removed with washings before being incubated with a secondary 
peroxidase conjugated antibody in blocking solution. A final wash was performed, before the 
membranes were dried and immuno-labelled proteins detected using the ECL 
chemiluminescence detection system in accordance with the manufacturer's instructions. 
Proteins were visualised on BioMax )(AR film (Kodak) and developed using a Compact X4 
Automatic X-ray Film processor (Xograph). 
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4.6.4 - Enzyme-linked Immunosorbent Assay (ELISA) 
Human TNF-cL ELISA was carried out in accordance with the manufacturer protocol 
(R &D Systems). In brief, a 96-well plate was coated with the capture antibody (4 j.tg/ml) 
and incubated overnight at room temperature. Each well was washed (3 x) with a wash 
buffer (PBS with 0.05% Tween, pH 7.2) before blocking solution (PBS with 1% BSA, pH 
7.2) was added for lhr at room temperature. Again each well was washed (3 x) with wash 
buffer. Either standards or LPS stimulated supernatants (100 l) were added to individual 
wells and incubated for 2 hrs at room temperature. After washing again (3 x), the detection 
antibody (goat anti-human TNF-a biotin conjugated antibody, 100 jJ) was applied for 2 hrs 
at room temperature. After three more washes, streptavidin-HRP was applied and incubated 
in the dark for 20 min at room temperature. After three more washes, a substrate solution 
(1:1 mixture of H 202 and Tetramethylbenzidine) was added and incubated in the dark for 20 
min at room temperature. Finally a stop solution (2N H2SO4)  was added and OD measured 
using a microplate reader set to 450 nm. 
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4.7 - Microbiology 
4.7.1 - Bacterial Strains 
All bacteria strains used were a kind gift from Prof. John Govan from the Edinburgh 
Cystic Fibrosis Microbiology Laboratory. 
ORGANISM STRAIN DESCRIPTION 
Gram-negative 
E.coli MG1655 Type strain 
P. aeruginosa PAO 1 Type strain 
Gram-positive 
S.aureus ATCC 25923 Type strain 
Fungi 
C.albicans J2922 Clinical Isolate 
Table 4.3. Bacterial Strains used in this Study. 
4.7.2 - Antimicrobial Assay 
Antimicrobial assays were performed as previously described [4]. Bacterial strains 
were initially spread on nutrient agar (Oxoid). 10 ml isosensitest broth (ISB) was inoculated 
with a single colony and incubated overnight at 37 °C on an orbital incubator (150 rpm). 
Cells were subcultured into fresh ISB and further incubated for 4 hrs or until an 0D 600 of 1 
was obtained. Bacteria were washed (3 x) in sodium phosphate buffer (10 mM, pH7.4) + 1% 
ISB to remove any residual NaCl from the ISB. The mid-logarithmic culture was diluted in 
10-fold increments in sodium phosphate buffer (10 mM, pH 7.4) + 1% ISB until an optimal 
concentration was achieved. 
Varying concentrations of peptides (1.5 ig/ml - 50 jtg/ml) were added to the 
bacterial suspension and incubated for 2 hrs. Concentrated and 100-fold dilutions, in 
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duplicate, were spread onto isosensitest agar (ISA) and incubated overnight at 37 °C. Colony 
forming units (CFU) were counted the next day and LD 50, LD90 and MBC were calculated. 
All experiments were repeated three times and values were obtained by taking the mean of 
all three experiments. 
4.8 - Protein Analysis 
4.8.1 - Polyacrylamide Gel Electrophoresis (PAGE) 
SDS-PAGE was used to analyse proteins on the basis of their molecular mass. The 
technique used was the discontinuous buffer system of Laemmli [5].  Denatured proteins 
were analysed on precast 12% Bis-Tris Nu-Page gels (Invitrogen) according to 
manufacturer's instructions. Alternatively, native proteins were analyzed on precast 16% 
Tricine gels (Invitrogen) according to the manufacturer's instructions. Protein gels were 
generally visualised using comassie blue stain or in cases of low concentration, 
ProteoSilverTM Silver Staining kit (Sigma-Aldrich) was used and performed according to the 
manufacturer's instructions. 
4.8.2 - Deglycosylation Gel-Shift Assay 
Deglycosylation was carried out in accordance with the manufacturer's instructions 
(Calbiochem). In brief, 10 p1 of reaction buffer (250 mM sodium phosphate buffer, pH 7.0) 
and 2.5 p1 denaturation solution (2% SDS, 1 M J3-mercaptoethanol) of 30 p1 of CCR6 (5 tg) 
and mixed gently. 2.5 p1 triton X-100 was added before 1 p1 of each deglycosylating enzyme 
was added to separate CCR6 aliquots and incubated for 24 hrs at room temperature to avoid 
aggregation. Samples were analyzed by SDS-PAGE and western blot as described above. 
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4.8.3 - Phosphoprotein Gel Analysis 
Phosphoprotein staining was performed using Pro-Q ® Diamond Phosphoprotein gel 
stain and carried out in accordance with the manufacturer's instructions (Invitrogen). 
Proteins were separated by SDS-PAGE and fixed (10% acetic acid, 50% methanol) 
overnight at room temperature to remove all the SDS. After one wash step (100% H 20), gel 
was stained in the dark with Pro-Q 0 Diamond gel stain for 90 mm. Gel was destained (200 
ml ACN, 50 ml 1 M sodium acetate, pH 4.0, 750 ml H20) for 30 mm. This step was repeated 
another 2 times before two more washing steps. Fluorescent gel images were obtained using 
the Cy3 filter on a BioAnalyzer 4F/4S (LaVision BioTech). 
4.8.4 - ID 1 H NMR Spectrum 
I mg of oxidized HBD2 was dissolved in 20 mM sodium acetate buffer, pH 4.0 at 25 
°C and 10% D 20 (v:v) was added to give to a final peptide concentration of 0.46 mM. The 
1D 'H NMR spectrum was recorded on a Bruker AVANCE spectrometer equipped with a 
cryoprobe operating at 600 MHz and 25 °C. 128 scans were taken with a sweep width (sw) 
of 15 ppm and 8000 complex points. For water suppression double-pulsed gradient spin echo 
was used. Oxidized HBD2 mutants were dissolved in 20 mM sodium acetate buffer, pH 4.0 
and 10% D20 (v:v) was added. The 1D 'H NMR was recorded on a Brucker AVANCE 
spectrometer operating at 600 MHz and 25 °C. 32 scans were taken with a sweep width of 8k 
Hz and 9000 complex points. NMR data acquisition and processing was carried out using 
TopSpin software (Brucker BioSpin). 
Method was optimized and carried out by Dr Emily Seo. 
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4.8.5 - Positive ESI-MS 
Direct infusion mass spectrometry was performed on a Micromass ZMID mass 
spectrometer equipped with an electrospray ion source. Samples purified from HPLC were 
filtered (0.22 tM) and directly infused at a flow rate of 10 p1/mm. Source parameters were 
kept constant except for the cone voltage and desolvation temperature. Cone voltage was 
typically set at 40-60 V and desolvation temperature set at 200 °C. All electrospray 
ionization was in positive mode and data acquired in continuum mode. Scans were 
accumulated, spectra combined and molecular mass calculated using the transform algorithm 
of the Mass Lynx 3.5 software (Micromass). 
4.8.6 - LC-ESI-MS 
ESI-MS was performed on a Micromass Platform equipped with an electrospray ion 
source. Protein samples were separated on a Waters HPLC 2795 using a Phenomenex Jupiter 
4u Proteo column (250 x 2.0 mm) directly attached to the mass spectrometer. Peptides were 
eluted using a 10-95% ACN gradient over 45 min at a flow rate of 200 p1/min. The tune 
parameters were kept constant with only cone voltage and source temperature fluctuating 
depending on sample. Cone voltage was typically set at 40 V and source temperature was set 
at 110 °C. Total ion current was measured from 500-1900 mlz. All electrospray ionization 
was in positive mode and data acquired in continuum mode. Scans were accumulated, 
spectra combined and molecular mass calculated using the transform algorithm of the Mass 
Lynx 4.0 software (Micromass). 
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4.8.7 - LC-ESI-tandem Mass Spectrometry (MS/MS) using Q-TOF Mass 
Spectrometry 
Positive LC-ESI-MS/MS was used for the characterisation of BioHBD2. 
Trypsinlchymotrypsin digested protein samples were separated using a C18 reverse phase 
column (Waters) on a CapLC system (Waters) connected directly to a Q-TOF Ultima 
(Micromass) mass spectrometer. Digested peptides were eluted using a 5-20% ACN with 
0.1% formic acid gradient over 60 min at a flow rate of 240 p.1/mm. Q-TOF was run in data 
directed analysis mode and switch from MS to MS/MS mode when a double or triple charge 
state ion exceeded a threshold of 10 counts/sec. Argon was used as fragmentation gas and 
data was acquired from 100-2000 mlz. 
4.8.8 - Fourier Transform Ion Cyclotron Resonance (FT-ICR) 
High resolution mass spectrometry was performed on either a 9.4 Tesla or 12 Tesla 
Apex Qe FT-ICR (Brucker Daltonics, Billerica,MA). Both were equipped with mass 
resolving quadrupole, coupled to a nano-electrospray ionization enabled Tn Versa Namomate 
(Advion Bioscience, Ithaca,NY). FT-ICR data was acquired using an AQS console and the 
acquisition rate was typically —1 scan/2 sec. Lyophilized peptides were dissolved in 50% 
methanol with 0.2% formic acid and directly infused at a flow rate of 50 nl/min. Fast Fourier 
Transforms and analysis were performed using Data Analysis (Bruker Daltonics, 
Billerica,MA). 
FT-JCR analysis was optimized and performed by Dr D Clarke. 
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4.8.9 - Nanospray LC-MS/MS using the HCT Mass Spectrometer 
Following CCR6 receptor purification and either trypsin and/or CNBr digestion, 
samples were analyzed by nanoLC-MS/MS using a High Capacity Trap (HCT) quadrupole 
ion trap mass spectrometer (Brucker Daltonics). 10 tl injections were loaded onto a trap 
column (PepMap500 trap column) using an Ultimate 3000 LC in NanoHPLC mode at 20 
.tl/min of mobile phase A. Mobile phase A consisted of 95% H 20, 5% ACN and 0.1% 
Formic Acid. Mobile phase B consisted of 100% ACN and 0.1% Formic Acid. Separation 
gradient was carried out on a PepMaplOO 3 jM Column (LC Packings, Dionex) at 20 
tl/min. A linear gradient from 5% B to 55% B over 45 min was used. Eluted peaks were 
injected into the mass spectrometer in positive ionisation mode and peptides were analyzed 
using DataAnalysis. Acquired MS/MS spectra were exported as .MGF files and searched 
against a locally installed Mascot database. 
HCT-MS analysis was optimized and performed by Dr D Clarke 
4.8.10 - Edman Degradation 
Oxidized HBD2 was digested with a mixture of trypsin/chymotrypsin as described in 
section 4.5.1 and both fragments were purified using RP-HPLC. Freeze-dried HBD2 
fragment containing Cysi, Cys3, Cys5 and Cys6 was resuspended in a 1:1 mixture 
pyridine:water and incubated for 30 min at 60 °C upon addition of phenylthiohydantoin 
(PTH, 100 1.d). After removal of the solvent under vacuum, the modified peptide fragment 
was incubated for 15 min at 60 °C with TFA (100 tl). After removal of TFA under vacuum, 
the peptide fragment without the N-terminal residue was resuspended in water (100 p1), 
washed with 4:1 mixture hexane:ethyl acetate and the aqueous phase analysed by ESI-MS. 
Edman degradation was optimized and carried out by Dr Emily Seo. 
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5.1 -Conclusion 
This study has achieved its aim of designing an efficient and reproducible method 
for production of functionally-active recombinant 13-defensin peptides (I-IBD I and HBD2). 
This was made possible due to the mutation of the KS! fusion protein to leave only a single 
CNBr cleavable methionine residue and manipulation of the pET-28a plasmid to allow 
expression as a N-terminal His-tagged KSI-fusion protein. Expression as inclusion bodies 
offered the host E.coli strain protection against the innate antimicrobial activity of 13-
defensins which if over expressed as a soluble protein would ultimately lead to the killing of 
the host. Functionally active rHBD2 was confirmed when both antimicrobial activity and 
chemotactic values were identified as comparable to other recombinantly produced or 
naturally purified HBD2 preparations [1-3]. Not only is the rFIBD2 functionally active, but 
results from 1D 'H NMR, high-resolution mass spectrometry and Edman degradation 
analysis indicate that the I-IBD2 peptide purified using this method is of the highest purity, 
fully oxidized and correctly folded. Careful construction of the expression plasmid allowed 
for the insertion of only one correctly orientated HBD2 gene. This provides a template for all 
future site-directed mutagenesis studies on HBD2. In fact this plasmid has now also been 
used to produce radioisotope ' 5N-labelled HBD2 suitable for ligand-binding studies by NMR 
[4]. Unfortunately this expression plasmid is restricted to investigations of HBD2 due to the 
inability to remove the HBD2 gene. However this problem was solved by re-engineering the 
plasmid with a HindIII restriction site directly upstream of the CNBr cleavage site. 
Originally this expression plasmid was used to purify rHBD1, confirming that the 
purification method is applicable to other 13-defensins and later replacement of the HBD1 
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gene with HBD2 mutants containing single disulfide bonds confirmed that this expression 
plasmid can be used for all future studies on recombinant 13-defensins. 
This study is the first to investigate the different effects that each individual 
canonical disulfide bond has on HBD2's function. None of the three single disulfide mutant 
HBD2 forms appeared to have the typical defensin 3-sheet topology in the oxidized form. 
Removal of two structurally constraining disulfide bonds resulted in a reduced antimicrobial 
activity against an E.coli strain in all cases as compared to wt 1-IBD2. Differences in activity 
between the single disulfide mutants are minimal although the disulfide bond Cys2-Cys4 
constrained HBD2 was able to kill E.coli at lower concentrations. In conclusion, HBD2 with 
only one structurally constraining disulfide bond still retains antimicrobial activity albeit at a 
higher concentration. This was not the case for the chemotactic activity of HBD2, with all 
three mutants failing to chemoattract CCR6 expressing H1EK293 cells. 
The finding that synthetic HBD2 with biotinylated N-terminus (Bio}IBD2) retains 
the ability to chemoattract CCR6 expressing cells was extremely important as there is a 
dogma in the chemokine society that the N-terminus should not be altered. This indicates 
that biotinylated HBD2 can still bind to CCR6, therefore providing a useful tool for both 
pull-down and binding experiments. Its ability to also act as an anti-inflammatory mediator 
agrees with a previous study that showed HBD2 could inhibit LPS induced TNF-a release 
from a murine RAW 264.7 macrophage cell line [5].  Although the mechanism of this 
inhibition was not investigated in this study, it is the first time to my knowledge, that kd0 2-
lipid A-induced TNF-a release has been reduced by a human 3-defensin in matured human 
monocytes. Again this raises the possibility of using BioHBD2 as 'bait' in the pull-down of 
interacting partners. 
Although the difficulties in purifying GPCRs are well documented, this study has 
shown for the first time the purification of CCR6 from transfected HEK293 mammalian 
cells. Identification of both complementary N and C-terminal tags by western blot analysis 
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provided evidence for the full-length chemokine receptor being isolated. The identity of 
CCR6 was confirmed by nanoelectrospray LC-MS/MS analysis which identified three 
separate peptides that corresponded to the sequence of CNBr and trypsin digested CCR6, 
including the highly conserved GPCR motif DRY. N-glycosylation modifications are 
conserved in the chemokine receptor family and CCR6 was predicted to contain five putative 
N-glycosylation sites. This modification was confirmed when enzymatic deglycosylation 
resulted in increased mobility by SDS-PAGE analysis indicative of a loss of the 
carbohydrate modification. Furthermore using the same expression system in which CCR6 
was purified, an N-terminal deletion of CCR6 was expressed. The mutated receptor was 
identified by western blot analysis; however surface expression could not be detected. 
Therefore although original designed to investigate residues important in binding, this N-
terminal section seems to be critical for cell surface trafficking. 
5.2 - Future Work 
Recent success in the purification and crystallization of a range of GPCRs has given 
renewed optimism that determination of the crystal structure of CCR6 is an achievable 
target. However what is clear is that using the current expression system of the wild-type 
receptor sequence would not produce the sufficient quantity required of a stable form of the 
protein to allow crystallization trails to begin. With the alternative heterologous expression 
systems now available the expression of CCR6 could be optimized to higher levels. To 
exploit a mammalian expression systems, the combination of a tetracycline inducible vector 
coupled with a suspension HEK293 cell line that resulted in high-level expression of 
rhodopsin could be investigated [6]. Very recently, CCRI was expressed and purified using 
this expression system showing that it is applicable to chemokine receptors [7]. Furthermore, 
with the exception of glycosylation, this method would still allow full proteomics analysis of 
the recombinant protein to be performed. Recent success in crystallization of recombinant 
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GPCRs has come from extensive engineering of the native receptor. This same process 
would need to be applied to CCR6, however great care must be taken so as to avoid altering 
the core structure and inactivating the receptor. Furthermore, any results on ligand binding or 
downstream signaling derived from mutant receptors would subsequently have to be verified 
with the wild-type receptor using various biochemical and biophysical techniques to confirm 
that the activity was not a consequence of engineered tags or domains. Recent crystal studies 
have highlighted a family A conserved tryptophan in TMVI that is an integral part of a 
rotamer "toggle-switch" where it acts as a pivot point upon receptor activation [8, 9]. This 
tryptophan is conserved in the CC chemokine receptor family except for CCR6, CCR7 and 
CCR9 where the tryptophan is replaced with a glutamine. Interestingly these latter receptors 
are also less promiscuous [10]. A crystal structure of CCR6 in both its inactive and active 
states would reveal how this glutamine affects the rotamer "toggle-switch" and as such could 
reveal differences in these receptors activation mechanism. 
The functional study of 26 single amino acid HBD1 mutants has set the standard for 
site-directed mutagenesis studies of defensins [11]. The expression plasmid constructed in 
this study could be used as a template for a similar study on HBD2. However a limitation in 
the defensin field is a lack of a reproducible binding assay for these mutants since 
radiolabeled ligands are not available and are no longer used in many laboratories. A method 
for production of fluorescently labeled defensins in E. coli or by solid phase peptide 
synthesis would be a great addition to the field and would allow for direct visualization of 
receptor binding both in vitro and in cells. Removal of the premature stop codon in our 
expression plasmid would allow for an additional methionine to be expressed as well as a C-
terminal 6 x His tag. CNBr cleavage of the fusion protein would then leave a highly reactive 
C-terminal homoserine lactone. This can be used to conjugate various useful labels such as 
fluorescein to the C-terminal as has been shown with the yeast a-mating factor [12]. This 
would facilitate each mutant defensin purified to be fluorescently tagged and therefore using 
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flow cytometly analysis or fluorescent microscopy one could identify receptor binding on 
CCR6 expressing cells. 
Finally, taking advantage of ' 5N (and 13C) labeled rHBD2; one could chemically 
synthesize the N-terminus of CCR6 and identify residues that interact during binding. The 
tactic of using N-terminal fragments rather than the full-length receptor has been successful 
in characterizing the interaction between various chemokine/chemokine receptors e.g., 
CXCL8I CXCR1 [13]. This would also provide a framework for studying the effects of post-
translational modifications on binding by modifying the N-terminus with recombinant 
glycotransferases or sulfotransferases. Although the CCR6 N-terminus is unlikely to be the 
only extracellular motif that binds defensins it would be an excellent starting point to 
elucidate the binding interactions of this important receptor. 
5.3 - Chapter 5 References 
Yang, D., et al., Beta-defensins: linking innate and adaptive immunity through 
dendritic and Tcell CCR6 Science, 1999. 286(5439): p.  525-8. 
Harder, J., et al., A peptide antibiotic from human skin. Nature, 1997. 387(6636): p. 
861. 
Antcheva, N., et al., Effects ofpositively selected sequence variations in human and 
Macacafascicularis beta-defensins 2 on antimicrobial activity. Antimicrob Agents 
Chemother, 2004. 48(2): p. 685-8. 
Seo, E.S., et al., Preparation of isotopically labelled recombinant beta-defensin for 
NMR studies. Protein Expr Purif, 2009. 65(2): p.  179-84. 
Scott, M.G., et al., Cutting edge: cationic antimicrobial peptides block the binding of 
lipopolysaccharide (LPS) to LPS binding protein. J Immunol, 2000. 164(2): p.  549-
53. 
Reeves, P.J., J.M. Kim, and H.G. Khorana, Structure andfunction in rhodopsin: a 
tetracycline-inducible system in stable mammalian cell lines for high-level 
expression of opsin mutants. Proc NatI Acad Sci U S A, 2002. 99(2 1): p.  13413-8. 
Allen, S.J., et al., Expression, purification and in vitro functional reconstitution of 
the chemokine receptor CCRJ. Protein Expr Purif, 2009. 66(1): p.  73-8 1. 
Park, J.H., et al., Crystal structure of the ligand-free G-protein-coupled receptor 
opsin. Nature, 2008. 454(7201): p.  183-7. 
Shi, L., et al., Beta2 adrenergic receptor activation. Modulation of the pro/me kink 
in transmembrane 6 by a rotamer toggle switch. J Biol Chem, 2002. 277(43): p. 
40989-96. 
Allen, S.J., S.E. Crown, and T.M. Handel, Chemokine: receptor structure, 
interactions, and antagonism. Annu Rev Immunol, 2007. 25: p.  787-820. 
170 
Chapter 5: Conclusion and Future Work 
Pazgier, M., et al., Studies of the biological properties of human beta-defensin 1. J 
Biol Chem, 2007. 282(3): p.  1819-29. 
Kuliopulos, A. and C. Walsh, Production, purification, and Cleavage of Tandem 
Repeats of Recombinant Peptides. Journal of the American Chemical Society, 1994. 
116: p. 4599-4607. 
Skelton, N.J., et al., Structure of a CXC chemokine-receptor fragment in complex 







(Al) Deconvoluted Mass Data showing the effect of Formylation on Oxidized HBD2. 
Masses indicated: oxidized HBD2 4328 ± 3 Da (theoretical mass 4328.2 Da); Mono-
formylated oxidized HBD2 4355 ± 0.8 Da (theorectical mass 4356.2 Da); Bis-formylated 
oxidized HBD2 4383 ± 3 Da (theoretical mass 4384.3 Da). 
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Isolated HBD2 sequence (51 
Human beta-defensin 2 	(87) 
Isolated HBD2 sequence (101) 
1300 
Human beta-defensin 2 (137. 
Isolated HBD2 sequence (151) 
201 	 250 
Human beta-defensin 2 (187) 
Isolated HBD2 sequence (201) 	 GGAGGCCAAGAAGCTGCTGTGGCTNATGCGGATTCAGAAAG 
(A3) Sequence alignment showing the SNP in the HBD2 gene identified in CaCo2 cells. 
The signal and mature peptide sequences are marked with blue and green lines 
respectively. Residue highlighted in green is SNP and if translated the HBD2 mature peptide 
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Abstract: Human 0-defensin 2 (HBD2) has been shown to interact with pathogenic bacteria and components of the 
mammalian innate and adaptive immune response. We describe a quick and reliable method for the production of FIBD2 
in Escherichia co/i. HBD2 was expressed as an insoluble fusion, chemically cleaved and oxidised to give a single, folded 
HBD2 -isoform. The purified peptide was analysed by high resolution mass spectrometry, displayed a well-dispersed 'H 
NMR spectrum, was a chemoattractant to HEK293 cells expressing CCR6 and acted as an antimicrobial agent against E. 
co/i, P. aeruginosa, C. a/b icans and S. aureus. 
Keywords: HBD2, Defensin, Peptide, E. co/i, Chemotaxis, Antimicrobial activity. 
INTRODUCTION 
Antimicrobial peptides (AMPs) are essential components 
of the innate immune response and act as the first line of 
defence against invading pathogens [1]. The AMP family 
displays enormous sequence, structural and functional diver-
sity and over 900 different eukaryotic peptides have been 
characterized to date (sequences are available in the Antimi-
crobial Sequences Database (AMSDb), http://www.bbcm. 
univ.trieste.itl). Defensins are a subset of the AMP family 
and are small (3-5 kDa), cationic peptides that play roles in 
both innate and adaptive immunity [2-7]. They are character-
ised by 6 conserved cysteine residues that form 3 disulfide 
bonds and are divided into two main subfamilies; alpha (a-) 
and beta (-) are defined by their cysteine spacing, disulfide 
bond connectivity and genomic organisation. The a-
defensins display Cys,—Cys6, Cys2-Cys4, Cys3 -Cys5 S-S con-
nectivity and contain 29-35 residues, whereas the - 
defensins display a S-S connectivity of Cys,-Cys5, Cys2-
Cys4 , Cys3-Cys6 and consist of 40-50 residues. A third sub-
family, the 6-defensins also contain 3 S-S bonds but are cy-
clic peptides, fused at the N- and C-termini, and have only 
been found in rhesus monkeys. 
Analysis of the human genome revealed the presence of 
considerably more -defensin genes than previously thought 
[8]. In contrast, only 6 human a-defensins have been identi-
fied [9] and elegant studies of the structures and properties of 
these peptides (HNPI-4 and HD5 and HD6) by a number of 
research groups have begun to provide a better understand-
ing of their role in the immune response [7,10-14]. The high 
resolution structures of a few of the known mammalian 13- 
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defensins have been determined by NMR spectroscopy and 
x-ray crystallography and include bovine neutrophil defensin 
(13NB13-12), penguin spheniscin (Sphe-2) and the human 13-
defensins (HBD1, HBD2, HBD3) [15-22], but more work is 
needed to explore the structure/functional relationship of this 
sub-family. We have chosen H13D2 as a target; it was shown 
that this defensin is expressed in epithelial cells and in the 
epidermis, and was originally isolated from human psoriatic 
scales [23]. It is expressed as a 64 amino acid precursor pep-
tide and the mature form consists of 41 residues with a net 
positive charge of +7. The 3D structure of mature HBD2 
revealed an amphipathic molecule with distinct patches of 
positively-charged and hydrophobic residues [17,19,20]. It is 
thought that this topology allows the defensin to interact 
with the outer cell components of bacterial membranes and 
act as a potent antimicrobial peptide against a range of 
pathogens [24]. Recent studies have shown that a number of 
defensins and their related peptide fragments, can act also as 
potent stimulators of the adaptive immune response, e.g. 
H13D2 acts as a chemoattractant for CD4 memory T cells 
and immature (but not mature) dendritic cells, by acting 
through the chemokine receptor CCR6, a member of the G-
protein coupled receptor (GPCR) family [25,26]. 
To study the molecular details of the interaction of HBD2 
with its various targets we required a robust method for the 
production of single isoform material. The production of 
defensins suitable for structural and functional studies has 
been achieved by solid-phase peptide synthesis but the in-
herent amphiphilic nature of the peptide, protection strate-
gies and losses upon oxidation have caused associated prob-
lems [27,28]. As an alternative, recombinant methods have 
also been developed, e.g., Ganz and colleagues have used a 
baculovirus/insect cell system to produce active human pep-
tides HNP-1, HD-5, HBD1 HBD2 [29-32]. As well as this 
method others have employed the common, easy-to-use host 
E. co/i [33-36]. Here however, there is the inevitable prob- 
© 2009 Bentham Science Publishers Ltd. 
Efficient Production of Human fi-Defensin 2 (HBD2) 
	
Protein & Peptide Letters, 2009, VoL 16, No. 6 669 
tern of toxicity of the defensins towards the host expression 
system but this has been overcome by expressing the peptide 
fused to a protein partner within inclusion bodies. This intro-
duces a further cleavage step to release the mature peptide 
and results in low overall yield. The use of expensive prote-
ases such as enterokinase also increases the cost of the over-
all production of sufficient quantities of peptide. New strate-
gies such as using the yeast Saccharomyces cerevisiae as a 
host organism or production by a cell-free system have also 
emerged recently [37,38]. These combined methods have 
allowed researchers to begin to explore the structure and 
activity of certain defensins [22,39-42]. 
To prepare defensins for a range of structural and func-
tional studies, we describe a method for the production of 
recombinant, active, single isoform 3-HBD2 from an Es-
cherichia co/i host. We designed a codon-optimised H13132 
gene for bacterial expression and synthesised this gene by 
recursive PCR [43} (Fig. 1). and developed a protocol to 
isolate mature HBD2. This peptide was characterised by a 
range of structural techniques and was active in functional 
assays. 
MATERIALS AND METHODS 
Materials 
E. co/i strains ToplO (Invitrogen) and BL21 (DE3) (No-
vagen) were used for construction of plasmids and expres-
sion of proteins respectively. Polymerase chain reaction 
(PCR) was carried out using Hercules polymerase (Strata-
gene) and puRe Taq Ready-To-Go PCR beads (GE 
Healthcare). PCR products were cloned initially in pGEM-T 
easy (Promega), then re-cloned into pET plasmids (No-
vagen). Site-directed mutagenesis used the Quick-change kit 
(Stratagene). Nickel-nitrilotriacetic acid (Ni-NTA) affinity 
resin was from Qiagen. Snakeskin dialysis tubing was from 
Pierce (3 kDa cut-off). Oligonucleotide primers were pur-
chased from SigmaGenosys. All restriction enzymes and T4 
DNA ligase were from New England Biolabs. Nu-PAGE 
12% Bis-Tris pre-cast gels were from Invitrogen. HPLC col-
umns were purchased from Phenomenex, synthetic human - 
defensin 2 (bHBD2, biotinylated at the N-terminus) was pur -
chased from Albachem and Polymyxin B (PMB) was ob-
tained from Calbiochem and tris(2-carboxyethyl)phosphine 
(TCEP) and CNBr were from Sigma. 
Synthesis and Cloning of Codon-Optimized HBD2 
Six overlapping primers (Table 1) with codons optimized 
for expression in E. co/i were designed using the mature 
HBD2 amino acid sequence (also known as DEFB4, Gen-
bank accession number, NM 004942). The reaction con-
tained in a final volume of 100 til:  10 tl (100 pmol) of the 
outermost 5' primers (P1 and P6) of each strand, 10 jil (10 
pmol) of the internal primers (P2 - P5), 4 pA DMSO, 10 pA 
10 x Herculase reaction buffer (Stratagene), 1 j.tl Herculase 
Hotstart DNA polymerase (Stratagene), 4 pA 25 mM dNTPs, 
21 tl dH20 and was subjected to 30 PCR cycles of 95 °C for 
2 minutes, 40°C for 3 minutes and 72°C for 30 seconds. A 
second amplification was performed to confirm annealing of 
all six primers in a final volume of 50 p1: 5 jtI primer P1(50 
pmol), 5 il primer P6 (50 pmol), 2 jil template, 38 tl dH20 
and 2 puRe Taq Ready-To-Go PCR beads were subjected to  
30 PCR cycles of 95°C for 2 minutes, 40°C for 3 minutes, 72 
°C for 30 seconds and a final extension of 72°C for 10 min-
utes to add A overhangs. The PCR product (Fig. 2A) con-
taining the codon-optimized gene preceded by Met and 
flanking A/wNl recognition sites was purified, cloned into 
pGEM-T Easy plasmid and a positive clone sequenced to 
confirm the fidelity of the insert. The target gene was then 
cut and ligated into the expression plasmid pET-3 lb (No-
vagen) to give pET-3 1 b/HBD2. To incorporate a N-terminal 
His(6)-tag sequence, both pET-3 1 b/HBD2 and pET-28a(+) 
vectors were cleaved by restriction enzymes NdeI and XhoI 
and the HBD2 fragment now containing the ketosteroid 
isomerase (KSI)-fused gene was cloned into pET-28a (Fig. 
1A). To avoid CNBr cleavage at unwanted sites within the 
fusion residues Met 1 and 126 of KSI were replaced with Ala 
by site-directed mutagenesis to give plasmid pET-28a/His-
KSI-HBD2 (Fig. 1C). The fidelity of this clone was con-
firmed by DNA sequencing. 
Expression of KSI-HBD2 in E. coil 
The freshly transformed BL2I (DE3) colony containing 
the pET-28a/His-KSI-HBD2 plasmid was used to inoculate 
250 ml, of 2YT medium at 37°C, with shaking containing 30 
ig/mL kanamycin. This was grown for 12 hours and then 
added to 3 litres of 2YT, containing 30 jig/mL kanamycin to 
give an 0D600 0.1 and divided into six one litre flasks, with 
approximately 500 mL in each flask. Cells were grown at 37 
°C until an 0D 600 = 0.5, induced with a final concentration of 
1 mM isopropyl--D- 1 -thiogalactopyranoside (IPTG), and 
incubated for a further 6 h. Cells were subsequently har-
vested by centrifugation (6000 rpm for 10 minutes, 4°C). 
Isolation of KSI-HBD2 Inclusion Bodies and Production 
of HBD2 
All centrifugation steps were carried out for 20 minutes 
at 11000 rpm and 4 °C. The cell pellet containing highly ex-
pressed HisKSI-HBD2 was suspended in 5 mL/g in resus-
pension buffer (50 mM Tris, 25% sucrose, 1 mM EDTA, 
0.1% sodium azide, 10 mM DIT, pH 8.0), before addition of 
50 mg/mL lysozyme, 500 mM M902  and lOpA DNase. After 
incubation for 30 minutes at room temperature, lysis buffer 
(50 mM Tris, 1% Triton X-100, 100 m NaCl, 0.1% sodium 
azide, 10 mM DTT, pH 8.0) was added (5 mL/g wet weight 
original pellet) and incubated for 45 minutes at room tem-
perature. To this cloudy suspension, EDTA (500 mM) was 
added to give a final concentration of 1 mM, and the sample 
was snap-frozen in liquid N 2 before immediately thawing for 
30 minutes in a 37°C water bath. To this thawed extract, 
MgCl2 (500 mM) was added to give a 1mM final concentra-
tion and the sample was incubated at room temperature for 1 
h to allow the viscosity to decrease before centrifugation. 
The supernatant was discarded and the pellet from this step 
was resuspended in an appropriate volume of buffer (50 mM 
Tris, 1% Triton X-100, 100 mM NaCl, 1 mM EDTA, 0.1% 
NaAzide, 1 mM DTT, pH 8.0), sonicated for 4 x 30 second 
blasts and centrifuged. The resulting pellet was then washed 
in 1 M Guanidine HCl buffer (I M GuHCI, 50 mM Tris, 1% 
Triton X-100, 100 mM NaCl, 1 mM EDTA, 0.1% sodium 
azide, 1 mM D1T, pH 8.0), sonicated with 4 x 30 second 
bursts and centrifuged. The resulting pellet (inclusion bodies 
containing highly enriched KSI-HBD2) was resuspended in 













1 CAGGCGTGTGGGTATCGGTGACCCGGTTACCTGCCTGAAATCCGGTGCTATCTGCCAC 60 
GTCCGCGACTACCCATAGCCACTGGGCCAATOGACGGACTTTAGGCCACGATAGACGGTG 
ProValPheCysProArgArgTyrLysGlnl leGlyThrCysGlyLeuProGly'ThrLys 
61 CCGGTTTTCTGTCCGCGTCGTTACAAACAGATCGGTACCTGCGGTCTGCCGGGTACCAAA 120 
GGCCAAAAGACAGGCGCAGCAATGTTTGTCTAGCCATGGACGCCAGACGGCCCATGGTT 
CyscysLysLyspro* * * A1wNI 
121 TGcTGcAAAAAAcCGTGACAGA'racTG 147 
ACGACGTTTTTTGGCACTGTCTACGAC 
1 MGSSHHHHHH SSGLVPRGSH AHTPEHITAV VQRFVAALNA GDLDGIVALF 
51 ADDA'rVEDPV GSEPRSGTAA IREFY?NSLK LPLAVELTQE VRAVANEAAF 
101 AFTVSFEYQG RKTVVAPIDH FRFNGAGKVV SIRALFGEKN I}{ACQALMGI 
151 GDPVTCLKSG AICHFVFCPR RYKQIGTCGL PGTKCCKKP 
Figure 1. A. Schematic representation of expression vector pET-28a!HIS-KSI-I-IBD2. 
B. Design of synthetic, codon-optimized l-IBD2 gene (147 bp) for E. coli expression. Primers were designed for overlapping recursive PCR 
(see Table 1). The 5' and 3' primers incorporated AIwNI restriction sites (bold) to allow cloning of KSI-HBD2 fusion into pET28a. C. The 
full-length His-KSI-HBD2 fusion sequence (189 aa) with mature 14BD2 (41 as) produced by CNBr cleavage after the Met residue highlighted 
in bold. The Met-Ala mutations in KSI (MIA and Metl26A) are underlined. 
Table 1. Primers Used in Synthesis of Codon-Optimised HBD2 







MIA For GCGGCAGCCATGCGCATACCCCAGAACACATC 
MIA Rev GATGTGTTCTGGGGTATGCGCATGGCTGCCGC 
Ml 26A For GAATATTCACGCATGCCAGGCGCTGATGGGTATCGGTGAC 
Ml 26A Rev GTCACCGATACCCATCAGCGCCTGGCATGCGTGAATATTC 
- 50m1 6 M GuHCI binding buffer (6 M GuHCI, 50 MM 	4°C, then decanted into an empty 25 ml column reservoir. 
Tris, 10 mM imidazole, 500 mM NaCl, 5 mM -mercapto- The packed resin was washed with 6 M GuHC1 binding 
ethanol, pH 8.0). These inclusion bodies were added to 10 ml 	buffer (50 ml) and then eluted with 25 ml of elution buffer (6 
pre-equilibrated nickel-nitrilotriacetic acid (Ni-NTA, M GuHCI, 50 mM Tris, 120 mM imidazole, 500 mM NaCl, 
Qiagen) agarose affinity resin, mixed by rotation for 1 h at 	5 mM -mercaptoethanol, pH 8.0). This elution step with 
A 
B 
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120 mM imidazole was then repeated to give 50 ml of puri-
fied HisKSI-HBD2. The eluted fusion protein was dialyzed 
against 25 mM Tris buffer, pH 8.0 overnight at 4 °C which 
caused precipitation of the fusion protein. 
The fusion was recovered by centrifugation and the pellet 
was resuspended in 6 M GuHCI, 25 mM Iris buffer, pH 8.0. 
To this HC1 (5 M stock) was added until the pH was -4.0. 
Solid Cyanogen Bromide (CNBr) was added to give a final 
concentration of 250 mM and cleavage was allowed to pro-
ceed for 24 h in the absence of light and under nitrogen. The 
cleaved mixture was evaporated at 42 °C using a rotary 
evaporator to remove any unreacted CNBr, and the concen-
trated sample was dialyzed against 25 mM Tris buffer, pH 
8.0 overnight at 4°C to cause precipitation of the KSI. The 
precipitate was removed by centrifugation and the super-
natant containing HBD2 was filtered (0. 45 j.tM) and purified 
by RP-HPLC as described below. 
Purification of HBD2 
Preparative RP-HPLC on a JupiterTM  Proteo column was 
performed with a Waters 600 control pump fitted with a pho-
todiode array 996 detector using Millenium 32 software. The 
HBD2 isolated from the Cynogen Bromide (CNBr) cleavage 
step was applied to the column in 3-4 ml batches, the column 
was washed with 5% acetonitrile then a linear gradient of 5-
55% acetonitrile over 50 minutes at a flow rate of 3 
mL/minute was used to elute the HBD2. Fractions were ana-
lysed by SDS-PAGE and those containing HBD2 were 
pooled and shown to be a mixture of partially reduced and 
oxidized peptides (by ESI-mass spectrometry). 
Oxidation of Recombinant HBD2 
The HBD2 recovered by prep-HPLC was freeze-dried 
then reconstituted in 25 mM Tris, pH 8.0, with 20 mM 
(TCEP) added to convert the peptide to the fully reduced 
form before re-purification by prep-HPLC using identical 
conditions as above. Fractions containing HBD2 were 
freeze-dried then dissolved in 50 mM Tris, pH 8.0, 3 mM 
cysteine, 0.3 mM cystine and stirred for 4 h at room tempera-
ture. The reaction was followed by analytical RP-HPLC and 
analyzed by ESI-mass spectrometry to confirm that the 
HBD2 was present in the oxidized form (elution at 40 mins). 
The final yield of oxidized -HBD2 is 3-6 mg from 3 litres 
of E. co/i culture (based on 10 preparations). 
Western Blot Analysis 
Peptides were separated on a 12% Bis-Tris gel as de-
scribed by the manufacturer (Invitrogen) followed by elec-
troblotting using a Trans blot SD Semi-Dry Transfer cell 
(Bio-Rad) onto a Hybond-ECL nitrocellulose membrane (GE 
Healthcare). HBD2 was detected with a 1-113132-specific anti-
body (Autogen Bioclear) and electrochemiluminescence plus 
(ECL) using a Streptavidin-HRP antibody according to the 
manufacturer's instructions (GE Healthcare). 
Disulfide Bond Connectivity 
The disulfide bond connectivity of the oxidized HBD2 
was determined by trypsinlchymotrypsin digest, Edman deg-
radation and mass spectrometry analysis as described previ-
ously [40,44].  
1D 'H NMR Spectrum 
1 mg of oxidized 1413132 was dissolved in 20 mM sodium 
acetate buffer, pH 4.0 at 25 °C and 10% D20 (v:v) was 
added to give to a final peptide concentration of 0.46 mM. 
The 'H NMR spectrum was recorded on a Bruker AVANCE 
spectrometer equipped with a cryoprobe operating at 600 
MHz and 25 °C. 128 scans were taken with a sweep width of 
15 ppm and 8000 complex points. For water suppression 
double-pulsed gradient spin echo was used. 
Antimicrobial Activity Assay 
The purified, oxidized HBD2 was dissolved into 0.01% 
acetic acid and centrifuged (13000 rpm for 10 minutes, 25 
°C) to remove precipitate. The HBD2 was concentrated 
(Vivaspin 0.5 mL concentrator, 3000 MWCO PES) to I 
mglmL and stock HBD2 solutions of concentrations 15, 30, 
60, 125, 250 and 500 tg/mL were prepared. Antimicrobial 
assays were carried out according to the method set out in 
our previous study [25,40,45]. Briefly, a laboratory strain of 
E. co/i K-12 MG 1655 was grown to midlogarithmic phase 
(OD at 600nm = 1.0). From this 90 jil E. co/i (-1.0 x 10 
cells) was incubated with 10 tl of each stock HBD2 solution 
and as a negative control 90 jtl E. co/i was incubated 10 tl 
0.01% acetic acid. These samples were incubated at 37°C for 
2 hours. Then 10-fold serial dilutions of the incubation mix-
ture were plated on Iso-Sensitest plates, incubated at 37 °C, 
and the CFU was determined the following day. Colonies 
were counted and the LD 50, LD90 (Lethal Dose: amount of 
peptide required to kill 50 % and 90% of viable cells) and 
the MBC9999 (Minimum Bactericidal Concentration at 99.99 
%) values were calculated from the resulting killing curve. 
The same antimicrobial assays were performed with Pseu-
domonas aeruginosa (PAO 1), a Gram-positive strain Staphy-
lococcus aureus (ATCC 25923) and a fungus, Candida alb!-
cans (J2922) [45]. In parallel, the same strains were used 
with the antimicrobial agent Polymyxin B (PMB) as a con-
trol. All the killing assays were performed at least 3 times for 
each strain and the values were obtained by taking the mean 
of each 3 experiments. 
High Resolution FT-ICR Mass Spectrometry 
The oxidized HBD2 was diluted to a final concentration 
of 1 .iM in electrospray buffer, consisting of 50:50 metha-
nol:H20 with 0.2 % formic acid. Data was acquired on a 12 
Tesla Apex Qe FT-ICR (Bruker Daltonics, Billerica, MA) 
equipped with mass resolving quadrupole, coupled to a nano-
electrospray ionization (nESI) enabled TriVersa Nanom ate 
(Advion Bioscience, Ithaca, NY). Samples were infused at a 
flow rate of 50 nanolitres per minute. Desolvated ions were 
transmitted to a 6 cm Infinity cell s penning trap. Trapped 
ions were excited (frequency chirp 48-500 kI-IZ at 100 steps 
of 25 lLs) and detected between m/z 600 and 2000 for 1 s to 
yield broadband 1 Mword time-domain data. Each spectrum 
was the sum of 64 mass analyses. Typical chamber base 
pressure was —9 x 10 11 mbar. Time-domain FT-ICR data 
was acquired using an AQS console and the aquisition rate 
was typically —I scan/2 s. Fast Fourier Transforms and sub-
sequent analyses were performed using DataAnalysis 
(Bruker Daltonics, Billerica, MA). 
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The chemotaxis activity analysis was carried out against 
HEK293 cells expressing CCR6 as we have previously re-
ported [25]. The migration of CCR6-transfected human em-
bryonic kidney HEK293 cells was assessed with a micro-
chemotaxis chamber technique. Chemotactic activity was 
measured as the optimal concentration of test compound at 
which the highest chemotactic index value was obtained. 
Experiments were carried out three times. CCL20 (also 
known as MIP3-a) was from Peprotech (London, UK). 
RESULTS AND DISCUSSION 
Synthesis of HBD2 Gene by Recursive PCR 
Our goal was to produce mature, untagged HBD2 as a 
single -defensin isoform. Our strategy to enhance the ex-
pression of the toxic human antimicrobial peptide HBD2 in 
the host E. co/i was to fuse it to the highly insoluble ketos-
teroid isomerase (KS!) tag using a commercially available 
plasmid. Six overlapping primers (Table I) with codons op-
timized for expression in E. co/i were designed to synthesise 
the HBD2 gene in a one step recursive PCR reaction [43] 
(Fig. I B). An ATG Met codon was incorporated at the 5' end 
of the HBD2 gene to enable cleavage of the peptide from the 
KS! tag by cyanogen bromide (CNBr) (Fig. IB). A similar 
chemical cleavage strategy had been used by Ganz and co-
workers to produce active HBD2 expressed in baculovirus-
infected insect cells [29]. Restriction sites for .4/wNI, flank-
ing the HBD2 sequence. were engineered into the gene to 
enable cloning into the KSI expression plasmid, pET-31b 
and a stop codon was engineered upstream of the 3' A/wNl 
site to avoid generation of a homoserine lactone HBD2 de-
rivative after cleavage. Initial PCR gave a gene product at 
the expected size of the 1-113132 target (144bp, Fig. 2A) and a 
second PCR amplification using this template with the 5 . 
and 3' terminal primers gave a gene that was cloned firstly 
into plasmid pGem-T Easy then into the expression plasmid 
pET-31b digested with the same enzyme. To utilize Ilis-tag 
purification technology, the KSI-HBD2 fusion gene was 
excised from pET-3 lb and ligated into pET-28a downstream 
of a 6xHis-tag. To improve the efficiency of the chemical  
cleavage and generate a single CNBr cleavage site within the 
KSI-HBD2 fusion, the Met! and Met126 residues within the 
KS! gene were converted to Ala by site-directed mutagenesis 
to generate the expression plasmid pET-28aIHis-KSI-HBD2 
which was used for all further studies (Fig. IA). 
Expression of His-KSI-HBD2 
Plasmid pET-28a/His-KSI-1 IBD2 was used to transforni 
131,2I (DE3) cells and on a small scale (lOmI) induction with 
LPTG, a strong band corresponding to His-KSI-FIBD2 at 
20.2 kDa was observed by SDS-PAGE in agreement with the 
predicted molecular weight of the KSI-l-IBD2 fusion protein 
of 189aa (Fig. 2B). This expression was scaled up to 3 litres 
of culture medium and yielded —9 g wet weight cell paste 
that was frozen at -20°C. 
Purification of His-KSI-HBD2 and Cleavage of HBD2 
The His-KSI-I-IBD2 fusion was isolated from the bacte-
rial pellet by a series washing and centrifugation steps. Ali-
quots were removed throughout the purification protocol and 
analysed by SDS-PAGE to monitor the increased purity and 
yield of His-KSI-HBD2. We engineered a methionine resi-
due at the N-terminus of the HBD2 protein to allow cleavage 
from the KS! tag by CNBr. This non-enzymatic cleavage is 
efficient and less expensive than using proteolytic enzymes 
such as enterokinase. After a one-step Ni-NTA affinity puri-
fication, the }-lis-KSI-HBD2 was sufficiently pure for CNBr 
cleavage (Fig. 3A). After 18-22 h, the cleavage was com-
plete and separation of the fusion protein from HBD2 was 
carried out by dialysis against buffer (25 mM Tris, pH 8.0) 
followed by centrifugation (10,000 r.p.m.) to remove any 
precipitate. Cleaved HBD2 was shown to be in the soluble 
fraction by SDS-PAGE (Fig. 3A). 
Characterisation of Oxidized, Folded -Defensin HBD2 
Soluble HBD2 was purified by preparative RP-HPLC 
and mass spectrometry showed that it was a mixture of re-
duced and oxidized forms. This HBD2 mixture was com-
pletely reduced using TCEP then purified by RP-HPLC. The 
recovered H13132 was oxidized at room temperature using a 
Figure 2. A. Synthesis of optimised HBD2 gene by recursive PCR. Lane 1, 1kb DNA Hyperladder I (Bioline): lane 2, recursive HBD2 PCR 
product. The band indicated by arrow is the 147bp codon-optimised HBD2 gene product. B. Expression of HIS-KSI-HBD2 in pET-
28/1-IisKSl. 12 % Bis-Tris acrylamide gel analysis before and after induction with IPTG. Lane M. SeeBlue 2 protein marker (Invitrogen): 
lane I, total bacteria] lysate before induction; lane 2 insoluble fraction after induction (His-KSI-I-IBD2, Mr 20.2 kDa). 
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Figure 3. Purification of recombinant HBD2 A. 12 % Bis-Tris acrylamide gel analysis of HIS-KSI-HBD2 fusion (lane 1) and recovered, 
soluble HBD2 after CNBr cleavage (lane 2) (M, SeeBlue 2 marker (Invitrogen)). B. Western blot of oxidized HBD2 probed with anti-HBD2 
antibody (Lane I. Oxidised HBD2 (2.5 j.tg); lane 2, Synthetic biotinylated bHBD2 (I jig)), C. Reverse-phase I-IPLC chromatograms of re-
duced HBD2 (upper trace. -34 mins) and oxidized HBD2 (lower trace, —38 mins). 
cysteine/cystine redox buffer. The fully oxidized form has a 
longer retention time (-4 minutes) compared to the reduced 
form (Fig. 3C) in agreement with previously published data 
[44]. This peptide was reactive in a Western blot assay with 
anti-H BD2 antibody that confirms the identity of the purified 
HBD2 (Fig. 3B). High resolution FT-ICR mass spectrometry 
was used to determine the accurate mass of HBD2 and con-
firm its oxidation state. The HBD2 ionized efficiently dis-
playing three charge states [(M+3H) 3 . (M+4H)4 and 
(M+5H) 5 ) and the isotopic distribution for the +4 charge 
state and mass fit to those predicted for fully oxidised HBD2 
with an elemental composition (C 188 H305 N 55050S6 ) and aver-
age mass of 4328.23 Da (Fig. 4). After purification and 
freeze drying. —3-6 mg of fully oxidised f-HBD2 was ob-
tained. The ID 'H NMR spectrum shows sharp, well-
dispersed peaks in the amide region, which is indicative of a 
folded structure (Fig. 5). Furthermore, it was important to 
carry out try psinlchymotiypsin digest and Edman degrada-
tion analysis which showed that the peptide displayed the - 
defensin (1-5, 2-4, 3-6) connectivity (data not shown). 
Antimicrobial and Chemotactic Activity of Recombinant 
H BD2 
Fully oxidised HBD2 was dissolved in 0.01% acetic acid 
and the sample was concentrated to 500 jig!mL for the assay. 
We analysed the activity of the fully oxidised HBD2 against 
E. coil K-12 MG1655, P. aeruginosa PAOI. S. aureus 
ATCC 25923 and C. aibicans J2922 using a previously pub-
lished assay [25,40,45]. Values of LD 50, LD90 and MBC9999  
values against I x 10 cells were determined (Table 2). 
HBD2 was found to be effective in killing Gram-negative 
bacteria (E. co/i and P. aeruginosa) and yeast C. ci/bicans in 
the jiM range, but showed a lower bactericidal effect toward 
Gram-positive S. aureus. These results are in good agree-
ment with that of the natural sample[23], the recombinant 
HBD2 preparations from other groups [29.46] and peptide 
prepared by solid-phase peptide synthesis [471 (Table 2). 
 
 
1080 	 1083 	 1086 
m/z 
Figure 4. FT-ICR high resolution mass spectrometry analysis of 
recombinant HBD2. A. The ion envelope for nanospray MICR 
analysis of oxidized HBD2 showing the +5 to ±3 charge states. B. 
The isotopic envelope of the ±4 charge state of oxidized HBD2. 
Closed circles represent the theoretical envelope expected from a 
HBD2 monomer with all cysteines reduced and the closed triangles 
represent that expected from a filly oxidized HBD2 with 3 S-S 
bonds. 
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Figure 5. ID 'H NMIR spectrum of oxidized HBD2 in 20mM sodium acetate buffer pH 4.0 and 10% D 20 on a Bruker AVANCE spectrome-
ter equipped with a cryoprobe operating at 600MIHz and 25 °C. Only the amide proton region is shown for clarity. 
Table 2. Comparison of Antimicrobial Activity of HBD2 with Previous Studies (Values are in pg/mL, PMB: Polymyxin B as Con-
trol AMP) 
Strain Source MBC9999*/MIC 1  L090' 
-7 
LD50" 
E. co/iKl2-MG1655 This paper MBC 9<20'(<1.5',PMB) 3-6 <1.5 
E.coliML-35 47 17 
b 
E. co/i 23 -10 
S. co/i ML35p 29 
4.2512.25f 
P. aeruginosa PAO1 This paper <25' (<1.5', PNIB) <3 <1.5 
P. aeruginosaATCC 27853 47 17 ' 
 
P. aeruginosa 23 -10 
P. aeruginosa ATCC 9027 29 
C. albicans J2922 This paper >50' (<3', PMB) >6 >1.5 
C. albicans 47 70 ' 
 
C. albicans 23 25 
C. alb/cans 820 29 
S. aureus ATCC 25923 This paper >50' (6', PMB) >12 >3 
S. aureus7l0A 47 
3570b 
S. aureus 23 100' 
S. aureusATCC 6341 29 ND.' 
'MBCw,gs values are the minimum concentration of peptide required to kill 99.99% of initial moculum. 
MIC values are the lowest concentration of peptide that will inhibit the visible growth of a microorganism. 
'LD90 values are the concentration of peptide required to kill 90% of initial inoculum. 
° LD50 values are the concentration required to kill 50% of initial inoculum. 
Bacteriostatic effect. 
'Bactericidal effect. 
Yang and colleagues discovered that many defensins are 
potent chemotactic agents against a range of cells from the 
mammalian immune system including dendritic cells and I 
cells [26]. The exact nature of the molecular interactions 
between HBD2 and the CCR6 receptor are presently 
unknown but a recent analysis of HBDI/CCR6 has begun to 
explore the residues involved [22]. It was shown that 1 ­113132 
was active in chemotaxis assays against CCR6, a GPCR pre-
viously been shown to be activated by the chemokine CCL20 
(MIP3-(x). We tested our recombinant 1 ­113132 against HEK 
293 cells expressing CCR6 in an assay we have used in our 
laboratory [25] and found that it had optimal activity at 100 
ng/ml (Fig. 6). 
CONCLUSION 
The method described in this paper is straight forward 
and low-cost, allowing for the production of milligram 
amounts of f-defensin 1 ­113132 in a commonly-used E. co/i 
host. The mature form of 1 ­113132 was isolated as a single, 
homogenous, oxidized isoform with -defensin S-S bond 
connectivity. This 1­113132 was an active chemokine for cells 
expressing the GPCR receptor CCR6 and a potent anti-
microbial peptide against a range of microbes. It displayed 
excellent structural properties (NMR spectroscopy and high 
resolution mass spectrometry) and is suitable for future 
analysis of 1­113132 in complex with a range of biological tar- 
Efficient Production of Human fi-Defensin 2 (HBD2) 
gets. The expression clone is also suitable for generation of a 
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Figure 6. Chemotactic activity of HBD2. The graph shows the 
number of HEK293 cells expressing the human ehemokine receptor 
CCR6 that migrate towards the peptides. The number of cells per 
high power field (No./HPF) under the microscope is given. Chemo-
taxis medium is the control, CCL20 (also known as MIP-3(c) is the 
known chemokine ligand of CCR6. Each assay was repeated three 
times, numerical data are means ± S.D. and columns with an aster-
isk indicate peptide with significant activity (p<0.05) above culture 
medium. 
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